Original Article
C-Reactive Protein Levels and Outcomes after Statin Therapy
N Engl J Med 2005; 352:20-28January 6, 2005
- Abstract
Background
Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown.
Methods
We evaluated relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes.
Results
Patients in whom statin therapy resulted in LDL cholesterol levels of less than 70 mg per deciliter (1.8 mmol per liter) had lower event rates than those with higher levels (2.7 vs. 4.0 events per 100 person-years, P=0.008). However, a virtually identical difference was observed between those who had CRP levels of less than 2 mg per liter after statin therapy and those who had higher levels (2.8 vs. 3.9 events per 100 person-years, P=0.006), an effect present at all levels of LDL cholesterol achieved. For patients with post-treatment LDL cholesterol levels of more than 70 mg per deciliter, the rates of recurrent events were 4.6 per 100 person-years among those with CRP levels of more than 2 mg per liter and 3.2 events per 100 person-years among those with CRP levels of less than 2 mg per liter; the respective rates among those with LDL cholesterol levels of less than 70 mg per deciliter were 3.1 and 2.4 events per 100 person-years (P<0.001). Although atorvastatin was more likely than pravastatin to result in low levels of LDL cholesterol and CRP, meeting these targets was more important in determining the outcomes than was the specific choice of therapy. Patients who had LDL cholesterol levels of less than 70 mg per deciliter and CRP levels of less than 1 mg per liter after statin therapy had the lowest rate of recurrent events (1.9 per 100 person-years).
Conclusions
Patients who have low CRP levels after statin therapy have better clinical outcomes than those with higher CRP levels, regardless of the resultant level of LDL cholesterol. Strategies to lower cardiovascular risk with statins should include monitoring CRP as well as cholesterol.
Media in This Article
Figure 1
Relationship between LDL Cholesterol and CRP Levels Achieved after 30 Days of Statin Therapy.Figure 2
Cumulative Incidence of Recurrent Myocardial Infarction or Death from Coronary Causes, According to Whether the Achieved LDL Cholesterol or CRP Levels Were above or below the Median.Article Activity
- Article
Statin therapy lowers the risk of cardiovascular events by reducing plasma cholesterol levels, and practice guidelines for patients with known cardiovascular disease emphasize the importance of reaching target goals for low-density lipoprotein (LDL) cholesterol.1 However, we have shown that statin therapy results in a greater clinical benefit when levels of the inflammatory biomarker C-reactive protein (CRP) are elevated2,3 and that statins lower CRP levels in a manner largely independent of LDL cholesterol levels.3-6 These findings, along with basic laboratory evidence, have led to the hypothesis that, in addition to being potent lipid-lowering agents, statins may also have antiinflammatory properties that are important for prognosis and treatment. If so, then the level of CRP achieved as a result of statin therapy may have clinical relevance analogous to that of the LDL cholesterol levels achieved through the use of statin therapy.
We prospectively addressed this issue among 3745 patients with acute coronary syndromes who were randomly assigned to receive either intensive or moderate lipid-lowering therapy with a statin. Specifically, on an a priori basis, we hypothesized that patients with acute coronary syndromes who had lower CRP levels as a result of statin therapy would have a lower risk of recurrent myocardial infarction or death from coronary causes than those who had higher CRP levels, even after we controlled for the achieved levels of LDL cholesterol. We also evaluated whether the specific type of statin modified the effect.
Methods
The study population was derived from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) study, a randomized trial performed between November 2000 and February 2004 that used a two-by-two factorial design to compare the effect of intensive statin therapy (80 mg of atorvastatin orally per day) and moderate statin therapy (40 mg of pravastatin orally per day) and of gatifloxacin and placebo on the risk of recurrent coronary events after acute coronary syndromes.7 In total, 4162 patients who had been hospitalized within the preceding 10 days with acute coronary syndromes and who provided written informed consent were enrolled at 349 sites in eight countries. Approximately two thirds had had an acute myocardial infarction, and the remainder had high-risk unstable angina. Descriptions of the study's inclusion and exclusion criteria have been presented previously.8
As part of the protocol, plasma samples were obtained at randomization, 30 days, 4 months, and the end of the study (mean, 24 months). For this analysis, we defined achieved LDL cholesterol levels and achieved CRP levels as the values obtained at the 30-day follow-up visit, a period adequate for the effect of statin therapy on these variables to be seen and for any residual effects of ischemia on each variable to have disappeared. Of the total cohort, 3745 participants (90.0 percent) were alive and free of a recurrent event at day 30 and had measurements of both LDL cholesterol and CRP at that time. All laboratory measurements were made in a core facility. A validated assay for high-sensitive CRP (Denka Seiken) was used.
We used Spearman correlation coefficients to evaluate the relationship between achieved LDL cholesterol levels and achieved CRP levels. We then used a multistage process to address the effect of achieved LDL cholesterol levels and achieved CRP levels on the rates of recurrent myocardial infarction or fatal coronary events that occurred after day 30 of the study. First, we divided the study population into quartiles according to the levels of achieved LDL cholesterol and achieved CRP and sought evidence that these levels were associated with the risk of recurrent myocardial infarction or death from coronary causes, both in age-adjusted analyses and after further adjustment for sex, smoking status (current smoker vs. nonsmoker), body-mass index, and the presence or absence of diabetes and a history of hypertension.
Second, we divided the study population at the approximate median value achieved for the LDL cholesterol level, 70 mg per deciliter (1.8 mmol per liter), and evaluated whether the rates of events differed between patients with values above the median and those with values below the median. In a similar manner, we divided the study population at the approximate median value achieved for the CRP level, 2 mg per liter, and determined whether the rates of recurrent events differed between patients with values above the median and those with values below the median. (None of the patients had the exact median value of either marker.) To address the relative effect of the achieved CRP level across the strata of achieved LDL cholesterol levels, we repeated this process after dividing the study cohort into four groups on the basis of achieved LDL cholesterol levels and achieved CRP levels above or below the respective values of 70 mg per deciliter and 2 mg per liter. A test for trend across groups was performed by assigning a score of 0 to those with low levels of both variables, a score of 1 to the two intermediate groups, and a score of 2 to those with high levels of both variables. Similar analyses were performed after stratification of the study group according to their assignment to atorvastatin or pravastatin. Estimates of hazard ratios were obtained with the use of Cox proportional-hazards models. All main analyses were prespecified in the PROVE IT–TIMI 22 protocol.8 All P values were two-tailed, all confidence intervals computed at the 95 percent level, and all analyses adjusted for assignment to gatifloxacin or placebo.
The investigators designed the protocol; collected, held, and analyzed the data; and wrote the article.
Results
The mean age of the 3745 participants at study entry was 58 years, and 22 percent were women. Forty-nine percent had a history of hypertension, 17 percent had diabetes, and 36 percent were current smokers. Although the levels of both LDL cholesterol and CRP were reduced by statin therapy at 30 days, the correlation between the achieved values was small (r=0.16, P=0.001), so that less than 3 percent of the variance in achieved CRP levels was explained by the variance in achieved LDL cholesterol levels (Figure 1Figure 1
Relationship between LDL Cholesterol and CRP Levels Achieved after 30 Days of Statin Therapy.). This minimal level of correlation was also observed in the subgroup of patients who subsequently had recurrent coronary events (r=0.18, P=0.004).There was a linear relationship between the levels of LDL cholesterol achieved after statin therapy and the risk of recurrent myocardial infarction or death from coronary causes. Fully adjusted relative risks for those in the second lowest, second highest, and highest quartiles of achieved LDL cholesterol level, as compared with those in the lowest quartile (the reference group) were 1.1 (P=0.80), 1.2 (P=0.30), and 1.7 (P=0.006), respectively (Table 1Table 1
Relative Risk of Recurrent Coronary Events after Statin Therapy, According to the Quartile of LDL Cholesterol and CRP Levels Achieved.). However, despite the almost complete independence of achieved CRP and achieved LDL cholesterol levels, there was also a linear relationship between the levels of CRP achieved after statin therapy and the risk of recurrent myocardial infarction or death from coronary causes, so that fully adjusted relative risks for those in the second lowest, second highest, and highest quartiles of achieved CRP level, as compared with those in the lowest quartile of achieved CRP level (the reference group), were 1.5 (P=0.06), 1.3 (P=0.15), and 1.7 (P=0.01). Additional adjustment for concomitant cardiovascular medications had no effect on these estimates.Age-adjusted rates of recurrent myocardial infarction or death from coronary causes are shown in Table 2Table 2
Age-Adjusted Rates of Recurrent Myocardial Infarction or Death from Coronary Causes, According to the LDL Cholesterol and CRP Level Achieved by Statin Therapy. according to whether the level of LDL cholesterol achieved was greater than or less than 70 mg per deciliter and whether the level of CRP achieved was greater than or less than 2 mg per liter. Patients in whom statin therapy resulted in LDL cholesterol levels of less than 70 mg per deciliter had lower age-adjusted rates of recurrent myocardial infarction or death from coronary causes than did patients in whom statin therapy did not achieve this goal (2.7 vs. 4.0 events per 100 person-years, P=0.008) (Table 2 and Figure 2Figure 2Cumulative Incidence of Recurrent Myocardial Infarction or Death from Coronary Causes, According to Whether the Achieved LDL Cholesterol or CRP Levels Were above or below the Median.). However, despite the minimal correlation between achieved LDL cholesterol and CRP levels, a virtually identical difference in the age-adjusted rates of events was also observed among patients in whom statin therapy resulted in CRP levels of less than 2 mg per liter as compared with those in whom statin therapy resulted in higher CRP values (2.8 vs. 3.9 events per 100 person-years, P=0.006) (Table 2 and Figure 2).As also shown in Table 2, those in whom statin therapy resulted in CRP levels of less than 2 mg per liter in general had better clinical outcomes regardless of the level of LDL cholesterol achieved. For example, in the group of patients who had LDL cholesterol levels of more than 70 mg per deciliter after statin therapy, the rates of recurrent events were 4.6 per 100 person-years among those with post-treatment CRP levels of more than 2 mg per liter and 3.2 per 100 person-years among those with CRP levels of less than 2 mg per liter. Among patients in whom statin therapy resulted in LDL cholesterol levels of less than 70 mg per deciliter, the respective rates of events were 3.1 and 2.4 per 100 person-years. These differences are presented graphically in Figure 3Figure 3
Cumulative Incidence of Recurrent Myocardial Infarction or Death from Coronary Causes, According to the Achieved Levels of Both LDL Cholesterol and CRP. in terms of the cumulative incidence of recurrent myocardial infarction or death from coronary causes.Hazard ratios for recurrent coronary events among patients whose values were above the median for LDL cholesterol and below the median for CRP, those whose values were below the median for LDL cholesterol and above the median for CRP, and those whose values were above the median for both LDL cholesterol and CRP, as compared with those whose values of achieved LDL cholesterol and CRP levels were below the median (the reference group), were 1.3, 1.4, and 1.9, respectively (P for trend across groups <0.001). Almost identical results were observed in analyses that eliminated patients with prior statin use.
Because study participants were randomly assigned to receive either 80 mg of atorvastatin or 40 mg of pravastatin daily, we had the additional opportunity to assess the relative effect of these two agents on the reduction in CRP levels and to assess whether the main effects observed in the total cohort according to the LDL cholesterol and CRP levels achieved were modified by the choice of statin therapy. With regard to CRP, the median levels were similar in the atorvastatin and pravastatin groups at randomization (12.2 and 11.9 mg per liter, respectively; P=0.60), but they were significantly lower in the atorvastatin group than in the pravastatin group at 30 days (1.6 vs. 2.3 mg per liter, P <0.001), 4 months (1.3 vs. 2.1 g per liter, P <0.001), and the end of the study (1.3 vs. 2.1 mg per liter, P <0.001) (Figure 4Figure 4
Median Levels of CRP at Randomization, 30 Days, 4 Months, and the End of the Study, According to Whether Patients Received 80 mg of Atorvastatin or 40 mg of Pravastatin Daily.).Despite these differences, there was substantial overlap between the two groups in terms of achieved CRP levels; 57.5 percent of those treated with atorvastatin had CRP levels below 2 mg per liter after 30 days, whereas 44.9 percent of patients in the pravastatin group had such levels (P<0.001). The levels of LDL cholesterol were identical in the two groups at randomization and, as expected, were significantly lower in the atorvastatin group than in the pravastatin group at day 30, four months, and the end of the study. At 30 days, 72.3 percent of those assigned to receive atorvastatin had met the LDL cholesterol goal of a level of less than 70 mg per deciliter, as compared with 21.7 percent of those assigned to pravastatin (P<0.001). The magnitude of the correlation between achieved LDL cholesterol and achieved CRP levels was small for both agents (r=0.04, P=0.07 for pravastatin, and r=0.15, P=0.001 for atorvastatin).
Despite the greater ability of atorvastatin than of pravastatin to reduce LDL cholesterol levels to below 70 mg per deciliter and CRP levels to below 2 mg per liter, there was little evidence that either agent led to better clinical outcomes once the target levels of both LDL cholesterol and CRP were achieved. Specifically, although atorvastatin was superior to pravastatin overall in the PROVE IT–TIMI 22 trial,7 there was no observed residual effect of randomization on clinical outcomes once the achieved levels of LDL cholesterol and CRP were accounted for (fully adjusted hazard ratio for atorvastatin as compared with pravastatin = 1.00; 95 percent confidence interval, 0.75 to 1.34; P=0.90). Similarly, for those in whom atorvastatin therapy resulted in LDL cholesterol levels of less than 70 mg per deciliter, the rates of recurrent events were 3.1 per 100 person-years for those with post-treatment CRP levels of more than 2 mg per liter and 2.3 per 100 person-years for those with CRP levels of less than 2 mg per liter, whereas the corresponding event rates for patients in whom pravastatin resulted in LDL cholesterol levels of less than 70 mg per deciliter were 3.4 and 2.5 per 100 person-years (P=0.70 for the difference between agents). Thus, achieving target levels of both LDL cholesterol and CRP was of substantially greater importance for subsequent event-free survival than was the specific type of statin therapy received.
We performed additional post hoc analyses to evaluate those in whom statin therapy resulted not only in a target LDL cholesterol level below 70 mg per deciliter but also in a CRP level below 1 mg per liter. Although only 15.9 percent of the study population reached these very aggressive target goals, this subgroup had the lowest age-adjusted rate of recurrent events (1.9 per 100 person-years) (Table 2); 81.8 percent of patients in this subgroup had been assigned to receive atorvastatin.
As indicated above, all analyses were adjusted for random assignment to gatifloxacin or placebo. This agent had no significant effect on CRP levels in this population.
Discussion
Our data indicate that among patients with acute coronary syndromes who are treated with a statin, achieving a target level of CRP of less than 2 mg per liter is associated with a significant improvement in event-free survival, an effect present at all levels of LDL cholesterol achieved. Our data also demonstrate that the relationship between the reduction in LDL cholesterol and that in CRP varies greatly from patient to patient, regardless of the intensity of lipid-lowering regimen used; this finding is consistent with those of previous studies of subjects without acute ischemia.3-6 In our study, less than 3 percent of the variation in achieved CRP levels was explained by the variation in achieved LDL cholesterol levels. Thus, these data suggest that strategies that aggressively lower cardiovascular risk by means of statin therapy may need to include monitoring of the levels of inflammation as well as cholesterol.
We believe our data have clinical relevance for several reasons. First, although the PROVE IT–TIMI 22 study demonstrated the importance of achieving LDL cholesterol levels of less than 70 mg per deciliter after acute coronary syndromes, the current analyses indicate that subsequent event-free survival is also linked to the achievement of CRP levels of less than 2 mg per liter. This concept is supported by observations made by Nissen et al.,9 which appear elsewhere in this issue. Nissen et al. used intravascular ultrasonography to show that the magnitude of change in CRP levels and the magnitude of change in LDL cholesterol levels were both independent predictors of plaque regression after statin therapy.9 Thus, while confirming the importance of achieving LDL cholesterol levels of less than 70 mg per deciliter in very-high-risk patients, as was recently advocated,10 our observations regarding the clinical relevance of the CRP levels achieved as a result of statin therapy may also be important for future guidelines designed to address the appropriate use of statin therapy.
Second, we believe our data are of pathophysiological importance, since they provide evidence that reducing inflammation in general and perhaps the levels of CRP in particular may well have a role in altering the atherothrombotic process. To date, a consistent series of prospective epidemiologic studies has demonstrated that CRP levels independently predict the risk of first coronary events at all levels of LDL cholesterol and across a full spectrum of Framingham risk categories11-16 and that CRP levels have prognostic value in patients with acute coronary syndromes.17-20 However, although statin therapy has been shown to lower CRP levels in a manner that is largely independent of LDL cholesterol levels,2-6,21,22 evidence linking a greater reduction in CRP levels to reduced rates of vascular events has been lacking. In the current analysis, we found evidence of incremental benefit for those in whom statin therapy resulted in CRP levels of less than 2 mg per liter, whether or not LDL cholesterol levels were also reduced to the target value of less than 70 mg per liter. In this regard, our data are consistent with laboratory work indicating the importance of inflammation as a determinant of plaque instability,23 as well as experimental data indicating that statins have lipid-lowering and antiinflammatory effects.24 Our data also provide support for ongoing efforts to find agents capable of lowering CRP as a potential method of reducing vascular risk.
Third, our data demonstrating the concomitant importance of both lipid reduction and CRP reduction provide insight into mechanisms by which more aggressive statin regimens augment the reduction in vascular risk. In our study, patients assigned to receive 80 mg of atorvastatin daily were significantly more likely than those assigned to receive 40 mg of pravastatin daily to have a decrease in the levels of both LDL cholesterol and CRP to the target values, data that are consistent with those in other studies.25 Nonetheless, once target levels were met, we found little evidence of a differential outcome according to the specific statin given, suggesting that achieving the target levels of LDL cholesterol and CRP was more important in determining the outcomes than was the specific choice of agent. The observation that the treatment group was not associated with the outcome after adjustment for the LDL cholesterol and CRP levels achieved provides strong support for the hypothesis that the appropriate use of more aggressive therapy to achieve these targets will reduce risk. Clinical trials testing two doses of the same statin will be needed to evaluate this issue fully.
Given that the participants had recently had a myocardial infarction or had high-risk unstable angina and thus had a clear indication for long-term statin therapy, we believe our findings should not be generalized beyond situations involving secondary prevention. Post hoc analysis of a recent primary-prevention trial suggests that apparently healthy persons who have elevated CRP levels but low lipid levels can benefit from statin therapy.3 However, whether statin therapy should be used for primary prevention among persons with elevated levels of CRP who do not have hyperlipidemia remains highly controversial and is the subject of an ongoing multinational trial.26,27
In summary, these secondary-prevention data demonstrate that the aggressive use of statin therapy to achieve target levels of both LDL cholesterol and CRP decreases the risk of recurrent myocardial infarction or death from coronary causes among patients with acute coronary syndromes. These data also provide strong evidence to support the hypothesis that therapies designed to reduce inflammation after acute coronary ischemia may improve cardiovascular outcomes.
Supported by grants from the Donald W. Reynolds Foundation, the Doris Duke Charitable Foundation, Bristol-Myers Squibb, and Sankyo.
Dr. Ridker reports being a coinventor of approaches related to the use of inflammatory biomarkers in cardiovascular disease for which patents are held by the Brigham and Women's Hospital and having received research support or lecture honoraria from Bristol-Myers Squibb, AstraZeneca, Merck, Pfizer, and Dade Behring. Dr. Pfeffer reports having received research support or lecture honoraria from Bristol-Myers Squibb, Merck, and Pfizer; Dr. Cannon, research support from Bristol-Myers Squibb, Sanofi, and Merck and consulting fees from AstraZeneca and GlaxoSmithKline; Dr. Morrow, research support or lecture honoraria from Dade Behring, Beckman Coulter, Bayer Diagnostics, and Biosite; Dr. Rifai, honoraria from Dade-Behring, Denka Seiken, and Bayer; and Dr. Braunwald, research support from Bristol-Myers Squibb, Merck, and AstraZeneca.
Source Information
From the Center for Cardiovascular Disease Prevention (P.M.R., N.R., L.M.R.), the Donald W. Reynolds Center for Cardiovascular Research (P.M.R., D.M., N.R.), and the Thrombolysis in Myocardial Infarction Study Group (C.P.C., D.M., C.H.M., M.A.P., E.B.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.
Address reprint requests to Dr. Ridker at the Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, 900 Commonwealth Ave. East, Boston, MA 02215, or at pridker@partners.org.
- References
References
1
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
CrossRef | Web of Science2
Ridker PM ,Rifai N ,Pfeffer MA , et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-844
Web of Science | Medline3
Ridker PM ,Rifai N ,Clearfield M , et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965
Full Text | Web of Science | Medline4
Ridker PM ,Rifai N ,Pfeffer MA ,Sacks F ,Braunwald E . Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-235
Web of Science | Medline5
Albert MA ,Danielson E ,Rifai N ,Ridker PM . Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70
CrossRef | Web of Science | Medline6
Ridker PM ,Rifai N ,Lowenthal SP . Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103:1191-1193
Web of Science | Medline7
Cannon CP ,Braunwald E ,McCabe CH , et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504
Full Text | Web of Science | Medline8
Cannon CP ,McCabe CH ,Belder R ,Breen J ,Braunwald E . Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 2002;89:860-861
CrossRef | Web of Science | Medline9
Nissen SE ,Tuzcu EM ,Schoenhagen P , et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38
Full Text | Web of Science | Medline10
Grundy SM ,Cleeman JI ,Merz CN , et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239
CrossRef | Web of Science | Medline11
Ridker PM ,Cushman M ,Stampfer MJ ,Tracy RP ,Hennekens CH . Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979[Erratum, N Engl J Med 1997;337:356.]
Full Text | Web of Science | Medline12
Ridker PM ,Rifai N ,Rose L ,Buring JE ,Cook NR . Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565
Full Text | Web of Science | Medline13
Koenig W ,Lowel H ,Baumert J ,Meisinger C . C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004;109:1349-1353
CrossRef | Web of Science | Medline14
Ballantyne CM ,Hoogeveen RC ,Bang H , et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004;109:837-842
CrossRef | Web of Science | Medline15
Danesh J ,Wheeler JG ,Hirschfield GM , et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-1397
Full Text | Web of Science | Medline16
Ridker PM ,Cook N . Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004;109:1955-1959
CrossRef | Web of Science | Medline17
Liuzzo G ,Biasucci LM ,Gallimore JR , et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-424
Full Text | Web of Science | Medline18
Haverkate F ,Thompson SG ,Pyke SD ,Gallimore JR ,Pepys MB . Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-466
CrossRef | Web of Science | Medline19
Lindahl B ,Toss H ,Siegbahn A ,Venge P ,Wallentin L . Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000;343:1139-1147
Full Text | Web of Science | Medline20
Morrow DA ,Rifai N ,Antman EM , et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 1998;31:1460-1465
CrossRef | Web of Science | Medline21
Kinlay S ,Timms T ,Clark M , et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 2002;89:1205-1207
CrossRef | Web of Science | Medline22
Jialal I ,Stein D ,Balis D , et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-1935
Web of Science | Medline23
Libby P . Inflammation in atherosclerosis. Nature 2002;420:868-874
CrossRef | Web of Science | Medline24
Davignon J . Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109:Suppl 1:III-3925
Kinlay S ,Schwartz GG ,Olsson AG , et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIR-ACL study. Circulation 2003;108:1560-1566
CrossRef | Web of Science | Medline26
Ridker PM ,Wilson PWF ,Grundy SM . Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818-2825
CrossRef | Web of Science | Medline27
Ridker PM . Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003;108:2292-2297
CrossRef | Web of Science | Medline
- Citing Articles (697)
Citing Articles
1
Mark A. Moyad. (2012) The Optimal Male Health Diet and Dietary Supplement Program. Urologic Clinics of North America 39:1, 89-107
CrossRef2
Ernst Rietzschel, Marc De Buyzere. (2012) High-sensitive C-reactive protein: universal prognostic and causative biomarker in heart disease?. Biomarkers in Medicine 6:1, 19-34
CrossRef3
Nabel, Elizabeth G., Braunwald, Eugene, . (2012) A Tale of Coronary Artery Disease and Myocardial Infarction. New England Journal of Medicine 366:1, 54-63
Full Text4
Jian-Jun Li, Ping Yang, Jun Liu, Yan-Jun Jia, Zi-Cheng Li, Yuan-Lin Guo, Na-Qiong Wu, Yi-Da Tang, Li-Xin Jiang. (2012) Impact of 10mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers. Clinica Chimica Acta 413:1-2, 139-142
CrossRef5
Eun-Seok Shin, Hector M. Garcia-Garcia, Takayuki Okamura, Patrick W. Serruys. (2011) Effect of statins on coronary bifurcation atherosclerosis: an intravascular ultrasound virtual histology study. The International Journal of Cardiovascular Imaging
CrossRef6
Gagandeep S. Gurm, Ahmed Tawakol. (2011) FDG-PET-CT as a Biomarker for Aortic Valve Inflammation. Current Cardiovascular Imaging Reports
CrossRef7
Claudia Stefanutti, Antonio Vivenzio, Pietro Manuel Ferraro, Claudia Morozzi, Dany Belotherkovsky. (2011) Apheresis-inducible cytokine pattern change in severe, genetic dyslipidemias. Cytokine 56:3, 835-841
CrossRef8
Charles L. Raison, Andrew H. Miller. (2011) Is Depression an Inflammatory Disorder?. Current Psychiatry Reports 13:6, 467-475
CrossRef9
Jeannette Y. Wick, Guido R. Zanni. (2011) C-Reactive Protein: The Evolution of a Laboratory Test. The Consultant Pharmacist 26:12, 929-933
CrossRef10
Kamran I Muhammad, Thomas Morledge, Ravish Sachar, Annette Zeldin, Kathy Wolski, Deepak L Bhatt. (2011) Treatment with ω-3 fatty acids reduces serum C-reactive protein concentration. Clinical Lipidology 6:6, 723-729
CrossRef11
Robert S. Rosenson, Heather Fraser, Michael A. Goulder, Colin Hislop. (2011) Anti-Inflammatory Effects of Varespladib Methyl in Diabetic Patients with Acute Coronary Syndrome. Cardiovascular Drugs and Therapy 25:6, 539-544
CrossRef12
Behnood Bikdeli. (2011) C-Reactive Protein, Statins and the Risk of Vascular Events: A Better Understanding. Cardiovascular Drugs and Therapy 25:6, 545-549
CrossRef13
M. Madjid, J. T. Willerson. (2011) Inflammatory markers in coronary heart disease. British Medical Bulletin 100:1, 23-38
CrossRef14
G. Pirzad Jahromi, S. Seidi, S.S. Sadr, A.P. Shabanzadeh, S.K. Hosseini, H. Sohanaki, G.R. Kaka, J. Charish. (2011) Therapeutic Effects of a Combination Treatment of Simvastatin and Bone Marrow Stromal Cells on Experimental Embolic Stroke. Basic & Clinical Pharmacology & Toxicologyno-no
CrossRef15
Tanica Lyngdoh, Peter Vollenweider, Gérard Waeber, Pedro Marques-Vidal. (2011) Association of statins with inflammatory cytokines: A population-based Colaus study. Atherosclerosis 219:1, 253-258
CrossRef16
Zhongsu Wang, Yong Zhang, Mei Gao, Jiangrong Wang, Qing Wang, Xiaojun Wang, Lequn Su, Yinglong Hou. (2011) Statin Therapy for the Prevention of Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials. Pharmacotherapy 31:11, 1051-1062
CrossRef17
Pál Maurovich-Horvat, Kimberly Kallianos, Leif-Christopher Engel, Jackie Szymonifka, Caroline S. Fox, Udo Hoffmann, Quynh A. Truong. (2011) Influence of pericoronary adipose tissue on local coronary atherosclerosis as assessed by a novel MDCT volumetric method. Atherosclerosis 219:1, 151-157
CrossRef18
Yuan-yuan Lv, Yue Jin, Guo-zhu Han, Yan-xia Liu, Tao Wu, Peng Liu, Qin Zhou, Ke-Xin Liu, Hui-Jun Sun. (2011) Ursolic acid suppresses IL-6 induced C-reactive protein expression in HepG2 and protects HUVECs from injury induced by CRP. European Journal of Pharmaceutical Sciences
CrossRef19
Paul M Ridker, Tom Thuren, Andrew Zalewski, Peter Libby. (2011) Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). American Heart Journal 162:4, 597-605
CrossRef20
Chin-Chou Huang, Wan-Leong Chan, Yu-Chun Chen, Tzeng-Ji Chen, Kun-Ta Chou, Shing-Jong Lin, Jaw-Wen Chen, Hsin-Bang Leu. (2011) Statin Use and Hospitalization in Patients with Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Cohort Study in Taiwan. Clinical Therapeutics 33:10, 1365-1370
CrossRef21
Ronen Gurfinkel, Tisha R. Joy. (2011) Anacetrapib: Hope for CETP Inhibitors?. Cardiovascular Therapeutics 29:5, 327-339
CrossRef22
Femke A.M.V.I. Hellenthal, Bianca Pulinx, Rob J. Th. J. Welten, Joep A.W. Teijink, Marja P. van Dieijen-Visser, Will K.W.H. Wodzig, Geert Willem H. Schurink. (2011) Circulating Biomarkers and Abdominal Aortic Aneurysm Size. Journal of Surgical Research
CrossRef23
Matthias Hermann, Dieter Fischer, Michael M. Hoffmann, Theo Gasser, Kurt Quitzau, Thomas Meinertz, Thomas Münzel, Thomas F. Lüscher. (2011) CRP and CD14 polymorphisms correlate with coronary plaque volume in patients with coronary artery disease – IVUS substudy of the ENCORE trials. Atherosclerosis
CrossRef24
Nina C. Raju, Qilong Yi, Mark Nidorf, Nick D. Fagel, Rajesh Hiralal, John W. Eikelboom. (2011) Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. Journal of Thrombosis and Thrombolysis
CrossRef25
E. Braunwald. (2011) Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. European Heart Journal
CrossRef26
Robert Kleemann, Lars Verschuren, Martine Morrison, Susanne Zadelaar, Marjan J. van Erk, Peter Y. Wielinga, Teake Kooistra. (2011) Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis 218:1, 44-52
CrossRef27
Christie M. Ballantyne, Michael H. Davidson, Carolyn M. Setze, Maureen T. Kelly. (2011) Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥2 mg/L). Journal of Clinical Lipidology 5:5, 401-407
CrossRef28
P.P.M. van Lümig, R.J.B. Driessen, M.A.M.A. Roelofs-Thijssen, J.B.M. Boezeman, P.C.M. van de Kerkhof, E.M.G.J. de Jong. (2011) Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab. British Journal of Dermatology 165:2, 375-382
CrossRef29
Mamoru Satoh, Tsuyoshi Tabuchi, Yoshitaka Minami, Yuji Takahashi, Tomonori Itoh, Motoyuki Nakamura. (2011) Expression of let-7i is associated with Toll-like receptor 4 signal in coronary artery disease: Effect of statins on let-7i and Toll-like receptor 4 signal. Immunobiology
CrossRef30
C.I. Daïen, P. Fesler. (2011) La polyarthrite rhumatoïde : une maladie cardiovasculaire ?. Annales de Cardiologie et d'Angéiologie
CrossRef31
Domenico Scrutinio, Andrea Passantino, Francesca Di Serio, Domenico Angiletta, Daniela Santoro, Guido Regina. (2011) High-sensitivity C-reactive protein predicts cardiovascular events and myocardial damage after vascular surgery. Journal of Vascular Surgery 54:2, 474-479
CrossRef32
Kenji Hara, Kyoko Omori, Yumiko Sumioka, Yoshimasa Aso. (2011) Spontaneous platelet aggregation evaluated by laser light scatter in patients with type 2 diabetes: Effects of short-term improved glycemic control and adiponectin. Translational Research
CrossRef33
P. S. Sever, N. R. Poulter, C. L. Chang, A. Hingorani, S. A. Thom, A. D. Hughes, P. Welsh, N. Sattar, . (2011) Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. European Heart Journal
CrossRef34
Hanen Belfki, Samir Ben Ali, Souha Bougatef, Decy Ben Ahmed, Najet Haddad, Awatef Jmal, Monia Abdennebi, Habiba Ben Romdhane. (2011) Association Between C-Reactive Protein and Type 2 Diabetes in a Tunisian Population. Inflammation
CrossRef35
Mehmet KOC, Cengiz DOGAN, Turgay ARINSOY, Zeki TONBUL, Deniz AYLI, Mustafa CIRIT, Mehmet Sukru SEVER, Mehmet Emin YILMAZ, Abdulkadir UNSAL, Gultekin SULEYMANLAR, Ercan OK, Ali BASCI, Alaatin YILDIZ. (2011) Statin use is associated with lower inflammation and erythropoietin responsiveness index in hemodialysis patients. Hemodialysis International 15:3, 366-373
CrossRef36
I. Ramasamy. (2011) Biochemical markers in acute coronary syndrome. Clinica Chimica Acta 412:15-16, 1279-1296
CrossRef37
Ana María Wägner, Jose Luis Sánchez-Quesada, Sonia Benítez, Cristina Bancells, Jordi Ordóñez-Llanos, Antonio Pérez. (2011) Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study. Diabetes Research and Clinical Practice 93:1, e25-e28
CrossRef38
Xuguang Li, Guangtian Yang, Gang Zhao, Bin Wu, Matthew L Edin, Darryl C Zeldin, Dao Wen Wang. (2011) Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein. Hypertension Research 34:7, 869-875
CrossRef39
Bernhard Föger. (2011) Lipid lowering therapy in type 2 diabetes. Wiener Medizinische Wochenschrift 161:11-12, 289-296
CrossRef40
Stephen J. Nicholls, Marilyn Borgman, Steven E. Nissen, Joel S. Raichlen, Christie Ballantyne, Philip Barter, M. John Chapman, Raimund Erbel, Peter Libby. (2011) Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin versus AtorvastatiN). Current Medical Research and Opinion 27:6, 1119-1129
CrossRef41
Cheng-Wen Chiang, Raul D. Santos, David D. Waters, Michael Messig, Lisa Tarasenko, J. Wouter Jukema, Jean Ferrières, JoAnne Foody, Ki-Bae Seung. (2011) Reaching C-Reactive Protein and Low-Density Lipoprotein Cholesterol Goals in Dyslipidemic Patients (from the Lipid Treatment Assessment Project [L-TAP] 2). The American Journal of Cardiology 107:11, 1639-1643
CrossRef42
Chi Chiu Mok, Chun Kwok Wong, Chi Hung To, Judy Po Shan Lai, Cheuk Sum Lam. (2011) Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: A randomized, double-blind, placebo-controlled trial. Arthritis Care & Research 63:6, 875-883
CrossRef43
Mikkel Malby Schoos, Henning Kelbæk, Klaus F. Kofoed, Lars Køber, Lene Kløvgaard, Steffen Helqvist, Thomas Engstrøm, Kari Saunamäki, Erik Jørgensen, Lene Holmvang, Peter Clemmensen. (2011) Usefulness of Preprocedure High-Sensitivity C-Reactive Protein to Predict Death, Recurrent Myocardial Infarction, and Stent Thrombosis According to Stent Type in Patients With ST-Segment Elevation Myocardial Infarction Randomized to Bare Metal or Drug-Eluting Stenting During Primary Percutaneous Coronary Intervention. The American Journal of Cardiology 107:11, 1597-1603
CrossRef44
Vera Krane, Christoph Wanner. (2011) Statins, inflammation and kidney disease. Nature Reviews Nephrology 7:7, 385-397
CrossRef45
Peter Libby, Paul M Ridker, Göran K. Hansson. (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473:7347, 317-325
CrossRef46
Chin-Chou Huang, Wan-Leong Chan, Yu-Chun Chen, Tzeng-Ji Chen, Kun-Ta Chou, Shing-Jong Lin, Jaw-Wen Chen, Hsin-Bang Leu. (2011) Statin use in patients with asthma - a nationwide population-based study. European Journal of Clinical Investigation 41:5, 507-512
CrossRef47
Raul D. Santos, Alberto J. Lorenzatti, Carlos Fernandez Barros, Edgardo Escobar. (2011) Clinical perspective: Have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidology. Journal of Clinical Lipidology 5:3, 124-132
CrossRef48
Torbjörn Åkerfeldt, Anders Larsson. (2011) Inflammatory response is associated with increased cathepsin B and decreased cathepsin S concentrations in the circulation. Scandinavian Journal of Clinical & Laboratory Investigation 71:3, 203-207
CrossRef49
Israel F. Charo, Rebecca Taub. (2011) Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nature Reviews Drug Discovery 10:5, 365-376
CrossRef50
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 57:19, e215-e367
CrossRef51
Cecilia M. Shikuma, Heather J. Ribaudo, Yu Zheng, Roy M. Gulick, William A. Meyer, Karen T. Tashima, Barbara Bastow, Daniel R. Kuritzkes, Marshall J. Glesby, and the AIDS Clinical Trial. (2011) Change in High-Sensitivity C-Reactive Protein Levels Following Initiation of Efavirenz-Based Antiretroviral Regimens in HIV-Infected Individuals. AIDS Research and Human Retroviruses 27:5, 461-468
CrossRef52
C. A. Michie, S. D. Rosen, R. Guirguis. (2011) Venous thromboembolism, statins and the protein unfolding response. International Journal of Clinical Practice 65:4, 376-377
CrossRef53
Triantafillos G Giannakopoulos, Efthimios D Avgerinos, Konstantinos G Moulakakis, Nikolaos P Kadoglou, Ourania Preza, Anastasios Papapetrou, Christos Papasideris, Christos D Liapis. (2011) Biomarkers for diagnosis of the vulnerable atherosclerotic plaque. Interventional Cardiology 3:2, 223-233
CrossRef54
David R. Thomas. (2011) Use of Orexigenic Medications in Geriatric Patients. The American Journal of Geriatric Pharmacotherapy 9:2, 97-108
CrossRef55
D. S. H. Bell, F. Al Badarin, J. H. O’Keefe. (2011) Therapies for diabetic dyslipidaemia. Diabetes, Obesity and Metabolism 13:4, 313-325
CrossRef56
Jonas Andersson, Henrik Almroth, Niklas Höglund, Steen Jensen, Per Tornvall, Anders Englund, Mårten Rosenqvist, Kurt Boman. (2011) Markers of fibrinolysis as predictors for maintenance of sinus rhythm after electrical cardioversion. Thrombosis Research 127:3, 189-192
CrossRef57
Jennifer M. Kaplan, Hector R. Wong. (2011) Biomarker discovery and development in pediatric critical care medicine*. Pediatric Critical Care Medicine 12:2, 165-173
CrossRef58
Margrit Schwarz, Jae B. Kim. 2011. Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL. , 199-234.
CrossRef59
Antonio Eduardo P. Pesaro, Carlos V. Serrano, Juliano L. Fernandes, Alexandre B. Cavalcanti, Alexandre H. Campos, Herlon S. Martins, Raul C. Maranhão, James A. de Lemos, Heraldo P. Souza, José C. Nicolau. (2011) Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. International Journal of Cardiology
CrossRef60
Jong Pil Park, Moon Ki Park, Jong Won Yun. (2011) Proteomic biomarkers for diagnosis in acute myocardial infarction. Biomarkers 16:1, 1-11
CrossRef61
Salima Mithani, Michael Kuskowski, Yelena Slinin, Areef Ishani, Edward McFalls, Selcuk Adabag. (2011) Dose-Dependent Effect of Statins on the Incidence of Acute Kidney Injury After Cardiac Surgery. The Annals of Thoracic Surgery 91:2, 520-525
CrossRef62
Volker Schettler, Katrin Völker, Egbert G Schulz, Eberhard Wieland. (2011) Impact of Lipid Apheresis on Egr-1, c-Jun, c-Fos, and Hsp70 Gene Expression in White Blood Cells. Therapeutic Apheresis and Dialysis 15:1, 105-112
CrossRef63
Sang-Hak Lee, Seok-Min Kang, Sungha Park, Yangsoo Jang, Namsik Chung, Donghoon Choi. (2011) The Effects of Statin Monotherapy and Low-Dose Statin/Ezetimibe on Lipoprotein-Associated Phospholipase A2. Clinical Cardiology 34:2, 108-112
CrossRef64
Myung-A Kim, Chee Jeong Kim, Jae-Bin Seo, Woo-Yong Chung, Sang-Hyun Kim, Joo-Hee Zo, Eun Yeon Rho, Sue Shin, Jong Hyun Yoon. (2011) The Effect of Aspirin on C-Reactive Protein in Hypertensive Patients. Clinical and Experimental Hypertension 33:1, 47-52
CrossRef65
Adriano Caixeta, Gregg W. Stone, Roxana Mehran, Edwin A. Lee, Brent T. McLaurin, David A. Cox, Michel E. Bertrand, A. Michael Lincoff, Jeffrey W. Moses, Harvey D. White, E. Magnus Ohman, Tullio Palmerini, George Syros, Christos Kittas, Martin Fahy, W. Craig Hooper, Alexandra J. Lansky, George D. Dangas. (2011) Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial. Journal of Thrombosis and Thrombolysis 31:2, 154-164
CrossRef66
Yoshiko Mizuno, Robert Francis Jacob, R Preston Mason. (2011) Inflammation and the Development of Atherosclerosis. Journal of Atherosclerosis and Thrombosis 18:5, 351-358
CrossRef67
Shin-ichiro Tanaka, Tetsuo Miki, Shoto Sha, Ken-ichi Hirata, Yuichi Ishikawa, Mitsuhiro Yokoyama. (2011) Serum Levels of Thiobarbituric Acid-Reactive Substances are Associated with Risk of Coronary Heart Disease. Journal of Atherosclerosis and Thrombosis 18:7, 584-591
CrossRef68
Lina Badimon, Gemma Vilahur. (2011) Beneficio clínico de las estatinas: ¿hemos cubierto todo el espectro?. Revista Española de Cardiología Suplementos 11, 3-13
CrossRef69
Sangheun Lee, In Tae Kim, Hyung Bok Park, Yu Kyung Hyun, Yoon Ji Kim, Sun Ok Song, Hyeongjin Kim. (2011) High-sensitivity C-reactive Protein Can Predict Major Adverse Cardiovascular Events in Korean Patients with Type 2 Diabetes. Journal of Korean Medical Science 26:10, 1322
CrossRef70
Soo Lim, Jean-Pierre Despres, Kwang Kon Koh. (2011) Prevention of Atherosclerosis in Overweight/Obese Patients. Circulation Journal 75:5, 1019-1027
CrossRef71
Wojciech Plazak, Krzysztof Gryga, Hanna Dziedzic, Lidia Tomkiewicz-Pajak, Malgorzata Konieczynska, Piotr Podolec, Jacek Musial. (2011) Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study. Arthritis Research & Therapy 13:4, R117
CrossRef72
Young Joon Hong, Myung Ho Jeong, Daisuke Hachinohe, Khurshid Ahmed, Yun Ha Choi, Sook Hee Cho, Seung Hwan Hwang, Jum Suk Ko, Min Goo Lee, Keun Ho Park, Doo Sun Sim, Nam Sik Yoon, Hyun Ju Yoon, Kye Hun Kim, Hyung Wook Park, Ju Han Kim, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2011) Comparison of Effects of Rosuvastatin and Atorvastatin on Plaque Regression in Korean Patients With Untreated Intermediate Coronary Stenosis. Circulation Journal 75:2, 398-406
CrossRef73
Tingting Li, Wenqiang Chen, Fengshuang An, Hongbo Tian, Jianning Zhang, Jie Peng, Yun Zhang, Yuan Guo. (2011) Probucol Attenuates Inflammation and Increases Stability of Vulnerable Atherosclerotic Plaques in Rabbits. The Tohoku Journal of Experimental Medicine 225:1, 23-34
CrossRef74
Enrique C. Morales-Villegas, Germano Di Sciascio, Carlo Briguori. (2011) Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins. International Journal of Hypertension 2011, 1-12
CrossRef75
Robert S Rosenson. (2011) After FRANCIS: next steps in the clinical evaluation of varespladib methyl. Future Cardiology 7:1, 11-18
CrossRef76
Min Chul Kim, Youngkeun Ahn, Su Young Jang, Kyung Hoon Cho, Seung Hwan Hwang, Min Goo Lee, Jum Suk Ko, Keun Ho Park, Doo Sun Sim, Nam Sik Yoon, Hyun Ju Yoon, Kye Hun Kim, Young Joon Hong, Hyung Wook Park, Ju Han Kim, Myung Ho Jeong, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2011) Comparison of Clinical Outcomes of Hydrophilic and Lipophilic Statins in Patients with Acute Myocardial Infarction. The Korean Journal of Internal Medicine 26:3, 294
CrossRef77
Benoit J. Arsenault, Philip Barter, David A. DeMicco, Weihang Bao, Gregory M. Preston, John C. LaRosa, Scott M. Grundy, Prakash Deedwania, Heiner Greten, Nanette K. Wenger, James Shepherd, David D. Waters, John J.P. Kastelein. (2011) Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients by Lipid and Nonlipid Biomarkers. Journal of the American College of Cardiology 57:1, 63-69
CrossRef78
Agneta Simionescu, Jason B. Schulte, George Fercana, Dan T. Simionescu. (2011) Inflammation in Cardiovascular Tissue Engineering: The Challenge to a Promise: A Minireview. International Journal of Inflammation 2011, 1-11
CrossRef79
Sachin Agarwal, J.P. Mohr, Mitchell S.V. Elkind. 2011. Collagen Vascular and Infectious Diseases. , 687-702.
CrossRef80
Keiko Yasuda, Koichi Sasaki, Masaya Yamato, Yuki Kawakami, Tatsuya Ohata, Chie Mishiro, Tadashi Iwamoto, Eiji Fuchiwaki, Hiromi Rakugi, Yoshitaka Isaka, Terumasa Hayashi. (2011) A cholesterol crystal embolism patient treated with LDL apheresis and corticosteroids. Nihon Toseki Igakkai Zasshi 44:12, 1185-1191
CrossRef81
Paul M. Ridker, Nina P. Paynter, Jacqueline S. Danik, Robert J. Glynn. (2010) Interpretation of Mendelian Randomization Studies and the Search for Causal Pathways in Atherothrombosis: The Need for Caution. Metabolic Syndrome and Related Disorders 8:6, 465-469
CrossRef82
Robert S Rosenson. (2010) Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes. Current Opinion in Lipidology 21:6, 473-480
CrossRef83
Mary H. Zhang, Beeya Na, Nelson B. Schiller, Mary A. Whooley. (2010) Resistin, exercise capacity, and inducible ischemia in patients with stable coronary heart disease: Data from the Heart and Soul study. Atherosclerosis 213:2, 604-610
CrossRef84
Natalie J. Carter. (2010) Rosuvastatin. American Journal Cardiovascular Drugs 10:6, 383-400
CrossRef85
Patrícia Lourenço, José Paulo Araújo, Cristiana Paulo, Joana Mascarenhas, Fernando Friões, Ana Azevedo, Paulo Bettencourt. (2010) Higher C-Reactive Protein Predicts Worse Prognosis in Acute Heart Failure Only in Noninfected Patients. Clinical Cardiology 33:11, 708-714
CrossRef86
L. M. Biasucci, I. Porto. (2010) Has atorvastatin more than a DUAAL face?. European Heart Journal 31:21, 2567-2568
CrossRef87
Sanjiv M. Narayan. 2010. Preventing Sudden Cardiac Arrest in the Heart Failure Patient. , 177-195.
CrossRef88
Sadik Acikel, Haldun Muderrisoglu, Aylin Yildirir, Alp Aydinalp, Elif Sade, Nilufer Bayraktar, Ugur Bal, Bulent Ozin. (2010) Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography. Blood Coagulation & Fibrinolysis1
CrossRef89
Masamichi Yoshika, Yutaka Komiyama, Midori Masuda, Toyohiko Yokoi, Hiroya Masaki, Hiroe Ohkura, Hakuo Takahashi. (2010) Pitavastatin Further Decreases Serum High-Sensitive C-Reactive Protein Levels in Hypertensive Patients with Hypercholesterolemia Treated with Angiotensin II, Type-1 Receptor Antagonists. Clinical and Experimental Hypertension 32:6, 341-346
CrossRef90
Ulrich Laufs, Uta C. Hoppe, Stephan Rosenkranz, Paulus Kirchhof, Michael Böhm, Hans-Christoph Diener, Matthias Endres, Martin Grond, Werner Hacke, Thomas Meinertz, E. Bernd Ringelstein, Joachim Röther, Martin Dichgans. (2010) Cardiological evaluation after cerebral ischaemia. Clinical Research in Cardiology 99:10, 609-625
CrossRef91
R. Caesar, F. Fåk, F. Bäckhed. (2010) Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. Journal of Internal Medicine 268:4, 320-328
CrossRef92
Raffaele De Caterina, Marika Massaro, Egeria Scoditti, Maria Annunziata Carluccio. (2010) Pharmacological modulation of vascular inflammation in atherothrombosis. Annals of the New York Academy of Sciences 1207:1, 23-31
CrossRef93
Terry A Jacobson, Peter H Jones, Eli M Roth. (2010) Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia: overview of efficacy and safety. Clinical Lipidology 5:5, 627-649
CrossRef94
Andrea Corsonello, Sabrina Garasto, Angela Marie Abbatecola, Giuseppina Rose, Giuseppe Passarino, Bruno Mazzei, Luigi Pranno, Enrico Eugenio Guffanti, Silvia Bustacchini, Fabrizia Lattanzio. (2010) Targeting inflammation to slow or delay functional decline: where are we?. Biogerontology 11:5, 603-614
CrossRef95
Juan Carlos Kaski, Daniel J. Fernández-Bergés, Luciano Consuegra-Sánchez, José M. Cruz Fernández, Xavier García-Moll, José M. Mostaza, Rocío Toro Cebada, José Ramón González Juanatey, Gabriela Guzmán Martínez, Jaume Marrugat. (2010) A comparative study of biomarkers for risk prediction in acute coronary syndrome—Results of the SIESTA (Systemic Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study. Atherosclerosis 212:2, 636-643
CrossRef96
Jiangtao Yan, James K. Liao, Daowen Wang. (2010) Elevated homocysteine and C-reactive protein levels independently predict worsening prognosis after stroke in Chinese patients. Journal of Huazhong University of Science and Technology [Medical Sciences] 30:5, 643-647
CrossRef97
Ioannis K. Karalis, Sandrin C. Bergheanu, Ron Wolterbeek, Geesje M. Dallinga-Thie, Hiroaki Hattori, Arie van Tol, Anho H. Liem, J. Wouter Jukema. (2010) Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. Current Medical Research and Opinion 26:10, 2301-2313
CrossRef98
Duane A. Burnett, Harry R. Davis. 2010. Atherosclerosis I: LDL Cholesterol Lowering. .
CrossRef99
Pradeep K Nair, Suresh R Mulukutla, Oscar C Marroquin. (2010) Stents and statins: history, clinical outcomes and mechanisms. Expert Review of Cardiovascular Therapy 8:9, 1283-1295
CrossRef100
Robert S. Rosenson, Colin Hislop, Michael Elliott, Yuri Stasiv, Michael Goulder, David Waters. (2010) Effects of Varespladib Methyl on Biomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients. Journal of the American College of Cardiology 56:14, 1079-1088
CrossRef101
G. Corso, E. Bottacchi, A. Brusa, M. Di Benedetto, G. Giardini, C. Lia, M. Reggiani, M. Veronese Morosini. (2010) Is there a prognostic role for C-reactive protein in ischemic stroke?. Acta Neurologica Scandinavica 122:3, 209-216
CrossRef102
Amit V. Khera, Megan L. Wolfe, Christopher P. Cannon, Jie Qin, Daniel J. Rader. (2010) On-Statin Cholesteryl Ester Transfer Protein Mass and Risk of Recurrent Coronary Events (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 [PROVE IT-TIMI 22] Study). The American Journal of Cardiology 106:4, 451-456
CrossRef103
F. Felices-Abad, J. Latour-Pérez, M.P. Fuset-Cabanes, M. Ruano-Marco, J. Cuñat-de la Hoz, F. del Nogal-Sáez. (2010) Indicadores de calidad en el síndrome coronario agudo para el análisis del proceso asistencial pre e intrahospitalario. Medicina Intensiva 34:6, 397-417
CrossRef104
S. A. E. Peters, M. K. Palmer, D. E. Grobbee, J. R. Crouse, D. H. O’Leary, J. S. Raichlen, M. L. Bots. (2010) C-reactive protein lowering with rosuvastatin in the METEOR study. Journal of Internal Medicine 268:2, 155-161
CrossRef105
Alexandre B. Rosendo, Luciana O. Lima, Felipe Dal-Pizzol, Silvana Almeida. (2010) Lipid and C-Reactive Protein Levels, Cardiovascular Disease Risk Factors and Simvastatin Treatment in Brazilian Individuals. Inflammation 33:4, 244-250
CrossRef106
James D. Chalmers, Philip M. Short, Pallavi Mandal, Ahsan R. Akram, Adam T. Hill. (2010) Statins in community acquired pneumonia: Evidence from experimental and clinical studies. Respiratory Medicine 104:8, 1081-1091
CrossRef107
Basem Azab, Medhat Zaher, Kera F. Weiserbs, Estelle Torbey, Kenson Lacossiere, Sainath Gaddam, Romel Gobunsuy, Sunil Jadonath, Duccio Baldari, Donald McCord, James Lafferty. (2010) Usefulness of Neutrophil to Lymphocyte Ratio in Predicting Short- and Long-Term Mortality After Non–ST-Elevation Myocardial Infarction. The American Journal of Cardiology 106:4, 470-476
CrossRef108
Feng Xue, Xiangjun Yang, Bing Zhang, Caiming Zhao, Jianping Song, Tingbo Jiang, Wenping Jiang. (2010) Postconditioning the Human Heart in Percutaneous Coronary Intervention. Clinical Cardiology 33:7, 439-444
CrossRef109
Kausik K. Ray, Babak Nazer, Richard Cairns, C. Michael Gibson, Christopher P. Cannon. (2010) Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes. Journal of Thrombosis and Thrombolysis 30:1, 10-13
CrossRef110
Petter Quist-Paulsen. (2010) Statins and inflammation: an update. Current Opinion in Cardiology 25:4, 399-405
CrossRef111
G.F. Gensini, A.M. Gori, B. Dilaghi, C. Rostagno, A. Gaw, L.M. Blanco-Colio, E. de Teresa, J. Egido, C. Farsang, L.A. Leiter, P. Martineau, A. Nozza, A. Langer. (2010) Effect of atorvastatin on circulating hsCRP concentrations: A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. International Journal of Cardiology 142:3, 257-264
CrossRef112
Anders Hovland, Inger Aagnes, Ole-Lars Brekke, John Helge Flage, Knut Tore Lappegård. (2010) No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treated with statins. Journal of Clinical Lipidology 4:4, 288-292
CrossRef113
Paul M. Ridker, Jean MacFadyen, Peter Libby, Robert J. Glynn. (2010) Relation of Baseline High-Sensitivity C-Reactive Protein Level to Cardiovascular Outcomes With Rosuvastatin in the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). The American Journal of Cardiology 106:2, 204-209
CrossRef114
Batya B Davidovici, Naveed Sattar, Prinz C Jörg, Luis Puig, Paul Emery, Jonathan N Barker, Peter van de Kerkhof, Mona Ståhle, Frank O Nestle, Giampiero Girolomoni, James G Krueger. (2010) Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions. Journal of Investigative Dermatology 130:7, 1785-1796
CrossRef115
Eric B. Loucks, Louise Pilote, John W. Lynch, Hugues Richard, Nisha D. Almeida, Emelia J. Benjamin, Joanne M. Murabito. (2010) Life course socioeconomic position is associated with inflammatory markers: The Framingham Offspring Study. Social Science & Medicine 71:1, 187-195
CrossRef116
Sakiko Inamoto, Toshitaka Yoshioka, Chika Yamashita, Masatoshi Miyamura, Tatsuhiko Mori, Akira Ukimura, Chika Matsumoto, Yasuo Matsumura, Yasushi Kitaura, Tetsuya Hayashi. (2010) Pitavastatin reduces oxidative stress and attenuates intermittent hypoxia-induced left ventricular remodeling in lean mice. Hypertension Research 33:6, 579-586
CrossRef117
Furio Colivicchi, Marco Tubaro, David Mocini, Alberto Genovesi Ebert, Stefano Strano, Giovanni Melina, Massimo Uguccioni, Massimo Santini. (2010) Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease. Current Medical Research and Opinion 26:6, 1277-1284
CrossRef118
Gina Biasillo, Milena Leo, Roberta Della Bona, Luigi Marzio Biasucci. (2010) Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Internal and Emergency Medicine 5:3, 225-233
CrossRef119
Tomotaka Dohi, Katsumi Miyauchi, Shinya Okazaki, Takayuki Yokoyama, Naotake Yanagisawa, Hiroshi Tamura, Takahiko Kojima, Ken Yokoyama, Takeshi Kurata, Hiroyuki Daida. (2010) Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): A follow-up study. Atherosclerosis 210:2, 497-502
CrossRef120
Raquel Melchior Roman, Paulo Vicente Camargo, Flávia Kessler Borges, Ana Paula Rossini, Carisi Anne Polanczyk. (2010) Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients. Coronary Artery Disease 21:3, 129-136
CrossRef121
I. Hernández-Lahoz Ortiz, J. Paz-Esquete, J.M. Vázquez-Lago, R. García-Casas. (2010) Valor predictivo de la PCR-hs en pacientes revascularizados por isquemia crítica de miembros inferiores. Angiología 62:3, 110-117
CrossRef122
Chan Seok Park, Sang-Hyun Ihm, Ki-Dong Yoo, Dong-Bin Kim, Jong-Min Lee, Hee-Yeol Kim, Wook-Sung Chung, Ki Bae Seung, Jae-Hyung Kim. (2010) Relation Between C-Reactive Protein, Homocysteine Levels, Fibrinogen, and Lipoprotein Levels and Leukocyte and Platelet Counts, and 10-Year Risk for Cardiovascular Disease Among Healthy Adults in the USA. The American Journal of Cardiology 105:9, 1284-1288
CrossRef123
George S. Abela. (2010) Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. Journal of Clinical Lipidology 4:3, 156-164
CrossRef124
C L Raison, A S Borisov, B J Woolwine, Breanne Massung, G Vogt, A H Miller. (2010) Interferon-α effects on diurnal hypothalamic–pituitary–adrenal axis activity: relationship with proinflammatory cytokines and behavior. Molecular Psychiatry 15:5, 535-547
CrossRef125
P. M. Ridker. (2010) Psoriasis, inflammation, and vascular risk: a problem more than skin deep?. European Heart Journal 31:8, 902-904
CrossRef126
U. Laufs, U.C. Hoppe, S. Rosenkranz, P. Kirchhof, M. Böhm, H.-C. Diener, M. Endres, M. Grond, W. Hacke, T. Meinertz, E.B. Ringelstein, J. Röther, M. Dichgans. (2010) Kardiologische Diagnostik nach zerebraler Ischämie. Der Nervenarzt 81:4, 444-462
CrossRef127
Vasilios G. Athyros, Konstantinos Tziomalos, Matilda Florentin, Asterios Karagiannis, Dimitri P. Mikhailidis. (2010) Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?. Current Medical Research and Opinion 26:4, 839-842
CrossRef128
Yasushi Akutsu, Kyouichi Kaneko, Yusuke Kodama, Hui-Ling Li, Jumpei Suyama, Akira Shinozuka, Takehiko Gokan, Mitsuharu Kawamura, Taku Asano, Yuji Hamazaki, Kaoru Tanno, Youichi Kobayashi. (2010) Significance of cardiac sympathetic nervous system abnormality for predicting vascular events in patients with idiopathic paroxysmal atrial fibrillation. European Journal of Nuclear Medicine and Molecular Imaging 37:4, 742-749
CrossRef129
Benjamin M. Scirica. (2010) Acute Coronary Syndrome. Journal of the American College of Cardiology 55:14, 1403-1415
CrossRef130
Paul M. Ridker, Jean MacFadyen, Michael Cressman, Robert J. Glynn. (2010) Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein. Journal of the American College of Cardiology 55:12, 1266-1273
CrossRef131
Simona Mega, Giuseppe Patti, Christopher P. Cannon, Germano Di Sciascio. (2010) Preprocedural Statin Therapy to Prevent Myocardial Damage in Percutaneous Coronary Intervention. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:1, 19-22
CrossRef132
Cedric Delhaye, Gabriel Maluenda, Kohei Wakabayashi, Itsik Ben-Dor, Gilles Lemesle, Sara D. Collins, Asmir I. Syed, Rebecca Torguson, Kimberly Kaneshige, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, Augusto D. Pichard, Ron Waksman. (2010) Long-Term Prognostic Value of Preprocedural C-Reactive Protein After Drug-Eluting Stent Implantation. The American Journal of Cardiology 105:6, 826-832
CrossRef133
Subroto Acharjee, Jie Qin, Sabina A. Murphy, Carolyn McCabe, Christopher P. Cannon. (2010) Distribution of Traditional and Novel Risk Factors and Their Relation to Subsequent Cardiovascular Events in Patients With Acute Coronary Syndromes (from the PROVE IT-TIMI 22 Trial). The American Journal of Cardiology 105:5, 619-623
CrossRef134
Craig D. Ferguson, Paula Clancy, Bernard Bourke, Philip J. Walker, Anthony Dear, Tim Buckenham, Paul Norman, Jonathan Golledge. (2010) Association of statin prescription with small abdominal aortic aneurysm progression. American Heart Journal 159:2, 307-313
CrossRef135
Sabin Shurraw, Marcello Tonelli. (2010) AURORA: Is There a Role for Statin Therapy in Dialysis Patients?. American Journal of Kidney Diseases 55:2, 237-240
CrossRef136
George S Abela. (2010) Role of cholesterol crystals in myocardial infarction and stroke. Clinical Lipidology 5:1, 57-69
CrossRef137
Young Song, Young Lan Kwak, Yong Seon Choi, Jong Chan Kim, Sang Baek Heo, Jae Kwang Shim. (2010) Effect of preoperative statin therapy on myocardial protection and morbidity endpoints following off-pump coronary bypass surgery in patients with elevated C-reactive protein level. Korean Journal of Anesthesiology 58:2, 136
CrossRef138
S. Sixt, S. Beer, M. Bluher, N. Korff, T. Peschel, M. Sonnabend, D. Teupser, J. Thiery, V. Adams, G. Schuler, J. Niebauer. (2010) Long- but not short-term multifactorial intervention with focus on exercise training improves coronary endothelial dysfunction in diabetes mellitus type 2 and coronary artery disease. European Heart Journal 31:1, 112-119
CrossRef139
Shinichiro UEDA. (2010) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 41:3, 90-94
CrossRef140
Hisashi Kai. (2010) Novel non-invasive approach for visualizing inflamed atherosclerotic plaques using fluorodeoxyglucose-positron emission tomography. Geriatrics & Gerontology International 10:1, 1-8
CrossRef141
Katsumi Miyauchi, Hiroyuki Daida. (2010) Clinical Significance of Intensive Lipid-Lowering Therapy Using Statins in Patients With Coronary Artery Disease. Circulation Journal 74:8, 1718-1730
CrossRef142
Yoshifumi Saisho, Hiroshi Hirose, Yoshie Seino, Ikuo Saito, Hiroshi Itoh. (2010) Usefulness of C-Reactive Protein to High-Molecular-Weight Adiponectin Ratio to Predict Insulin Resistance and Metabolic Syndrome in Japanese Men. Journal of Atherosclerosis and Thrombosis 17:9, 944-952
CrossRef143
Terumasa Inoue, Makoto Kawai, Tokiko Nakane, Ayumi Nojiri, Kosuke Minai, Kimiaki Komukai, Takayuki Ogawa, Kenichi Hongo, Masato Matsushima, Michihiro Yoshimura. (2010) Influence of Low-Grade Inflammation on Plasma B-type Natriuretic Peptide Levels. Internal Medicine 49:24, 2659-2668
CrossRef144
Rishi Gupta, Archit Bhatt, Mounzer Kassab, Arshad Majid. (2010) Elevated Levels of Pre-Procedural High-Sensitivity C-Reactive Protein Is Associated with Midterm Restenosis after Extra- and Intracranial Stenting. Journal of Neuroimaging 20:1, 74-77
CrossRef145
Azza S. Awad, Rehab Kamel. (2010) Effect of rosuvastatin on cholestasis-induced hepatic injury in rat livers. Journal of Biochemical and Molecular Toxicologyn/a-n/a
CrossRef146
Shepard D. Weiner, LeRoy E. Rabbani. (2010) Secondary prevention strategies for coronary heart disease. Journal of Thrombosis and Thrombolysis 29:1, 8-24
CrossRef147
Parag H. Joshi, Terry A. Jacobson. (2010) Therapeutic Options to Further Lower C-Reactive Protein for Patients on Statin Treatment. Current Atherosclerosis Reports 12:1, 34-42
CrossRef148
Konstantinos Tziomalos, Hariklia V. Dimitroula, Niki Katsiki, Christos Savopoulos, Apostolos I. Hatzitolios. (2010) Effects of Lifestyle Measures, Antiobesity Agents, and Bariatric Surgery on Serological Markers of Inflammation in Obese Patients. Mediators of Inflammation 2010, 1-14
CrossRef149
Jonathan M. Meyer, Joseph P. McEvoy, Vicki G. Davis, Donald C. Goff, Henry A. Nasrallah, Sonia M. Davis, John K. Hsiao, Marvin S. Swartz, T. Scott Stroup, Jeffrey A. Lieberman. (2009) Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. Biological Psychiatry 66:11, 1013-1022
CrossRef150
S. Devaraj, J.-M. Yun, G. Adamson, J. Galvez, I. Jialal. (2009) C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovascular Research 84:3, 479-484
CrossRef151
Carl J. Lavie, Richard V. Milani, Anil Verma, James H. OʼKeefe. (2009) C-Reactive Protein and Cardiovascular Diseases—Is it Ready for Primetime?. The American Journal of the Medical Sciences 338:6, 486-492
CrossRef152
Peter Libby, Paul M. Ridker, Göran K. Hansson. (2009) Inflammation in Atherosclerosis. Journal of the American College of Cardiology 54:23, 2129-2138
CrossRef153
Vicente Bertomeu Martínez, J. Ramón González-Juanatey. (2009) Markers of Inflammation and Cardiovascular Disease. American Journal Cardiovascular Drugs 9:Supplement 1, 3-7
CrossRef154
Stephen J Nicholls. (2009) Relationship between LDL, HDL, blood pressure and atheroma progression in the coronaries. Current Opinion in Lipidology 20:6, 491-496
CrossRef155
Julio Núñez, Juan Sanchis, Vicent Bodí, Eduardo Núñez, Anne M. Heatta, Gema Miñana, Pilar Merlos, Eva Rumiz, Patricia Palau, Rafael Sanjuán, Maria L. Blasco, Angel Llàcer. (2009) Therapeutic implications of low lymphocyte count in non-ST segment elevation acute coronary syndromes. European Journal of Internal Medicine 20:8, 768-774
CrossRef156
Helene Glassberg. (2009) Statins in the prevention of heart failure after myocardial infarction. Current Heart Failure Reports 6:4, 215-219
CrossRef157
R. Klingenberg, G. K. Hansson. (2009) Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. European Heart Journal 30:23, 2838-2844
CrossRef158
Giuseppe Lippi, Massimo Franchini, Martina Montagnana, Emmanuel J. Favaloro, Gian Cesare Guidi, Giovanni Targher. (2009) Dark chocolate: consumption for pleasure or therapy?. Journal of Thrombosis and Thrombolysis 28:4, 482-488
CrossRef159
Flávia K. Borges, Fernando K. Borges, Steffan F. Stella, Juliana F. Souza, Andréa E. Wendland, Luis Carlos Werres Junior, Jorge P. Ribeiro, CarÃsi A. Polanczyk. (2009) Serial Analyses of C-Reactive Protein and Myeloperoxidase in Acute Coronary Syndrome. Clinical Cardiology 32:11, E58-E62
CrossRef160
A. S. Wierzbicki. (2009) Hot and bothered: C-reactive protein, inflammation and atherosclerosis. International Journal of Clinical Practice 63:11, 1550-1553
CrossRef161
Sylvie Perreault, Alice Dragomir, Lucie Blais, Anick Bérard, Lyne Lalonde, Michel White, Danielle Pilon. (2009) Impact of better adherence to statin agents in the primary prevention of coronary artery disease. European Journal of Clinical Pharmacology 65:10, 1013-1024
CrossRef162
Ali A. Rizvi. (2009) Cytokine Biomarkers, Endothelial Inflammation, and Atherosclerosis in the Metabolic Syndrome: Emerging Concepts. The American Journal of the Medical Sciences 338:4, 310-318
CrossRef163
B.G. Nordestgaard, J. Zacho. (2009) Lipids, atherosclerosis and CVD risk: Is CRP an innocent bystander?. Nutrition, Metabolism and Cardiovascular Diseases 19:8, 521-524
CrossRef164
S. G. WANNAMETHEE, P. H. WHINCUP, A. G. SHAPER, A. RUMLEY, L. LENNON, G. D. O. LOWE. (2009) Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men. Journal of Thrombosis and Haemostasis 7:10, 1605-1611
CrossRef165
Abdulmaged M. Traish, Robert J. Feeley, Andre Guay. (2009) Mechanisms of obesity and related pathologies: Androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. FEBS Journal 276:20, 5755-5767
CrossRef166
A. Kumar, C. P. Cannon. (2009) Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clinic Proceedings 84:10, 917-938
CrossRef167
Schouten, Olaf, Boersma, Eric, Hoeks, Sanne E., Benner, Robbert, van Urk, Hero, van Sambeek, Marc R.H.M., Verhagen, Hence J.M., Khan, Nisar A., Dunkelgrun, Martin, Bax, Jeroen J., Poldermans, Don, . (2009) Fluvastatin and Perioperative Events in Patients Undergoing Vascular Surgery. New England Journal of Medicine 361:10, 980-989
Full Text168
D. Baldassarre, B. Porta, M. Camera, M. Amato, M. Arquati, B. Brusoni, C. Fiorentini, P. Montorsi, S. Romano, F. Veglia, E. Tremoli, M. Cortellaro. (2009) Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. Nutrition, Metabolism and Cardiovascular Diseases 19:7, 481-490
CrossRef169
Oliver Zimmermann, Magdalena Bienek-Ziolkowski, Bettina Wolf, Martin Vetter, Regine Baur, Volker Mailänder, Vinzenz Hombach, Jan Torzewski. (2009) Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein?. Basic Research in Cardiology 104:5, 591-599
CrossRef170
Francisco AH Fonseca, Maria Cristina O Izar. (2009) Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study. Expert Review of Cardiovascular Therapy 7:9, 1041-1056
CrossRef171
Jens Metrikat, Marlies Albrecht, Peter Maya-Pelzer, Jan R. Ortlepp. (2009) Physical fitness is associated with lower inflammation, even in individuals with high cholesterol – An alternative to statin therapy?. CVD Prevention and Control 4:3, 149-156
CrossRef172
T Wethal, M-B Lund, T Edvardsen, S D Fosså, A H Pripp, H Holte, J Kjekshus, A Fosså. (2009) Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. British Journal of Cancer 101:4, 575-581
CrossRef173
Louai Razzouk, Paul Muntner, Sameer Bansilal, Annapoorna S. Kini, Ashish Aneja, Joshua Mozes, Oana Ivan, Madhavi Jakkula, Samin Sharma, Michael E. Farkouh. (2009) C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention. American Heart Journal 158:2, 277-283
CrossRef174
Stephan Gielen, Marcus Sandri, Gerhard Schuler, Daniel Teupser. (2009) Risk factor management: antiatherogenic therapies. European Journal of Cardiovascular Prevention & Rehabilitation 16:Supplement 1, S29-S36
CrossRef175
Fred A. Kummerow. (2009) The negative effects of hydrogenated trans fats and what to do about them. Atherosclerosis 205:2, 458-465
CrossRef176
Femke A. M. V. I. Hellenthal, Willem A. Buurman, Will K. W. H. Wodzig, Geert Willem H. Schurink. (2009) Biomarkers of abdominal aortic aneurysm progression. Part 2: inflammation. Nature Reviews Cardiology 6:8, 543-552
CrossRef177
Anju Nohria, Adnan Prsic, Ping-Yen Liu, Ryuji Okamoto, Mark A. Creager, Andrew Selwyn, James K. Liao, Peter Ganz. (2009) Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 205:2, 517-521
CrossRef178
Young Joon Hong, Myung Ho Jeong, Yun Ha Choi, Jum Suk Ko, Min Goo Lee, Won Yu Kang, Shin Eun Lee, Soo Hyun Kim, Keun Ho Park, Doo Sun Sim, Nam Sik Yoon, Hyun Ju Youn, Kye Hun Kim, Hyung Wook Park, Ju Han Kim, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2009) Predictors of no-reflow after percutaneous coronary intervention for culprit lesion with plaque rupture in infarct-related artery in patients with acute myocardial infarction. Journal of Cardiology 54:1, 36-44
CrossRef179
Raul D. Santos, Khurram Nasir. (2009) Insights into atherosclerosis from invasive and non-invasive imaging studies: Should we treat subclinical atherosclerosis?. Atherosclerosis 205:2, 349-356
CrossRef180
Kazunori Hashimoto, Muthuvel Jayachandran, Whyte G Owen, Virginia M Miller. (2009) Aggregation and Microparticle Production Through Toll-like Receptor 4 Activation in Platelets From Recently Menopausal Women. Journal of Cardiovascular Pharmacology 54:1, 57-62
CrossRef181
Peter A. Kavsak, Xuesong Wang, Matthew Henderson, Dennis T. Ko, Andrew R. MacRae, Allan S. Jaffe. (2009) PAPP-A as a marker of increased long-term risk in patients with chest pain. Clinical Biochemistry 42:10-11, 1012-1018
CrossRef182
James C. Thomas, Ravinder S. Vohra, Sarah Beer, Kashif Bhatti, Sreenivasan Ponnambalam, Shervanthi Homer-Vanniasinkam. (2009) Biomarkers in Peripheral Arterial Disease. Trends in Cardiovascular Medicine 19:5, 147-151
CrossRef183
Cédric Delhaye, Arnaud Sudre, Gilles Lemesle, Sylvestre Maréchaux, Damien Broucqsault, Bernadette Hennache, Christophe Bauters, Jean-Marc Lablanche. (2009) Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention. Cardiovascular Revascularization Medicine 10:3, 144-150
CrossRef184
Miriam Jacob, Leslie Cho. (2009) Lipid reduction in acute coronary syndrome: How much, when, and how?. Current Cardiology Reports 11:4, 276-281
CrossRef185
James K. Liao. (2009) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. Current Atherosclerosis Reports 11:4, 243-244
CrossRef186
Subodh Verma, Eva M. Lonn, Alykhan Nanji, Kevin Browne, Richard Ward, Annette Robertson, Heather Conradson, Kathy Hildebrand, Rollin Brant, Todd J. Anderson. (2009) Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: The Ramipril C-Reactive pRotein Randomized evaluation (4R) trial results. Canadian Journal of Cardiology 25:7, e236-e240
CrossRef187
Maurizio S. Tonetti. (2009) Periodontitis and risk for atherosclerosis: an update on intervention trials. Journal of Clinical Periodontology 36, 15-19
CrossRef188
Paul M Ridker, Robert J Glynn. (2009) Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial – Authors' reply. The Lancet 374:9683, 26-27
CrossRef189
Stephen D. Wiviott, Satishkumar Mohanavelu, Joel S. Raichlen, Valerie A. Cain, Steven E. Nissen, Peter Libby. (2009) Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein Cholesterol Levels With Rosuvastatin 40 mg Daily (from the ASTEROID Study). The American Journal of Cardiology 104:1, 29-35
CrossRef190
Paul M. Ridker. (2009) Moving toward new statin guidelines in a post-JUPITER world: Principles to consider. Current Atherosclerosis Reports 11:4, 249-256
CrossRef191
Kenya Nasu, Etsuo Tsuchikane, Osamu Katoh, Nobuyoshi Tanaka, Masashi Kimura, Mariko Ehara, Yoshihisa Kinoshita, Tetsuo Matsubara, Hitoshi Matsuo, Keiko Asakura, Yasushi Asakura, Mitsuyasu Terashima, Tadateru Takayama, Junko Honye, Atsushi Hirayama, Satoshi Saito, Takahiko Suzuki. (2009) Effect of Fluvastatin on Progression of Coronary Atherosclerotic Plaque Evaluated by Virtual Histology Intravascular Ultrasound. JACC: Cardiovascular Interventions 2:7, 689-696
CrossRef192
PAUL M. RIDKER. (2009) Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). Journal of Thrombosis and Haemostasis 7, 332-339
CrossRef193
D. C. Wheeler. (2009) The Jupiter trial--new territory for statins?. Nephrology Dialysis Transplantation 24:7, 2036-2037
CrossRef194
Christopher R. deFilippi, Stephen L. Seliger. (2009) Biomarkers for Prognostication After Acute Coronary Syndromes. Journal of the American College of Cardiology 54:4, 365-367
CrossRef195
Alex D.H. Brown, David A. Barton, Gavin W. Lambert. (2009) Cardiovascular Abnormalities in Patients with Major Depressive Disorder. CNS Drugs 23:7, 583-602
CrossRef196
Wen Qiang Chen, Lin Zhong, Lei Zhang, Xiao Ping Ji, Yu Xia Zhao, Cheng Zhang, Hong Jiang, Yi Ling Wu, Yun Zhang. (2009) Chinese medicine tongxinluo significantly lowers serum lipid levels and stabilizes vulnerable plaques in a rabbit model. Journal of Ethnopharmacology 124:1, 103-110
CrossRef197
B. Bankier, J. Barajas, A. Martinez-Rumayor, J. L. Januzzi. (2009) Association Between Anxiety and C-Reactive Protein Levels in Stable Coronary Heart Disease Patients. Psychosomatics 50:4, 347-353
CrossRef198
2009. Risk Assessment for Complications of Diabetes Mellitus. , 195-241.
CrossRef199
René R. S. Packard, Andrew H. Lichtman, Peter Libby. (2009) Innate and adaptive immunity in atherosclerosis. Seminars in Immunopathology 31:1, 5-22
CrossRef200
Anne Fougerat, Stéphanie Gayral, Nicole Malet, Fabienne Briand-Mesange, Monique Breton-Douillon, Muriel Laffargue. (2009) Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis?. Clinical Science 116:11, 791-804
CrossRef201
Viviane Z. Rocha, Peter Libby. (2009) Obesity, inflammation, and atherosclerosis. Nature Reviews Cardiology 6:6, 399-409
CrossRef202
Paolo Calabrò, Enrica Golia, Edward T. H. Yeh. (2009) CRP and the risk of atherosclerotic events. Seminars in Immunopathology 31:1, 79-94
CrossRef203
Peter W. Parodi. (2009) Has the association between saturated fatty acids, serum cholesterol and coronary heart disease been over emphasized?. International Dairy Journal 19:6-7, 345-361
CrossRef204
José L. Martín-Ventura, Luis M. Blanco-Colio, José Tuñón, Begoña Muñoz-García, Julio Madrigal-Matute, Juan A. Moreno, Melina Vega de Céniga, Jesús Egido. (2009) Biomarcadores en la medicina cardiovascular. Revista Española de Cardiología 62:6, 677-688
CrossRef205
Alexander Torres, Ali D Askari, Charles J Malemud. (2009) Cardiovascular disease complications in systemic lupus erythematosus. Biomarkers in Medicine 3:3, 239-252
CrossRef206
Erdal Cavusoglu. 2009. The Effects of Antiplatelet, Antithrombotic, and Thrombolytic Agents on Inflammation and Circulating Inflammatory Biomarkers. , 67-98.
CrossRef207
Robert A. Stockley. (2009) Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention. Current Medical Research and Opinion 25:5, 1235-1245
CrossRef208
Ramón Arroyo-Espliguero, Pablo Avanzas, Juan Quiles, Juan Carlos Kaski. (2009) Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease. Atherosclerosis 204:1, 239-243
CrossRef209
Gianna Fabbri, Aldo Pietro Maggioni. (2009) Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?. Advances in Therapy 26:5, 469-487
CrossRef210
Paul M Ridker, Daniel H. Solomon. (2009) Should patients with rheumatoid arthritis receive statin therapy?. Arthritis & Rheumatism 60:5, 1205-1209
CrossRef211
Carla Schulze Horn, Ruediger Ilg, Kerstin Sander, Horst Bickel, Claus Briesenick, Bernhard Hemmer, Holger Poppert, Dirk Sander. (2009) High-sensitivity C-reactive protein at different stages of atherosclerosis: results of the INVADE study. Journal of Neurology 256:5, 783-791
CrossRef212
Paul M Ridker, Eleanor Danielson, Francisco AH Fonseca, Jacques Genest, Antonio M Gotto, John JP Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen, Børge G Nordestgaard, James Shepherd, James T Willerson, Robert J Glynn. (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. The Lancet 373:9670, 1175-1182
CrossRef213
Luisa Corral, María L. Carrió, Josep L. Ventura, Herminia Torrado, Casimiro Javierre, David Rodriguez-Castro, Elisabet Farrero, José Valero, Daniel Ortiz. (2009) Is C-Reactive Protein a Biomarker for Immediate Clinical Outcome After Cardiac Surgery?. Journal of Cardiothoracic and Vascular Anesthesia 23:2, 166-169
CrossRef214
Elena Galkina, Klaus Ley. (2009) Immune and Inflammatory Mechanisms of Atherosclerosis *. Annual Review of Immunology 27:1, 165-197
CrossRef215
D Gómez-Garre, P Muñoz-Pacheco, ML González-Rubio, P Aragoncillo, R Granados, A Fernández-Cruz. (2009) Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. British Journal of Pharmacology 156:8, 1218-1227
CrossRef216
Harry Southworth, Aaron Dane. (2009) Models for the analysis of C-reactive protein in statin trials. Pharmaceutical Statistics 8:2, 87-97
CrossRef217
L. Padayachee, R. N. Rodseth, B. M. Biccard. (2009) A meta-analysis of the utility of C-reactive protein in predicting early, intermediate-term and long term mortality and major adverse cardiac events in vascular surgical patients. Anaesthesia 64:4, 416-424
CrossRef218
Daria Pašalić, Natalija Marinković, Branka Gršković, Goran Ferenčak, Robert Bernat, Ana Stavljenić-Rukavina. (2009) C-reactive protein gene polymorphisms affect plasma CRP and homocysteine concentrations in subjects with and without angiographically confirmed coronary artery disease. Molecular Biology Reports 36:4, 775-780
CrossRef219
María G. Barderas, José Tuñón, Verónica M. Dardé, Fernando De la Cuesta, José J. Jiménez-Nácher, Nieves Tarín, Lorenzo López-Bescós, Jesús Egido, Fernando Vivanco. (2009) Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome. PROTEOMICS 9:7, 1982-1993
CrossRef220
Sheng-Bin Chen, Yi-Chih Lee, Kong-Han Ser, Jung-Chien Chen, Shu Chung Chen, Hsing-Fang Hsieh, Wei-Jei Lee. (2009) Serum C-Reactive Protein and White Blood Cell Count in Morbidly Obese Surgical Patients. Obesity Surgery 19:4, 461-466
CrossRef221
José Paulo Araújo, Patricia Lourenço, Ana Azevedo, Fernando Friões, Francisco Rocha-Gonçalves, António Ferreira, Paulo Bettencourt. (2009) Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure: A Systematic Review. Journal of Cardiac Failure 15:3, 256-266
CrossRef222
Angela D Armendariz, Ronald M Krauss. (2009) Hepatic nuclear factor 1-α: inflammation, genetics, and atherosclerosis. Current Opinion in Lipidology 20:2, 106-111
CrossRef223
(2009) Rosuvastatin in Patients with Elevated C-Reactive Protein. New England Journal of Medicine 360:10, 1038-1042
Full Text224
Stephan von Haehling, Mitja Lainscak, Jochen Springer, Stefan D. Anker. (2009) Cardiac cachexia: A systematic overview. Pharmacology & Therapeutics 121:3, 227-252
CrossRef225
Yuval Konstantino, Tu T. Nguyen, Robert Wolk, Robert J. Aiello, Steven G. Terra, David A. Fryburg. (2009) Potential implications of matrix metalloproteinase-9 in assessment and treatment of coronary artery disease. Biomarkers 14:2, 118-129
CrossRef226
Jiangtao Yan, Rutai Hui, Daowen Wang. (2009) Elevated C-reactive protein levels predict worsening prognosis in Chinese patients with first-onset stroke. Frontiers of Medicine in China 3:1, 30-35
CrossRef227
Sridevi Devaraj, Mohan R. Dasu, Uma Singh, L. Vijaya Mohan Rao, Ishwarlal Jialal. (2009) C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis 203:1, 67-74
CrossRef228
Wen Qiang Chen, Lin Zhong, Lei Zhang, Xiao Ping Ji, Mei Zhang, Yu Xia Zhao, Cheng Zhang, Yun Zhang. (2009) Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. British Journal of Pharmacology 156:6, 941-951
CrossRef229
Young Joon Hong, Myung Ho Jeong, Yun Ha Choi, Jum Suk Ko, Min Goo Lee, Won Yu Kang, Shin Eun Lee, Soo Hyun Kim, Keun Ho Park, Doo Sun Sim, Nam Sik Yoon, Hyun Ju Yoon, Kye Hun Kim, Hyung Wook Park, Ju Han Kim, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2009) Plaque Characteristics in Culprit Lesions and Inflammatory Status in Diabetic Acute Coronary Syndrome Patients. JACC: Cardiovascular Imaging 2:3, 339-349
CrossRef230
Sameed Ahmed M. Khatana, Tracey H. Taveira, Gaurav Choudhary, Charles B. Eaton, Wen-Chih Wu. (2009) Change in Hemoglobin A 1c and C-Reactive Protein Levels in Patients With Diabetes Mellitus. Journal of the CardioMetabolic Syndrome 4:2, 76-80
CrossRef231
Venkateshwar R. Polsani, Salim S. Virani, Vijay Nambi. (2009) Lipid management: Considerations in acute coronary syndrome. Current Atherosclerosis Reports 11:2, 149-156
CrossRef232
Alawi A. Alsheikh-Ali, Richard H. Karas. (2009) The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: Evidence from clinical trials. Current Atherosclerosis Reports 11:2, 100-104
CrossRef233
Douglas Triffon, Erminia Guarneri. 2009. Dyslipidemia and Atherosclerosis. .
CrossRef234
I. Jialal, S. Devaraj. (2009) Jupiter to Earth: CRP Promotes Atherothrombosis. Metabolic Syndrome and Related Disorders 7:1, 1-3
CrossRef235
Annapoorna S. Kini, Paul Muntner, Pedro R. Moreno, Devin Mann, Prakash Krishnan, Michael C. Kim, Oana C. Rafael, Michael E. Farkouh, Samin K. Sharma. (2009) Relation of High-Density Lipoprotein Cholesterol to Mortality After Percutaneous Coronary Interventions in Patients With Low-Density Lipoprotein <70 mg/dl. The American Journal of Cardiology 103:3, 350-354
CrossRef236
Meri P. Nantz, Cheryl A. Rowe, Jack F. Bukowski, Susan S. Percival. (2009) Standardized capsule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study. Nutrition 25:2, 147-154
CrossRef237
Milind Y Desai, Paul Schoenhagen. (2009) Emergence of targeted molecular imaging in atherosclerotic cardiovascular disease. Expert Review of Cardiovascular Therapy 7:2, 197-204
CrossRef238
S. I. VAN LEUVEN, R. S. BIRJMOHUN, R. FRANSSEN, R. J. BISOENDIAL, H. DE KORT, J. H. M. LEVELS, R. L. BASSER, J. C. M. MEIJERS, J. A. KUIVENHOVEN, J. J. KASTELEIN, E. S. STROES. (2009) ApoAI-phosphatidylcholine infusion neutralizes the atherothrombotic effects of C-reactive protein in humans. Journal of Thrombosis and Haemostasis 7:2, 347-354
CrossRef239
Daniel Bloomfield, Gary L. Carlson, Aditi Sapre, Diane Tribble, James M. McKenney, Thomas W. Littlejohn, Christine McCrary Sisk, Yale Mitchel, Richard C. Pasternak. (2009) Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. American Heart Journal 157:2, 352-360.e2
CrossRef240
Jaroslav Hubacek, Rashpal S Basran, Fiona M Shrive, Lana Shewchuk, David M Goodhart, Todd J Anderson. (2009) Prognostic implications of C-reactive protein and troponin following percutaneous coronary intervention. Canadian Journal of Cardiology 25:2, e42-e47
CrossRef241
Thomas A. Pearson, Christie M. Ballantyne, Enrico Veltri, Arvind Shah, Steven Bird, Jianxin Lin, Elizabeth Rosenberg, Andrew M. Tershakovec. (2009) Pooled Analyses of Effects on C-Reactive Protein and Low Density Lipoprotein Cholesterol in Placebo-Controlled Trials of Ezetimibe Monotherapy or Ezetimibe Added to Baseline Statin Therapy. The American Journal of Cardiology 103:3, 369-374
CrossRef242
H. Wedel, J. J.V. McMurray, M. Lindberg, J. Wikstrand, J. G.F. Cleland, J. H. Cornel, P. Dunselman, A. Hjalmarson, J. Kjekshus, M. Komajda, T. Kuusi, J. Vanhaecke, F. Waagstein, . (2009) Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. European Journal of Heart Failure 11:3, 281-291
CrossRef243
Takashi Motomura, Maki Okamoto, Tetsuhiro Kitamura, Hiroyasu Yamamoto, Michio Otsuki, Nobuyuki Asanuma, Miki Takagi, Shogo Kurebayashi, Kunihiko Hashimoto, Satoru Sumitani, Hiroshi Saito, Haruhiko Kouhara, Kazumasa Nshii, Makoto Nakao, Masafumi Koga, Bunzo Sato, Yasuhiko Morimoto, Soji Kasayama. (2009) Effects of Pitavastatin on Serum Lipids and High Sensitivity C-Reactive Protein in Type 2 Diabetic Patients. Journal of Atherosclerosis and Thrombosis 16:5, 546-552
CrossRef244
Christine Dalgård, Flemming Nielsen, Jason D. Morrow, Henrik Enghusen-Poulsen, Torbjörn Jonung, Mogens Hørder, Moniek P. M. de Maat. (2009) Supplementation with orange and blackcurrant juice, but not vitamin E, improves inflammatory markers in patients with peripheral arterial disease. British Journal of Nutrition 101:02, 263
CrossRef245
Konstantinos Tziomalos, Vasilios G. Athyros, Asterios Karagiannis, Dimitri P. Mikhailidis. (2009) JUPITER: major implications for vascular risk assessment. Current Medical Research and Opinion 25:1, 133-137
CrossRef246
V. G. Athyros, A. I. Kakafika, A. S. Wierzbicki, A. Karagiannis, D. P. Mikhailidis. (2009) Targeting triglycerides in secondary prevention: should we bother?. International Journal of Clinical Practice 63:1, 15-18
CrossRef247
Fang Luo, Xian-Liang Zhou, Jian-Jun Li, Ru-Tai Hui. (2009) Inflammatory response is associated with aortic dissection. Ageing Research Reviews 8:1, 31-35
CrossRef248
Mitchell S. V. Elkind. (2009) Inflammatory markers and stroke. Current Cardiology Reports 11:1, 12-20
CrossRef249
Marissa G. Daniels, Cheng-Hon Yap, Harshall Nandurkar, Andrew Macisaac, Michael Y. Yii. (2009) Inflammatory myocardial injury: the role of lymphocytes in atherosclerosis and other heart diseases. Journal of Organ Dysfunction 5:4, 224-232
CrossRef250
Goran Damnjanovic, Marija Jelic, Boris Djindjic, Stevan Ilic. (2009) Serum concentration of soluble adhesive molecules in patients with different forms of coronary artery disease. Vojnosanitetski pregled 66:4, 265-270
CrossRef251
Brendan M. Everett, Sandeep Bansal, Nader Rifai, Julie E. Buring, Paul M. Ridker. (2009) Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. Atherosclerosis 202:1, 282-288
CrossRef252
Kyeong Ho Yun, Ik-Sang Shin, Sang Jae Rhee, Eun Mi Lee, Nam Jin Yoo, Nam-Ho Kim, Seok Kyu Oh, Jin-Won Jeong. (2009) Clinical Significance of On-Treatment Triglyceride Level in Patients Treated by Percutaneous Coronary Intervention for Non-ST-Segment Elevation Acute Coronary Syndrome. The Korean Journal of Internal Medicine 24:4, 330
CrossRef253
Peter Ganz, Priscilla Y. Hsue. (2009) Individualized Approach to the Management of Coronary Heart Disease. Journal of the American College of Cardiology 53:4, 331-333
CrossRef254
A. Vijaya Anand, M. Chandrasekharan, S. Kalavathy, K. Uma, M.P. Saravanan, A. Mohamed Saleem Gani, K. Vijaya Kumar, R. Senthil, P. Sampath Kumar. (2009) The Influencing Aspects of Atorvastatin on C-Reactive Protein and Lipid Profile in Patients with Stroke. International Journal of Biological Chemistry 3:1, 30-34
CrossRef255
Anna Oksaharju, Jani Lappalainen, Anita M. Tuomainen, Pirkko J. Pussinen, Mirja Puolakkainen, Petri T. Kovanen, Ken A. Lindstedt. (2009) Pro-atherogenic lung and oral pathogens induce an inflammatory response in human and mouse mast cells. Journal of Cellular and Molecular Medicine 13:1, 103-113
CrossRef256
Yoshitaka Okamura. (2009) Is C-Reactive Protein a Predictor of Perioperative Events Before Coronary Artery Bypass?. Circulation Journal 73:5, 818-819
CrossRef257
Feng Xu, Yaning Sun, Yuguo Chen, Yi Sun, Ruijian Li, Chunxi Liu, Cheng Zhang, Rong Wang, Yun Zhang. (2009) Endothelial Cell Apoptosis is Responsible for the Formation of Coronary Thrombotic Atherosclerotic Plaques. The Tohoku Journal of Experimental Medicine 218:1, 25-33
CrossRef258
Kenei Shimada, Masatoshi Fujita, Atsushi Tanaka, Ken Yoshida, Satoshi Jisso, Hidemasa Tanaka, Junichi Yoshikawa, Takahide Kohro, Doubun Hayashi, Yoshihiro Okada, Tsutomu Yamazaki, Ryozo Nagai, The JCAD Investigators. (2009) Elevated Serum C-Reactive Protein Levels Predict Cardiovascular Events in the Japanese Coronary Artery Disease (JCAD) Study. Circulation Journal 73:1, 78-85
CrossRef259
Dae Hee Kim, Jae Kwang Shim, Seong Wook Hong, Kwang Rae Cho, Seung Youn Kang, Young Lan Kwak. (2009) Predictive Value of C-Reactive Protein for Major Postoperative Complications Following Off-Pump Coronary Artery Bypass Surgery. Circulation Journal 73:5, 872-877
CrossRef260
Boris Djindjic, Goran Rankovic, Misko Zivic, Todorka Savic, Mirjana Spasic, Maja Bubanj. (2009) Gender difference in hipolipemic and anti-inflammatory effects of statins in diabetics with coronary artery disease. Vojnosanitetski pregled 66:12, 966-972
CrossRef261
Jacques Bonnet, R. McPherson, A. Tedgui, D. Simoneau, A. Nozza, P. Martineau, Jean Davignon. (2008) Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: Results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clinical Therapeutics 30:12, 2298-2313
CrossRef262
Michael H. Davidson, Nicola Abate, Christie M. Ballantyne, Alberico L. Catapano, Xia Xu, Jianxin Lin, Elizabeth Rosenberg, Andrew M. Tershakovec. (2008) Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non–HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. Journal of Clinical Lipidology 2:6, 436-446
CrossRef263
Maritta K Pöyhönen-Alho, Karin Manhem, Per Katzman, Aleksandras Kibarskis, Riitta L Antikainen, Risto U Erkkola, Jaakko O Tuomilehto, Pertti E Ebeling, Risto J Kaaja. (2008) Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women. Journal of Hypertension 26:12, 2445-2449
CrossRef264
Vera Krane, Karl Winkler, Christiane Drechsler, Jürgen Lilienthal, Winfried März, Christoph Wanner. (2008) Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International 74:11, 1461-1467
CrossRef265
Ridker, Paul M, Danielson, Eleanor, Fonseca, Francisco A.H., Genest, Jacques, Gotto, Antonio M. Jr., Kastelein, John J.P., Koenig, Wolfgang, Libby, Peter, Lorenzatti, Alberto J., MacFadyen, Jean G., Nordestgaard, Børge G., Shepherd, James, Willerson, James T., Glynn, Robert J., . (2008) Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine 359:21, 2195-2207
Full Text266
Dolf Segers, Hector Garcia-Garcia, Caroline Cheng, Rini de Crom, Rob Krams, Jolanda Wentzel, Anton van der Steen, Patrick Serruys, Pieter Leenen, Jon Laman. (2008) A primer on the immune system in the pathogenesis and treatment of atherosclerosis. EuroIntervention 4:3, 378-390
CrossRef267
Bente Halvorsen, Kari Otterdal, Tuva B. Dahl, Mona Skjelland, Lars Gullestad, Erik Øie, Pål Aukrust. (2008) Atherosclerotic Plaque Stability—What Determines the Fate of a Plaque?. Progress in Cardiovascular Diseases 51:3, 183-194
CrossRef268
F. Roubille, G. Cayla, M.-C. Picot, V. Pradet, F. Massin, R. Gervasoni, J.-L. Pasquie, J.-C. Macia, C. Piot, F. Leclercq. (2008) Intérêt de la C-reactive protein (CRP) dans l’évaluation pronostique de l’infarctus du myocarde revascularisé. La Revue de Médecine Interne 29:11, 868-874
CrossRef269
Christopher P. Cannon, Robert P. Giugliano, Michael A. Blazing, Robert A. Harrington, John L. Peterson, Christine McCrary Sisk, John Strony, Thomas A. Musliner, Carolyn H. McCabe, Enrico Veltri, Eugene Braunwald, Robert M. Califf. (2008) Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. American Heart Journal 156:5, 826-832
CrossRef270
F. Montecucco, F. Burger, G. Pelli, N. K. Poku, C. Berlier, S. Steffens, F. Mach. (2008) Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology 48:3, 233-242
CrossRef271
Gloria Alvarez-Llamas, Fernando de la Cuesta, Maria Eugenia G Barderas, Veronica Darde, Luis R Padial, Fernando Vivanco. (2008) Recent advances in atherosclerosis-based proteomics: new biomarkers and a future perspective. Expert Review of Proteomics 5:5, 679-691
CrossRef272
Andrew T. Yan, Raymond T. Yan, Thao Huynh, Paul DeYoung, Andrew Weeks, David H. Fitchett, Anatoly Langer, Shaun G. Goodman. (2008) Bleeding and outcome in acute coronary syndrome: Insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. American Heart Journal 156:4, 769-775
CrossRef273
Kiran Musunuru, Brian G Kral, Roger S Blumenthal, Valentin Fuster, Catherine Y Campbell, Ty J Gluckman, Richard A Lange, Eric J Topol, James T Willerson, Milind Y Desai, Michael H Davidson, Samia Mora. (2008) The use of high-sensitivity assays for C-reactive protein in clinical practice. Nature Clinical Practice Cardiovascular Medicine 5:10, 621-635
CrossRef274
A. Bakhai. (2008) Adipokines--targeting a root cause of cardiometabolic risk. QJM 101:10, 767-776
CrossRef275
Richard J. Willke, Steve Zhou, Robert A. Vogel. (2008) Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience. Current Medical Research and Opinion 24:10, 2873-2882
CrossRef276
Koichiro Imai, Hiroyuki Okura, Teruyoshi Kume, Ryotaro Yamada, Yoshinori Miyamoto, Takahiro Kawamoto, Nozomi Watanabe, Yoji Neishi, Eiji Toyota, Kiyoshi Yoshida. (2008) C-Reactive protein predicts severity, progression, and prognosis of asymptomatic aortic valve stenosis. American Heart Journal 156:4, 713-718
CrossRef277
Seth D. Yandell, William C. Harvey, Neil J. Fernandes, Patrick W. Barr, Mark Feldman. (2008) Radioiodine Studies, Low Serum Thyrotropin, and the Influence of Statin Drugs. Thyroid 18:10, 1039-1042
CrossRef278
Mohammed Al-Omran, Muhammad M. Mamdani, Thomas F. Lindsay, Magda Melo, David N. Juurlink, Subodh Verma. (2008) Suboptimal use of statin therapy in elderly patients with atherosclerosis: A population-based study. Journal of Vascular Surgery 48:3, 607-612.e1
CrossRef279
Hiroshi Yamagami, Manabu Sakaguchi, Shigetaka Furukado, Taku Hoshi, Yuko Abe, Hidetaka Hougaku, Masatsugu Hori, Kazuo Kitagawa. (2008) Statin Therapy Increases Carotid Plaque Echogenicity in Hypercholesterolemic Patients. Ultrasound in Medicine & Biology 34:9, 1353-1359
CrossRef280
Alireza P. Shabanzadeh, Ashfaq Shuaib, Chen Xu Wang. (2008) Reduction of ischemic brain injury in rats with normothermic and hyperthermic conditions. Journal of Neurosurgery 109:3, 522-529
CrossRef281
Gerard J. Linden, Kathy McClean, Ian Young, Alun Evans, Frank Kee. (2008) Persistently raised C-reactive protein levels are associated with advanced periodontal disease. Journal of Clinical Periodontology 35:9, 741-747
CrossRef282
Barbara J. Messinger-Rapport, David R. Thomas, Julie K. Gammack, John E. Morley. (2008) Clinical Update on Nursing Home Medicine: 2008. Journal of the American Medical Directors Association 9:7, 460-475
CrossRef283
W. Gulliver. (2008) Long-term prognosis in patients with psoriasis. British Journal of Dermatology 159, 2-9
CrossRef284
Kirstie A. Eccles, Heather Sowden, Karen E. Porter, Sue M. Parkin, Shervanthi Homer-Vanniasinkam, Anne M. Graham. (2008) Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow. Atherosclerosis 200:1, 69-79
CrossRef285
Ankur Gupta, Dinesh K. Badyal, Prem P. Khosla, Bharti Uppal, Thannikot M. Jaison, Sandeep Chopra. (2008) Effect of atorvastatin on hs-CRP in acute coronary syndrome. British Journal of Clinical Pharmacology 66:3, 411-413
CrossRef286
Handrean Soran, Paul Durrington. (2008) Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opinion on Pharmacotherapy 9:12, 2145-2160
CrossRef287
Shin-Seok Lee, Sukhminder Singh, Kimberly Link, Michelle Petri. (2008) High-Sensitivity C-Reactive Protein as an Associate of Clinical Subsets and Organ Damage in Systemic Lupus Erythematosus. Seminars in Arthritis and Rheumatism 38:1, 41-54
CrossRef288
Michael Clearfield. (2008) Another inconvenient truth: Combining the risks from obesity and metabolic syndrome with global warming. Current Atherosclerosis Reports 10:4, 273-276
CrossRef289
B. Strober, C. Teller, P. Yamauchi, J.L. Miller, M. Hooper, Y-C. Yang, F. Dann. (2008) Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. British Journal of Dermatology 159:2, 322-330
CrossRef290
Dan Justo, Yaron Arbel, Gal Altberg, Michael Kinori, Arie Shirom, Samuel Melamed, Itzhak Shapira, Ori Rogowski. (2008) Inflammation Markers in Individuals with History of Mental Health Crisis. Inflammation 31:4, 254-259
CrossRef291
Luis M Moura, Francisco Rocha-Gonçalves, José L Zamorano, Isabel Barros, Paulo Bettencourt, Nalini Rajamannan. (2008) New cardiovascular biomarkers: clinical implications in patients with valvular heart disease. Expert Review of Cardiovascular Therapy 6:7, 945-954
CrossRef292
Stephen J Nicholls. (2008) Rosuvastatin and progression of atherosclerosis. Expert Review of Cardiovascular Therapy 6:7, 925-933
CrossRef293
Christina C. Wee, Saket Girotra, Amy R. Weinstein, Murray A. Mittleman, Kenneth J. Mukamal. (2008) The Relationship Between Obesity and Atherosclerotic Progression and Prognosis Among Patients With Coronary Artery Bypass Grafts. Journal of the American College of Cardiology 52:8, 620-625
CrossRef294
Paul M Ridker, Josh D Silvertown. (2008) Inflammation, C-Reactive Protein, and Atherothrombosis. Journal of Periodontology 79:8s, 1544-1551
CrossRef295
Faisal A. Arain, Leslie T. Cooper. (2008) Peripheral Arterial Disease: Diagnosis and Management. Mayo Clinic Proceedings 83:8, 944-950
CrossRef296
F. A. Arain, L. T. Cooper. (2008) Peripheral Arterial Disease: Diagnosis and Management. Mayo Clinic Proceedings 83:8, 944-950
CrossRef297
Barbora de Courten, Melissa N Barber, Renea V Johnston, Danny Liew, Maximilian de Courten, Sharon van Doornum, Christopher Reid, Rachelle Buchbinder, Melissa N Barber. 2008. Hypolipidemic and antihypertensive drugs for prevention of cardiovascular complications in patients with rheumatoid arthritis. .
CrossRef298
Ignatios Ikonomidis, Kimon Stamatelopoulos, John Lekakis, Georgia D. Vamvakou, Dimitrios Th Kremastinos. (2008) Inflammatory and non-invasive vascular markers: The multimarker approach for risk stratification in coronary artery disease. Atherosclerosis 199:1, 3-11
CrossRef299
Venkateshwar R. Polsani, Salim S. Virani, Vijay Nambi. (2008) Lipid management: Considerations in acute coronary syndrome. Current Cardiology Reports 10:4, 334-341
CrossRef300
Almudena Gómez-Hernández, Eva Sánchez-Galán, Mónica Ortego, José Luis Martín-Ventura, Luis Miguel Blanco-Colio, Nieves Tarín-Vicente, José Julio Jiménez-Nacher, Lorenzo López-Bescos, Jesús Egido, José Tuñón. (2008) Effect of Intensive Atorvastatin Therapy on Prostaglandin E2 Levels and Metalloproteinase-9 Activity in the Plasma of Patients With Non-ST-Elevation Acute Coronary Syndrome. The American Journal of Cardiology 102:1, 12-18
CrossRef301
Ilan Gottlieb, Sachin Agarwal, Sandeep Gautam, Milind Desai, Henning Steen, William P Warren, Sérgio Salles Xavier, João AC Lima. (2008) Aortic plaque regression as determined by magnetic resonance imaging with high-dose and low-dose statin therapy. Journal of Cardiovascular Medicine 9:7, 700-706
CrossRef302
Carl J Lavie, Richard V Milani, Hector O Ventura. (2008) Untangling the heavy cardiovascular burden of obesity. Nature Clinical Practice Cardiovascular Medicine 5:7, 428-429
CrossRef303
Pim van der Harst, Folkert W. Asselbergs, Hans L. Hillege, Adriaan A. Voors, Dirk J. van Veldhuisen, Wiek H. van Gilst. (2008) Effect of Fosinopril Treatment on Serum C-Reactive Protein Levels in Patients With Microalbuminuria. The American Journal of Cardiology 102:2, 223-225
CrossRef304
Justin M. Bachmann, Maulik Majmudar, Christine Tompkins, Roger S. Blumenthal, Joseph E. Marine. (2008) Lipid-Altering Therapy and Atrial Fibrillation. Cardiology in Review 16:4, 197-204
CrossRef305
Maheshwar Pauriah, Allan D. Struthers, Chim C. Lang. (2008) Biomarkers and Surrogate Endpoints in Cardiovascular Therapeutics Research: Under Scrutiny Following Results of the ENHANCE Study. Cardiovascular Therapeutics 26:2, 85-88
CrossRef306
Carl J. Lavie, Ali Morshedi-Meibodi, Richard V. Milani. (2008) Impact of Cardiac Rehabilitation on Coronary Risk Factors, Inflammation, and the Metabolic Syndrome in Obese Coronary Patients. Journal of the CardioMetabolic Syndrome 3:3, 136-140
CrossRef307
Stanley Chia, Owen Christopher Raffel, Masamichi Takano, Guillermo J. Tearney, Brett E. Bouma, Ik-Kyung Jang. (2008) Association of statin therapy with reduced coronary plaque rupture: an optical coherence tomography study. Coronary Artery Disease 19:4, 237-242
CrossRef308
S. P. Bhavnani, C. I. Coleman, C. M. White, C. A. Clyne, R. Yarlagadda, D. Guertin, J. Kluger. (2008) Association between statin therapy and reductions in atrial fibrillation or flutter and inappropriate shock therapy. Europace 10:7, 854-859
CrossRef309
T. B. Grammer, W. Marz, W. Renner, B. O. Bohm, M. M. Hoffmann. (2008) C-reactive protein genotypes associated with circulating C-reactive protein but not with angiographic coronary artery disease: the LURIC study. European Heart Journal 30:2, 170-182
CrossRef310
LOTTE EBDRUP, JAN KROG, ASGER GRANFELDT, PERNILLE Ø. LARSEN, CHRISTIAN VESTERGAARD, MARIANNE HOKLAND, ELSE TØNNESEN. (2008) Leukocyte, plasma, and organ-associated cytokine profiles in an animal model of acute inflammation. APMIS 116:5, 352-360
CrossRef311
Hirofumi Yasue, Yuji Mizuno, Eisaku Harada, Teruhiko Itoh, Hitoshi Nakagawa, Masafumi Nakayama, Hisao Ogawa, Shinji Tayama, Takasi Honda, Seiji Hokimoto, Shuichi Ohshima, Youichi Hokamura, Kiyotaka Kugiyama, Minoru Horie, Michihiro Yoshimura, Masaki Harada, Shiroh Uemura, Yoshihiko Saito. (2008) Effects of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Fluvastatin, on Coronary Spasm After Withdrawal of Calcium-Channel Blockers. Journal of the American College of Cardiology 51:18, 1742-1748
CrossRef312
Kyrylo Tron, Dimitar E. Manolov, Carlheinz Röcker, Martin Kächele, Jan Torzewski, G. Ulrich Nienhaus. (2008) C-reactive protein specifically binds to Fcγ receptor type I on a macrophage-like cell line. European Journal of Immunology 38:5, 1414-1422
CrossRef313
Bernard Abi-Saleh, Said B. Iskandar, Nader Elgharib, Michael V. Cohen. (2008) C-Reactive Protein: The Harbinger of Cardiovascular Diseases. Southern Medical Journal 101:5, 525-533
CrossRef314
Andres Peisajovich, Lorraine Marnell, Carolyn Mold, Terry W Du Clos. (2008) C-reactive protein at the interface between innate immunity and inflammation. Expert Review of Clinical Immunology 4:3, 379-390
CrossRef315
P. Libby. (2008) The molecular mechanisms of the thrombotic complications of atherosclerosis. Journal of Internal Medicine 263:5, 517-527
CrossRef316
Farahnak Assadi. (2008) Relation of Left Ventricular Hypertrophy to Microalbuminuria and C-Reactive Protein in Children and Adolescents with Essential Hypertension. Pediatric Cardiology 29:3, 580-584
CrossRef317
John Rogus, James D. Beck, Steven Offenbacher, Kenneth Huttner, Licia Iacoviello, Maria Carmela Latella, Monica Gaetano, Hwa-Ying Wang, Kenneth S. Kornman, Gordon W. Duff. (2008) IL1B gene promoter haplotype pairs predict clinical levels of interleukin-1β and C-reactive protein. Human Genetics 123:4, 387-398
CrossRef318
Aysha Arshad, Anisha Mandava, Ganesh Kamath, Dan Musat. (2008) Sudden Cardiac Death and the Role of Medical Therapy. Progress in Cardiovascular Diseases 50:6, 420-438
CrossRef319
R Keith Randolph. 2008. Genotype-selective Inhibition Of Il-1 By Botanicals A Nutrigenetics Proof Of Principle. , 189-195.
CrossRef320
William R. Hiatt. 2008. Medical Treatment of Peripheral Arterial Disease. , 163-168.
CrossRef321
Tze Vun Liew, Kausik K. Ray. (2008) Intensive statin therapy in acute coronary syndromes. Current Atherosclerosis Reports 10:2, 158-163
CrossRef322
Jennifer G. Robinson. (2008) Models for Describing Relations Among the Various Statin Drugs, Low-Density Lipoprotein Cholesterol Lowering, Pleiotropic Effects, and Cardiovascular Risk††Conflicts of interest: In the past 2 years, Dr. Robinson has received grants from Abbott Laboratories, Abbott Park, Illinois, Astra-Zeneca, Wilmington, Delaware, Bristol-Myers Squibb, Princeton, New Jersey, GlaxoSmithKline, Pittsburgh, Pennsylvania, Hoffman La Roche, Basel, Switzerland, Merck & Company, West Point, Pennsylvania, Pfizer, New York, New York, Procter & Gamble, Cinncinnati, Ohio, Sankyo, Parsippany, New Jersey, Schering-Plough, Kenilworth, New Jersey, and Takeda Pharmaceuticals, Lincolnshire, Illinois and honoraria for education programs from Merck & Company, and has been a consultant and advisory board member for Merck Schering Plough.. The American Journal of Cardiology 101:7, 1009-1015
CrossRef323
Vijaya Anand, Chenniappan ., Kalavathy ., Uma ., Saravanan ., Sampath Kumar. (2008) Redeeming Measure of Atorvastatin in the Risk Factors of Cardiovascular Disease. International Journal of Pharmacology 4:4, 305-309
CrossRef324
Marijn C. Meuwese, Mieke D. Trip, Sanne van Wissen, Joram N.I. van Miert, John J.P. Kastelein, Erik S.G. Stroes. (2008) Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia. Atherosclerosis 197:2, 916-921
CrossRef325
Justin M.S. Lee, Frank Wiesmann, Cheerag Shirodaria, Paul Leeson, Steffen E. Petersen, Jane M. Francis, Clare E. Jackson, Matthew D. Robson, Stefan Neubauer, Keith M. Channon, Robin P. Choudhury. (2008) Early changes in arterial structure and function following statin initiation: Quantification by magnetic resonance imaging. Atherosclerosis 197:2, 951-958
CrossRef326
Harold E Bays, David Neff, Joanne E Tomassini, Andrew M Tershakovec. (2008) Ezetimibe: cholesterol lowering and beyond. Expert Review of Cardiovascular Therapy 6:4, 447-470
CrossRef327
Emile R. Mohler, Christie M. Ballantyne, Michael H. Davidson, Markolf Hanefeld, Luis M. Ruilope, Joel L. Johnson, Andrew Zalewski. (2008) The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent. Journal of the American College of Cardiology 51:17, 1632-1641
CrossRef328
Amit Kumar, Christopher P. Cannon. (2008) The Role of Statins in the Prevention of Heart Failure After Acute Coronary Syndrome. Heart Failure Clinics 4:2, 129-139
CrossRef329
A. H. Liem, A. P. van de Woestijne, A. H. Zwinderman, F. L. J. Visseren, J. W. Jukema. (2008) Determinants of CRP level in statin-treated patients. Current Medical Research and Opinion 24:4, 1065-1068
CrossRef330
M. Florentin, E. N. Liberopoulos, D. P. Mikhailidis, M. S. Elisaf. (2008) Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Current Medical Research and Opinion 24:4, 995-1009
CrossRef331
Weintraub, William S., Diamond, George A., . (2008) Predicting Cardiovascular Events with Coronary Calcium Scoring. New England Journal of Medicine 358:13, 1394-1396
Full Text332
B. Bankier, J. Barajas, A. Martinez-Rumayor, J. L. Januzzi. (2008) Association between C-reactive protein and generalized anxiety disorder in stable coronary heart disease patients. European Heart Journal 29:18, 2212-2217
CrossRef333
François Charbonneau, Todd J. Anderson, Lawrence Title, Jean Jobin, Paul Poirier, Thao Huyhn, Sammy Chan, Ann Walling, Stuart Hutchison, Thang Tran, Eva Lonn, Jean Buithieu, Jacques Genest. (2008) Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX). Atherosclerosis 197:1, 420-427
CrossRef334
W. James Waldman, Marshall V. Williams, Stanley Lemeshow, Philip Binkley, Denis Guttridge, Janice K. Kiecolt-Glaser, Deborah A. Knight, Katherine J. Ladner, Ronald Glaser. (2008) Epstein-Barr virus-encoded dUTPase enhances proinflammatory cytokine production by macrophages in contact with endothelial cells: Evidence for depression-induced atherosclerotic risk. Brain, Behavior, and Immunity 22:2, 215-223
CrossRef335
Michael Miller, Christopher P. Cannon, Sabina A. Murphy, Jie Qin, Kausik K. Ray, Eugene Braunwald. (2008) Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial. Journal of the American College of Cardiology 51:7, 724-730
CrossRef336
Gregory G Schwartz. (2008) Lipid management after acute coronary syndrome. Current Opinion in Internal Medicine 7:1, 75-81
CrossRef337
J. F. P. Berbee, S. P. Mooijaart, A. J. M. de Craen, L. M. Havekes, D. van Heemst, P. C. N. Rensen, R. G. J. Westendorp. (2008) Plasma Apolipoprotein CI Protects Against Mortality From Infection in Old Age. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 63:2, 122-126
CrossRef338
Tsung-Ming Lee, Mei-Shu Lin, Nen-Chung Chang. (2008) Usefulness of C-Reactive Protein and Interleukin-6 as Predictors of Outcomes in Patients With Chronic Obstructive Pulmonary Disease Receiving Pravastatin. The American Journal of Cardiology 101:4, 530-535
CrossRef339
Tatsuya Nakachi, Masami Kosuge, Kiyoshi Hibi, Toshiaki Ebina, Katsutaka Hashiba, Takayuki Mitsuhashi, Mitsuaki Endo, Satoshi Umemura, Kazuo Kimura. (2008) C-Reactive Protein Elevation and Rapid Angiographic Progression of Nonculprit Lesion in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. Circulation Journal 72:12, 1953-1959
CrossRef340
Paresh Dandona, Husam Ghanim, Ajay Chaudhuri, Priya Mohanty. (2008) Thiazolidinediones—improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes. Journal of Diabetes and its Complications 22:1, 62-75
CrossRef341
B. M. Biccard. (2008) A peri-operative statin update for non-cardiac surgery. Part I: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (non-surgical) patients. Anaesthesia 63:1, 52-64
CrossRef342
Bijesh P Maroo, Carl J Lavie, Richard V Milani. (2008) Secondary Prevention of Coronary Heart Disease in Elderly Patients Following Myocardial Infarction. Drugs & Aging 25:8, 649-664
CrossRef343
Yoshifumi SAISHO, Hiroshi HIROSE, Yukihiro YAMAMOTO, Hiroshi NAKATANI, Hiroshi ITOH. (2008) Combination of C-reactive Protein and High Molecular Weight (HMW)-Adiponectin Reflects Further Metabolic Abnormalities Compared with Each of Them Alone in Japanese Type 2 Diabetic Subjects. Endocrine Journal 55:2, 331-338
CrossRef344
J. David Orr. (2008) Statins in the spectrum of neurologic disease. Current Atherosclerosis Reports 10:1, 11-18
CrossRef345
Brendan M. Everett, Paul M. Ridker. (2008) Using inflammatory biomarkers to guide lipid therapy. Current Cardiovascular Risk Reports 2:1, 29-34
CrossRef346
Shani Shenhar-Tsarfaty, Einor Ben Assayag, Irena Bova, Ludmila Shopin, Shlomo Berliner, Itzhak Shapira, Natan M. Bornstein. (2008) Early signaling of inflammation in acute ischemic stroke: Clinical and rheological implications. Thrombosis Research 122:2, 167-173
CrossRef347
David A. Morrow, Yunmei Wang, Kevin Croce, Masashi Sakuma, Marc S. Sabatine, Huiyun Gao, Aruna D. Pradhan, Aileen M. Healy, Jacki Buros, Carolyn H. McCabe, Peter Libby, Christopher P. Cannon, Eugene Braunwald, Daniel I. Simon. (2008) Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. American Heart Journal 155:1, 49-55
CrossRef348
Ofir Wolach, Yaron Arbel, Michael Cohen, Uri Goldbourt, Uzi Rebhun, Itzhak Shapira, Shlomo Berliner, Ori Rogowski. (2008) Ethnic groups and high sensitivity C-reactive protein in Israel. Biomarkers 13:3, 296-306
CrossRef349
Juliano Lara Fernandes, Romulo Tadeu Dias de Oliveira, Ronei Luciano Mamoni, Otavio Rizzi Coelho, Jose Carlos Nicolau, Maria Heloisa S.L. Blotta, Carlos Vicente Serrano. (2008) Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease—A randomized placebo-controlled study. Atherosclerosis 196:1, 434-442
CrossRef350
Shinichi Okamura, Yoshie Sawada, Teturou Satoh, Hironosuke Sakamoto, Yuichiro Saito, Hiroyuki Sumino, Takako Takizawa, Toshiaki Kogure, Chiayo Chaichantipyuth, Yoshihiro Higuchi, Tsutomu Ishikawa, Tetsuo Sakamaki. (2008) Pueraria Mirifica Phytoestrogens Improve Dyslipidemia in Postmenopausal Women Probably by Activating Estrogen Receptor Subtypes. The Tohoku Journal of Experimental Medicine 216:4, 341-351
CrossRef351
Knut Pettersson, Martin Kjerrulf, Lennart Jungersten, Kicki Johansson, Göran Långström, Inge Kalies, Rodica Lenkei, Göran Walldius, Lars Lind. (2008) The new oral immunomodulating drug DiNAC induces brachial artery vasodilatation at rest and during hyperemia in hypercholesterolemic subjects, likely by a nitric oxide-dependent mechanism. Atherosclerosis 196:1, 275-282
CrossRef352
Frank de Vries, Sander Pouwels, Madelon Bracke, Jan-Willem Lammers, Hubert Leufkens, Olaf Klungel, Tjeerd van Staa. (2008) Use of inhaled corticosteroids and the risk of non-fatal acute myocardial infarction. Journal of Hypertension 26:1, 124-129
CrossRef353
Hiroyuki Koshiyama, Ataru Taniguchi, Kiyoshi Tanaka, Shinji Kagimoto, Yoshio Fujioka, Kenichi Hirata, Yoshio Nakamura, Akane Iwakura, Kyoko Hara, Taizo Yamamoto, Akira Kuroe, Michihiro Ohya, Shimpei Fujimoto, Yoshiyuki Hamamoto, Sachiko Honjo, Hiroki Ikeda, Koichiro Nabe, Kinsuke Tsuda, Nobuya Inagaki, Yutaka Seino, Noriaki Kume. (2008) Effects of Pitavastatin on Lipid Profiles and High-Sensitivity CRP in Japanese Subjects with Hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) Investigatars. Journal of Atherosclerosis and Thrombosis 15:6, 345-350
CrossRef354
Maureen E. Mays, Carlos A. Dujovne. (2008) Pleiotropic effects: Should statins be considered an essential component in the treatment of dyslipidemia?. Current Atherosclerosis Reports 10:1, 45-52
CrossRef355
Tamás Fischer. (2008) Az időskori maculadegeneratio gyógyszeres megelőzésének és preventív kezelésének lehetséges új stratégiája. Orvosi Hetilap 149:3, 121-127
CrossRef356
Jerzy Krupinski, Marta M. Turu, Mark Slevin, José Martínez-González. (2008) Carotid plaque, stroke pathogenesis, and CRP: Treatment of ischemic stroke. Current Cardiology Reports 10:1, 25-30
CrossRef357
Luis A. Alvarez-Sala, Victoria Cachofeiro, Luis Masana, Carmen Suarez, Blanca Pinilla, Nuria Plana, Ferran Trias, Miguel Angel Moreno, Gemma Gambus, Vicente Lahera, Xavier Pintó. (2008) Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: A 12-week, multicenter, randomized, open-label, parallel-group study. Clinical Therapeutics 30:1, 84-97
CrossRef358
RG Craig. (2008) Interactions between chronic renal disease and periodontal disease. Oral Diseases 14:1, 1-7
CrossRef359
Olga A. Iakoubova, Marc S. Sabatine, Charles M. Rowland, Carmen H. Tong, Joseph J. Catanese, Koustubh Ranade, Katy L. Simonsen, Todd G. Kirchgessner, Christopher P. Cannon, James J. Devlin, Eugene Braunwald. (2008) Polymorphism in KIF6 Gene and Benefit From Statins After Acute Coronary Syndromes. Journal of the American College of Cardiology 51:4, 449-455
CrossRef360
Ilke Sipahi, E Murat Tuzcu. (2008) Candidate Mechanisms for Regression of Coronary Atherosclerosis with High-Dose Statins. American Journal of Cardiovascular Drugs 8:6, 365-371
CrossRef361
Kosmas I. Paraskevas, Dimitri P. Mikhailidis. (2008) C-reactive protein (CRP): more than just an innocent bystander?. Current Medical Research and Opinion 24:1, 75-78
CrossRef362
Yoshiki Matsuo, Toshikazu Hashizume, Shusaku Shioji, Takashi Akasaka. (2008) Metabolic Syndrome is Strongly Associated With Chronic Subclinical Inflammation in Patients Achieving Optimal Low-Density Lipoprotein-Cholesterol Levels in Secondary Prevention of Cardiovascular Disease. Circulation Journal 72:12, 2046-2050
CrossRef363
Kosmas I. Paraskevas, George Hamilton, Jenny M. Cross, Dimitri P. Mikhailidis. (2008) Atherosclerotic Renal Artery Stenosis: Association with Emerging Vascular Risk Factors. Nephron Clinical Practice 108:1, c56-c66
CrossRef364
Naveed Sattar. (2008) Inflammation, insulin resistance, and cardiovascular disease: Cause or correlate?. Current Cardiovascular Risk Reports 2:1, 53-59
CrossRef365
AMIT KUMAR, CHRISTOPHER P. CANNON. (2007) Importance of Intensive Lipid Lowering in Acute Coronary Syndrome and Percutaneous Coronary Intervention. Journal of Interventional Cardiology 20:6, 447-457
CrossRef366
Sami P Moubayed, Therese M Heinonen, Jean-Claude Tardif. (2007) Anti-inflammatory drugs and atherosclerosis. Current Opinion in Lipidology 18:6, 638-644
CrossRef367
Paul M. Ridker, Francisco A.H. Fonseca, Jacques Genest, Antonio M. Gotto, John J.P. Kastelein, Nardev S. Khurmi, Wolfgang Koenig, Peter Libby, Alberto J. Lorenzatti, Borge G. Nordestgaard, James Shepherd, James T. Willerson, Robert J. Glynn. (2007) Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. The American Journal of Cardiology 100:11, 1659-1664
CrossRef368
Radjesh J. Bisoendial, John J.P. Kastelein, Erik S.G. Stroes. (2007) C-reactive protein and atherogenesis: From fatty streak to clinical event. Atherosclerosis 195:2, e10-e18
CrossRef369
John M Galla, Stephen J Nicholls. (2007) Impact of statin therapy on the artery wall in the low-risk patient: implications from the METEOR study. Future Lipidology 2:6, 595-601
CrossRef370
Dimitri P Mikhailidis, Martin Press. (2007) The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes. Expert Opinion on Pharmacotherapy 8:17, 3009-3020
CrossRef371
Paul M Ridker. (2007) Inflammatory Biomarkers and Risks of Myocardial Infarction, Stroke, Diabetes, and Total Mortality: Implications for Longevity. Nutrition Reviews 65, S253-S259
CrossRef372
Christophe Zawadzki, Sophie Susen, Florence Richard, Stéphan Haulon, Delphine Corseaux, Emmanuelle Jeanpierre, André Vincentelli, Christian Lucas, Gérard Torpier, Annie Martin, Eric Van Belle, Bart Staels, Brigitte Jude. (2007) Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques. Atherosclerosis 195:2, e117-e125
CrossRef373
Stephan J. Ott, Nour Eddine El Mokhtari, Ateequr Rehman, Philip Rosenstiel, Stephan Hellmig, Tanja Kühbacher, Markus Lins, Rüdiger Simon, Stefan Schreiber. (2007) Fungal rDNA signatures in coronary atherosclerotic plaques. Environmental Microbiology 9:12, 3035-3045
CrossRef374
Martin Soubrier, Sylvain Mathieu, Jean-Jacques Dubost. (2007) Atheroma and systemic lupus erythematosus. Joint Bone Spine 74:6, 566-570
CrossRef375
Kamyar Kalantar-Zadeh. (2007) CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: What Is So Bad about Reverse Epidemiology Anyway?. Seminars in Dialysis 20:6, 593-601
CrossRef376
M. Thoenes, A. Oguchi, S. Nagamia, C. S. Vaccari, R. Hammoud, G. E. Umpierrez, B. V. Khan. (2007) The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. International Journal of Clinical Practice 61:11, 1942-1948
CrossRef377
Kausik K. Ray. (2007) Biomarkers, C-reactive proteins and statins in acute coronary syndromes. Fundamental & Clinical Pharmacology 21:s2, 31-33
CrossRef378
Loukianos S. Rallidis, John Lekakis, Dimitrios T. Kremastinos. (2007) Current questions regarding the use of statins in patients with coronary heart disease. International Journal of Cardiology 122:3, 188-194
CrossRef379
M. Hartford, O. Wiklund, L. Mattsson Hultén, A. Persson, T. Karlsson, J. Herlitz, K. Caidahl. (2007) C-reactive protein, interleukin-6, secretory phospholipase A 2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes. Journal of Internal Medicine 262:5, 526-536
CrossRef380
Rakesh S. Birjmohun, Radjesh J. Bisoendial, Sander I. van Leuven, Mariette Ackermans, Aelko Zwinderman, John J.P. Kastelein, Erik S.G. Stroes, Hans P. Sauerwein. (2007) A single bolus infusion of C-reactive protein increases gluconeogenesis and plasma glucose concentration in humans. Metabolism 56:11, 1576-1582
CrossRef381
Kenneth Kornman, John Rogus, Haeri Roh-Schmidt, David Krempin, Audra J. Davies, Kerry Grann, R. Keith Randolph. (2007) Interleukin-1 genotype-selective inhibition of inflammatory mediators by a botanical: a nutrigenetics proof of concept. Nutrition 23:11-12, 844-852
CrossRef382
Catherine Y. Campbell, Juan J. Rivera, Roger S. Blumenthal. (2007) Residual risk in statin-treated patients: Future therapeutic options. Current Cardiology Reports 9:6, 499-505
CrossRef383
D. John Betteridge, J. Martin Gibson, Philip T. Sager. (2007) Comparison of Effectiveness of Rosuvastatin Versus Atorvastatin on the Achievement of Combined C-Reactive Protein (<2 mg/L) and Low-Density Lipoprotein Cholesterol (<70 mg/dl) Targets in Patients With Type 2 Diabetes Mellitus (from the ANDROMEDA Study). The American Journal of Cardiology 100:8, 1245-1248
CrossRef384
(2007) Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. Revista Española de Cardiología 60:10, 1070.e1-1070.e80
CrossRef385
Hon-Kan Yip, Cheuk-Kwan Sun, Li-Teh Chang, Chiung-Jen Wu, Sarah Chua, Morgan Fu. (2007) Strong suppression of high-sensitivity C-reactive protein level and its mediated pro-atherosclerotic effects with simvastatin: In vivo and in vitro studies. International Journal of Cardiology 121:3, 253-260
CrossRef386
Sabina A. Murphy, Christopher P. Cannon, Stephen D. Wiviott, James A. de Lemos, Michael A. Blazing, Carolyn H. McCabe, Robert M. Califf, Eugene Braunwald. (2007) Effect of Intensive Lipid-Lowering Therapy on Mortality After Acute Coronary Syndrome (a Patient-Level Analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 Trials). The American Journal of Cardiology 100:7, 1047-1051
CrossRef387
Mario Cazzola, Chiara Ciaprini, Clive P Page, Maria G Matera. (2007) Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Therapeutic Targets 11:10, 1273-1286
CrossRef388
Marek Naruszewicz, Iwona Łaniewska, Barbara Millo, Mirosław Dłużniewski. (2007) Combination therapy of statin with flavonoids rich extract from chokeberry fruits enhanced reduction in cardiovascular risk markers in patients after myocardial infraction (MI). Atherosclerosis 194:2, e179-e184
CrossRef389
Daniela Cota. (2007) CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes/Metabolism Research and Reviews 23:7, 507-517
CrossRef390
Angela Pucci, Imad Sheiban, Luisa Formato, Angela Celeste, Elvis Brscic, Claudio Moretti, Alberto De Bernardi, Alessandro Alberti, Laura Bergamasco, Gianpaolo Trevi, Valentin Fuster. (2007) In vivo coronary plaque histology in patients with stable and acute coronary syndromes. Atherosclerosis 194:1, 189-195
CrossRef391
M. Möckel, Reinhold Müller, Jörn O. Vollert, Christian Müller, Oilver Danne, Ragnar Gareis, Thomas Störk, Rainer Dietz, Wolfgang Koenig. (2007) Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach. Clinical Research in Cardiology 96:9, 604-612
CrossRef392
Stephen J. Nicholls, Srinivasa Kalidindi, Steven E. Nissen. (2007) Intensive lipid lowering in the cardiovascular patient: Who, how low, and for how long?. Current Cardiovascular Risk Reports 1:4, 290-295
CrossRef393
Jordan Asher, Mark Houston. (2007) Statins and C-Reactive Protein Levels. The Journal of Clinical Hypertension 9:8, 622-628
CrossRef394
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliott M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:7, e1-e157
CrossRef395
Aziz Momin, Narbeh Melikian, Stephen B. Wheatcroft, David Grieve, Lindsay C. John, Ahmad El Gamel, Michael T. Marrinan, Jatin B. Desai, Catherine Driver, Roy Sherwood, Ajay M. Shah, Mark T. Kearney. (2007) The association between saphenous vein endothelial function, systemic inflammation, and statin therapy in patients undergoing coronary artery bypass surgery. The Journal of Thoracic and Cardiovascular Surgery 134:2, 335-341
CrossRef396
David Conen, Paul M Ridker. (2007) Clinical significance of high-sensitivity C-reactive protein in cardiovascular disease. Biomarkers in Medicine 1:2, 229-241
CrossRef397
Nancy Frasure-Smith, François Lespérance, Michael R. Irwin, Claude Sauvé, Jacques Lespérance, Pierre Théroux. (2007) Depression, C-reactive Protein and Two-year Major Adverse Cardiac Events in Men after Acute Coronary Syndromes. Biological Psychiatry 62:4, 302-308
CrossRef398
Ulrich Broeckel, Christian Hengstenberg, Bjoern Mayer, Karen Maresso, Daniel Gaudet, Ondrej Seda, Johanne Tremblay, Stephan Holmer, Jeanette Erdmann, Christian Glöckner, Michael Harrison, Lisa J. Martin, Jeff T. Williams, Gerd Schmitz, Guenter A. J. Riegger, Howard J. Jacob, Pavel Hamet, Heribert Schunkert. (2007) A locus on chromosome 10 influences C-reactive protein levels in two independent populations. Human Genetics 122:1, 95-102
CrossRef399
Tze Vun Liew, BChir, Kausik K Ray. (2007) Aggressive statin therapy for acute coronary syndromes. Current Cardiology Reports 9:4, 298-302
CrossRef400
John C. LaRosa. (2007) Low-Density Lipoprotein Cholesterol Reduction: The End Is More Important Than the Means. The American Journal of Cardiology 100:2, 240-242
CrossRef401
Jerzy Krupinski, Marta M. Turu, Mark Slevin, José Martínez-González. (2007) Carotid plaque, stroke pathogenesis, and CRP: Treatment of ischemic stroke. Current Treatment Options in Cardiovascular Medicine 9:3, 229-235
CrossRef402
Pierre Cherfan, Andrea Tompa, Anders Wikby, Sture Löfgren, Lena Jonasson. (2007) Effects of simvastatin on human T cells in vivo. Atherosclerosis 193:1, 186-192
CrossRef403
Amy K. Saenger, Allan S. Jaffe. (2007) The Use of Biomarkers for the Evaluation and Treatment of Patients with Acute Coronary Syndromes. Medical Clinics of North America 91:4, 657-681
CrossRef404
Alawi A. Alsheikh-Ali, Prasad V. Maddukuri, Hui Han, Richard H. Karas. (2007) Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer. Journal of the American College of Cardiology 50:5, 409-418
CrossRef405
Carolyn Katrinchak, Kathryn Fritz. (2007) Clinical implications of C-reactive protein as a predictor of vascular risk. Journal of the American Academy of Nurse Practitioners 19:7, 335-340
CrossRef406
Konstantinos Toutouzas, Maria Drakopoulou, Virginia Markou, Ioannis Karabelas, Sophia Vaina, Manolis Vavuranakis, Eleftherios Tsiamis, Costas Tsioufis, Aris Androulakis, Christodoulos Stefanadis. (2007) Correlation of systemic inflammation with local inflammatory activity in non-culprit lesions: Beneficial effect of statins. International Journal of Cardiology 119:3, 368-373
CrossRef407
Birna Bjarnason-Wehrens, Klaus Held, Eike Hoberg, Marthin Karoff, Bernhard Rauch. (2007) Deutsche Leitlinie zur Rehabilitation von Patienten mit Herz-Kreislauferkrankungen (DLL-KardReha). Clinical Research in Cardiology Supplements 2:3, 1-54
CrossRef408
Peter Muennig, Nancy Sohler, Bisundev Mahato. (2007) Socioeconomic status as an independent predictor of physiological biomarkers of cardiovascular disease: Evidence from NHANES. Preventive Medicine 45:1, 35-40
CrossRef409
Peter P. Toth, Chris J. Cadman. (2007) Implications of recent statin trials for primary care practice. Journal of Clinical Lipidology 1:3, 182-190
CrossRef410
Eva Rohde, Christina Bartmann, Katharina Schallmoser, Andreas Reinisch, Gerhard Lanzer, Werner Linkesch, Christian Guelly, Dirk Strunk. (2007) Immune Cells Mimic the Morphology of Endothelial Progenitor Colonies In Vitro. Stem Cells 25:7, 1746-1752
CrossRef411
Irina Buhaescu, Hassane Izzedine. (2007) Mevalonate pathway: A review of clinical and therapeutical implications. Clinical Biochemistry 40:9-10, 575-584
CrossRef412
Xinkang Wang, J Lynn Rutkowsky, Giora Z Feuerstein. (2007) Imaging and molecular biomarkers of vulnerable atheromatous plaques. Biomarkers in Medicine 1:1, 23-35
CrossRef413
Christodoulos Stefanadis, Konstantinos Toutouzas, Eleftherios Tsiamis, Manolis Vavuranakis, Costas Tsioufis, Elli Stefanadi, Harisios Boudoulas. (2007) Relation between local temperature and C-reactive protein levels in patients with coronary artery disease: Effects of atorvastatin treatment. Atherosclerosis 192:2, 396-400
CrossRef414
Yannick Le Manach, Gilles Godet, Pierre Coriat, Claire Martinon, Mich??le Bertrand, Marie-H??l??ne Fl??ron, Bruno Riou. (2007) The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery. Anesthesia & Analgesia 104:6, 1326-1333
CrossRef415
Keith W Muir, Pippa Tyrrell, Naveed Sattar, Elizabeth Warburton. (2007) Inflammation and ischaemic stroke. Current Opinion in Neurology 20:3, 334-342
CrossRef416
M Bhattacharya, J Wang, F M Ribeiro, S J Dixon, R D Feldman, R A Hegele, S S G Ferguson. (2007) Analysis of a missense variant of the human N-formyl peptide receptor that is associated with agonist-independent β-arrestin association and indices of inflammation. The Pharmacogenomics Journal 7:3, 190-199
CrossRef417
Dorit Almoznino-Sarafian, Sylvia Berman, Anat Mor, Miriam Shteinshnaider, Oleg Gorelik, Irma Tzur, Irena Alon, David Modai, Natan Cohen. (2007) Magnesium and C-reactive protein in heart failure: an anti-inflammatory effect of magnesium administration?. European Journal of Nutrition 46:4, 230-237
CrossRef418
L. Puccetti, A.L. Pasqui, F. Bruni, M. Pastorelli, F. Ciani, A. Palazzuoli, A. Pontani, A. Ghezzi, A. Auteri. (2007) Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment. International Journal of Cardiology 119:1, 41-47
CrossRef419
Jung-Sun Kim, Tae Soo Kang, Jin-Bae Kim, Hye-Sun Seo, Sungha Park, Changsoo Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Namsik Chung. (2007) Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients. Atherosclerosis 192:2, 401-406
CrossRef420
Mohamed H. Ahmed. (2007) Cardiovascular disease: Is C-reactive protein the bad guy?. Diabetes Research and Clinical Practice 76:3, 472-473
CrossRef421
Lennart TH Jacobsson, Stefan Jovinge, Carl Turesson. (2007) Is there a future role for anti-TNF therapy in cardiovascular disease?. Future Rheumatology 2:3, 265-269
CrossRef422
Jean-Pierre Monassier, Laurent Monassier. (2007) Prise en charge du post-infarctus. La Presse Médicale 36:6, 999-1006
CrossRef423
Manu Sethi, Charles D. Collard. (2007) Perioperative Statin Therapy: Are Formal Guidelines and Physician Education Needed?. Anesthesia & Analgesia 104:6, 1322-1324
CrossRef424
Douwe J. Mulder, Paul L. Haelst, Martgriet H. Wobbes, Rijk O. Gans, Felix Zijlstra, Johan F. May, Andries J. Smit, Jan Willem Cohen Tervaert, Jasper J. Doormaal. (2007) The Effect of Aggressive Versus Conventional Lipid-lowering Therapy on Markers of Inflammatory and Oxidative Stress. Cardiovascular Drugs and Therapy 21:2, 91-97
CrossRef425
Yi-Guan Xu, Sheng-Hua Zhou, Yu-Guang Li, Chun-Hua Zheng, Xu-Ping Li, Qi-Ming Liu, Duan-Min Xu, Shang Chen. (2007) The Mechanism Underlying Vascular Smooth Muscle Cell Apoptosis Induced by Atorvastatin may be Mainly Associated with Down-regulation of Survivin Expression. Cardiovascular Drugs and Therapy 21:3, 145-153
CrossRef426
Aarti A. Patel, C. Michael White, Sachin A. Shah, Krista M. Dale, Jeffrey Kluger, Craig I. Coleman. (2007) The relationship between statin use and atrial fibrillation*. Current Medical Research and Opinion 23:5, 1177-1185
CrossRef427
Martina Zaninotto, Monica Maria Mion, Enrica Novello, Sara Altinier, Mario Plebani. (2007) New biochemical markers: From bench to bedside. Clinica Chimica Acta 381:1, 14-20
CrossRef428
A.D. Pearle, C.R. Scanzello, S. George, L.A. Mandl, E.F. DiCarlo, M. Peterson, T.P. Sculco, M.K. Crow. (2007) Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis and Cartilage 15:5, 516-523
CrossRef429
F. Chenot, P. F. Montant, O. Marcovitch, M. Blaimont, A. de Meester, O. S. Descamps. (2007) Co-administration of ezetimibe and simvastatin in acute myocardial infarction. European Journal of Clinical Investigation 37:5, 357-363
CrossRef430
E. Murat Tuzcu, Stephen J. Nicholls. (2007) Statins. Journal of the American College of Cardiology 49:20, 2010-2012
CrossRef431
Harm H.H. Feringa, Stefanos E. Karagiannis, Virginie H. van Waning, Eric Boersma, Olaf Schouten, Jeroen J. Bax, Don Poldermans. (2007) The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. Journal of Vascular Surgery 45:5, 936-943
CrossRef432
Luis Miguel Blanco-Colio, Jose Luis Martín-Ventura, Eduardo de Teresa, Csaba Farsang, Allan Gaw, GianFranco Gensini, Lawrence A. Leiter, Anatoly Langer, Pierre Martineau, Jesús Egido. (2007) Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: A substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. American Heart Journal 153:5, 881-888
CrossRef433
Paul M. Ridker. (2007) C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk. Journal of the American College of Cardiology 49:21, 2129-2138
CrossRef434
B. ilerigelen, Y. Üresin, M. Şan, H. KÜltÜrsay, S. GÜneri, O. A. Serdar, S. GÜleç, H. Pençedemir. (2007) Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULiPS (Turkish Lipid Study). Current Medical Research and Opinion 23:5, 1093-1102
CrossRef435
A. Lawrence Gould, Glenn M. Davies, Evo Alemao, Donald D. Yin, John R. Cook. (2007) Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clinical Therapeutics 29:5, 778-794
CrossRef436
James R. Sowers. (2007) The Role of C-Reactive Protein in the Metabolic Syndrome and Diabetes Mellitus. The Endocrinologist 17:3, 163-168
CrossRef437
Allan S. Jaffe. (2007) Cardiovascular biomarkers: The state of the art in 2006. Clinica Chimica Acta 381:1, 9-13
CrossRef438
Jacqueline Suk Danik, Paul M. Ridker. (2007) Genetic determinants of C-reactive protein. Current Atherosclerosis Reports 9:3, 195-203
CrossRef439
C. J. Lavie, R. V. Milani, J. H. O'Keefe. (2007) Statin Wars-Emphasis on Potency vs Event Reduction and Safety?. Mayo Clinic Proceedings 82:5, 539-542
CrossRef440
Kamyar Kalantar-Zadeh, Eric S. Daar, Viktor E. Eysselein, Loren G. Miller. (2007) Hepatitis C inflection in dialysis patients: a link to poor clinical outcome?. International Urology and Nephrology 39:1, 247-259
CrossRef441
Christopher P. Cannon, Eugene Braunwald. (2007) Reply. Journal of the American College of Cardiology 49:13, 1502-1503
CrossRef442
Thomas Forst, Andreas Pfützner, Georg Lübben, Matthias Weber, Nikolaus Marx, Efstrathios Karagiannis, Carsta Koehler, Werner Baurecht, Cloth Hohberg, Markolf Hanefeld. (2007) Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk—the PIOSTAT Study. Metabolism 56:4, 491-496
CrossRef443
Zhiqiang Wang, Wendy E. Hoy. (2007) C-reactive protein and the risk of developing type 2 diabetes in Aboriginal Australians. Diabetes Research and Clinical Practice 76:1, 37-43
CrossRef444
Vijay Nambi, Christie M. Ballantyne. (2007) Role of Biomarkers in Developing New Therapies for Vascular Disease. World Journal of Surgery 31:4, 676-681
CrossRef445
M Mahmoudi, N Curzen, P J Gallagher. (2007) Atherogenesis: the role of inflammation and infection. Histopathology 50:5, 535-546
CrossRef446
William L. Baker, C. Michael White, Jeffrey Kluger, Aaron Denowitz, Christopher P. Konecny, Craig I. Coleman. (2007) Effect of perioperative corticosteroid use on the incidence of postcardiothoracic surgery atrial fibrillation and length of stay. Heart Rhythm 4:4, 461-468
CrossRef447
Derek J. Stocker, Allen J. Taylor, Roy W. Langley, Matthew R. Jezior, Robert A. Vigersky. (2007) A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. American Heart Journal 153:3, 445.e1-445.e6
CrossRef448
Consuelo Fernández-Miranda, X. Pintó Sala. (2007) Nuevas perspectivas en la medición del riesgo cardiovascular: exploraciones para detectar la aterosclerosis subclínica y marcadores de inflamación. Medicina Clínica 128:9, 344-351
CrossRef449
Herbert Schuster. (2007) The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Review of Cardiovascular Therapy 5:2, 177-193
CrossRef450
Mark Nidorf, Peter L. Thompson. (2007) Effect of Colchicine (0.5 mg Twice Daily) on High-Sensitivity C-Reactive Protein Independent of Aspirin and Atorvastatin in Patients With Stable Coronary Artery Disease. The American Journal of Cardiology 99:6, 805-807
CrossRef451
Stephen J Nicholls, Adnan K Chhatriwalla, Pia Lundman. (2007) Impact of statins on atherosclerotic plaque. Future Cardiology 3:2, 157-164
CrossRef452
Spencer D. Dorn, Robert S. Sandler. (2007) Inflammatory Bowel Disease Is Not a Risk Factor for Cardiovascular Disease Mortality: Results from a Systematic Review and Meta-Analysis. The American Journal of Gastroenterology 102:3, 662-667
CrossRef453
Peter A. Kavsak, Andrew R. MacRae, Alice M. Newman, Viliam Lustig, Glenn E. Palomaki, Dennis T. Ko, Jack V. Tu, Allan S. Jaffe. (2007) Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure. Clinical Biochemistry 40:5-6, 326-329
CrossRef454
Antonio M. Gotto. (2007) Role of C-Reactive Protein in Coronary Risk Reduction: Focus on Primary Prevention. The American Journal of Cardiology 99:5, 718-725
CrossRef455
Stephen J Nicholls, Jordan Andrews, Keon-Woong Moon. (2007) Exploring the natural history of atherosclerosis with intravascular ultrasound. Expert Review of Cardiovascular Therapy 5:2, 295-306
CrossRef456
Kausik K. Ray, Christopher P. Cannon. (2007) Lipid-independent pleiotropic effects of statins in the management of acute coronary coronary syndromes. Current Treatment Options in Cardiovascular Medicine 9:1, 46-51
CrossRef457
Carlos Lahoz, José M. Mostaza. (2007) La Aterosclerosis como enfermedad sistémica. Revista Española de Cardiología 60:2, 184-195
CrossRef458
Carlheinz Röcker, Dimitar E. Manolov, Elza V. Kuzmenkina, Kyrylo Tron, Holger Slatosch, Jan Torzewski, G. Ulrich Nienhaus. (2007) Affinity of C-Reactive Protein toward FcγRI Is Strongly Enhanced by the γ-Chain. The American Journal of Pathology 170:2, 755-763
CrossRef459
Gordon D. O. Lowe, Mark B. Pepys. (2007) C-reactive protein and cardiovascular disease: Weighing the evidence. Current Cardiovascular Risk Reports 1:1, 72-79
CrossRef460
Steven Woloshin, Lisa M. Schwartz, Kevin Kerin, H. Gilbert Welch. (2007) Estimating the Impact of Adding C-Reactive Protein as a Criterion for Lipid Lowering Treatment in the United States. Journal of General Internal Medicine 22:2, 197-204
CrossRef461
Javier Sanz, Pedro R Moreno, Valentin Fuster. (2007) Update on advances in atherothrombosis. Nature Clinical Practice Cardiovascular Medicine 4:2, 78-89
CrossRef462
Helmut Gohlke, Moritz Winter, Marthin Karoff, Klaus Held. (2007) CARRISMA: a new tool to improve risk stratification and guidance of patients in cardiovascular risk management in primary prevention. European Journal of Cardiovascular Prevention & Rehabilitation 14:1, 141-148
CrossRef463
Rakesh K. Mishra, Craig T. Basson. (2007) Treatment goals for the management of lipids and inflammation for patients with coronary artery disease. Current Treatment Options in Cardiovascular Medicine 9:1, 3-10
CrossRef464
Johannes Mair. (2007) Kardiale Labordiagnostik – State-of-the-Art 2007. Wiener Medizinische Wochenschrift 157:3-4, 48-56
CrossRef465
Vinodh Jeevanantham, Natasha Singh, Kenneth Izuora, John P. D'souza, David H. Hsi. (2007) Correlation of High Sensitivity C-Reactive Protein and Calcific Aortic Valve Disease. Mayo Clinic Proceedings 82:2, 171-174
CrossRef466
V. Jeevanantham, N. Singh, K. Izuora, J. P. D'souza, D. H. Hsi. (2007) Correlation of High Sensitivity C-Reactive Protein and Calcific Aortic Valve Disease. Mayo Clinic Proceedings 82:2, 171-174
CrossRef467
S. Efrati, M. Averbukh, V. Dishy, M. Faygenzo, L. Friedensohn, A. Golik. (2007) The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. European Journal of Clinical Pharmacology 63:2, 113-121
CrossRef468
Filip K. Swirski, Peter Libby, Elena Aikawa, Pilar Alcaide, F. William Luscinskas, Ralph Weissleder, Mikael J. Pittet. (2007) Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. Journal of Clinical Investigation 117:1, 195-205
CrossRef469
Michael Clearfield. (2007) Clinical trials report. Current Atherosclerosis Reports 9:1, 5-9
CrossRef470
Carlos Lahoz, José M. Mostaza. (2007) Atherosclerosis As a Systemic Disease. Revista Española de Cardiología (English Edition) 60:2, 184-195
CrossRef471
Christopher D. Owens, Paul M. Ridker, Michael Belkin, Allen D. Hamdan, Frank Pomposelli, Frank Logerfo, Mark A. Creager, Michael S. Conte. (2007) Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. Journal of Vascular Surgery 45:1, 2-9
CrossRef472
Saif Anwaruddin, Arman T. Askari, Eric J. Topol. (2007) Redefining Risk in Acute Coronary Syndromes Using Molecular Medicine. Journal of the American College of Cardiology 49:3, 279-289
CrossRef473
Valentin Fuster, Javier Sanz. (2007) Vascular inflammation. Journal of the American Society of Hypertension 1:1, 68-81
CrossRef474
Teruhiko Itoh, Yuji Mizuno, Eisaku Harada, Michihiro Yoshimura, Hisao Ogawa, Hirofumi Yasue. (2007) Coronary Spasm is Associated With Chronic Low-Grade Inflammation. Circulation Journal 71:7, 1074-1078
CrossRef475
Giovanna Liuzzo, Matteo Santamaria, Luigi M. Biasucci, Michela Narducci, Valeria Colafrancesco, Annalisa Porto, Salvatore Brugaletta, Michela Pinnelli, Vittoria Rizzello, Attilio Maseri, Filippo Crea. (2007) Persistent Activation of Nuclear Factor Kappa-B Signaling Pathway in Patients With Unstable Angina and Elevated Levels of C-Reactive Protein. Journal of the American College of Cardiology 49:2, 185-194
CrossRef476
Marcello Arca, Achille Gaspardone. (2007) Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events. Drugs 67:Supplement 1, 29-42
CrossRef477
Bernhard Richter, Michael Derntl, Manfred Marx, Peter Lercher, Heinz D. Gössinger. (2007) Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: No effect on ablation outcome after ablation of atrial fibrillation. American Heart Journal 153:1, 113-119
CrossRef478
Shinichiro UEDA. (2007) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 38:5, 295-298
CrossRef479
Sridevi Devaraj, Jason Rogers, Ishwarlal Jialal. (2007) Statins and biomarkers of inflammation. Current Atherosclerosis Reports 9:1, 33-41
CrossRef480
Tye DAWOOD, Elisabeth A. LAMBERT, David A. BARTON, Dominique LAUDE, Jean-Luc ELGHOZI, Murray D. ESLER, Deepak HAIKERWAL, David M. KAYE, Elodie J. HOTCHKIN, Gavin W. LAMBERT. (2007) Specific Serotonin Reuptake Inhibition in Major Depressive Disorder Adversely Affects Novel Markers of Cardiac Risk. Hypertension Research 30:4, 285-293
CrossRef481
Vilborg Sigurdardottir, Björn Fagerberg, John Wikstrand, Caroline Schmidt, Johannes Hulthe. (2007) Circulating oxidized low-density lipoprotein is associated with echolucent plaques in the femoral artery independently of hsCRP in 61-year-old men. Atherosclerosis 190:1, 187-193
CrossRef482
Sarah D. de Ferranti, Nader Rifai. (2007) C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovascular Pathology 16:1, 14-21
CrossRef483
Kent G. Meredith, Benjamin D. Horne, Robert R. Pearson, Chloe Allen Maycock, Donald L. Lappe, Jeffrey L. Anderson, Joseph B. Muhlestein. (2007) Comparison of Effects of High (80 mg) Versus Low (20 mg) Dose of Simvastatin on C-Reactive Protein and Lipoproteins in Patients With Angiographic Evidence of Coronary Arterial Narrowing. The American Journal of Cardiology 99:2, 149-153
CrossRef484
John David Clements, Fakhreddin Jamali. (2007) Pravastatin reverses the down-regulating effect of inflammation on β-Adrenergic receptors: A disease–drug interaction between inflammation, pravastatin, and propranolol. Vascular Pharmacology 46:1, 52-59
CrossRef485
F. Purroy, J. Montaner, C. A. Molina, P. Delgado, J. F. Arenillas, P. Chacon, M. Quintana, J. Alvarez-Sabin. (2007) C-reactive protein predicts further ischemic events in transient ischemic attack patients. Acta Neurologica Scandinavica 115:1, 60-66
CrossRef486
Ishwarlal Jialal, Sridevi Devaraj. (2007) The Role of C-Reactive Protein Activation of Nuclear Factor Kappa-B in the Pathogenesis of Unstable Angina. Journal of the American College of Cardiology 49:2, 195-197
CrossRef487
Markolf Hanefeld, Nikolaus Marx, Andreas Pfützner, Werner Baurecht, Georg Lübben, Efstrathios Karagiannis, Ulf Stier, Thomas Forst. (2007) Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein. Journal of the American College of Cardiology 49:3, 290-297
CrossRef488
D. Brandon Williams, Judith C. Hagedorn, Elise H. Lawson, Joseph A. Galanko, Bassem Y. Safadi, Myriam J. Curet, John M. Morton. (2007) Gastric bypass reduces biochemical cardiac risk factors. Surgery for Obesity and Related Diseases 3:1, 8-13
CrossRef489
Lloyd W. Klein. (2007) Atherosclerosis Regression, Vascular Remodeling, and Plaque Stabilization. Journal of the American College of Cardiology 49:2, 271-273
CrossRef490
Mary Cushman, Barbara M. Alving. 2007. Risk Factors for Cardiovascular Disease and Arterial Thrombosis. , 371-378.
CrossRef491
William R. Hiatt. 2007. Peripheral Arterial Disease. , 379-388.
CrossRef492
J. J. Puder, S. Varga, C. P. G. Nusbaumer, H. Zulewski, S. Bilz, B. Müller, U. Keller. (2006) Women with polycystic ovary syndrome are sensitive to the TNF-?-lowering effect of glucose-induced hyperinsulinaemia. European Journal of Clinical Investigation 36:12, 883-889
CrossRef493
Luigina Guasti, Franca Marino, Marco Cosentino, Mariagrazia Cimpanelli, Ramona C Maio, Catherine Klersy, Chiara Crespi, Daniela Restelli, Cinzia Simoni, Ivano Franzetti, Giovanni Gaudio, Patrizio Marnini, Anna M Grandi, Sergio Lecchini, Achille Venco. (2006) Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk individuals: a longitudinal study. Journal of Hypertension 24:12, 2423-2430
CrossRef494
Wolfgang Meyer-Sabellek, Helmut Brasch. (2006) Atherosclerosis, inflammation, leukocyte function and the effect of statins. Journal of Hypertension 24:12, 2349-2351
CrossRef495
J. Suk Danik, D. I. Chasman, C. P. Cannon, D. T. Miller, R. Y. L. Zee, P. Kozlowski, D. J. Kwiatkowski, P. M. Ridker. (2006) Influence of Genetic Variation in the C-Reactive Protein Gene on the Inflammatory Response During and After Acute Coronary Ischemia. Annals of Human Genetics 70:6, 705-716
CrossRef496
Mitchell SV Elkind. (2006) Are C-reactive protein levels before thrombolysis of prognostic value?. Nature Clinical Practice Neurology 2:11, 588-589
CrossRef497
Peter Libby, Paul M. Ridker. (2006) Inflammation and Atherothrombosis. Journal of the American College of Cardiology 48:9, A33-A46
CrossRef498
Nicola Ferri, Rodolfo Paoletti, Alberto Corsini. (2006) Biomarkers for atherosclerosis: pathophysiological role and pharmacological modulation. Current Opinion in Lipidology 17:5, 495-501
CrossRef499
Ronald Goldberg. 2006. Type 2 Diabetes. , 187-254.
CrossRef500
Kamyar KALANTAR-ZADEH, Vaidyanathapuram S. BALAKRISHNAN. (2006) The kidney disease wasting: Inflammation, oxidative stress, and diet-gene interaction. Hemodialysis International 10:4, 315-325
CrossRef501
William B. Kannel, Peter W. F. Wilson. 2006. Risk Factors for Cardiovascular Disease and the Framingham Study Equation. , 1-18.
CrossRef502
Kausik K Ray, Christopher P Cannon. (2006) Intensive statin therapy for treating acute coronary syndromes. Expert Opinion on Investigational Drugs 15:10, 1151-1159
CrossRef503
John A. Farmer. 2006. Inflammatory Mediators and C-Reactive Protein. , 441-462.
CrossRef504
R. R. Miller, A. R. Cappola, M. D. Shardell, W. G. Hawkes, J. A. Yu-Yahiro, J. R. Hebel, J. Magaziner. (2006) Persistent Changes in Interleukin-6 and Lower Extremity Function Following Hip Fracture. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 61:10, 1053-1058
CrossRef505
Hans Carl Hasselbalch, Caroline H. Riley. (2006) Statins in the treatment of polycythaemia vera and allied disorders: An antithrombotic and cytoreductive potential?. Leukemia Research 30:10, 1217-1225
CrossRef506
James T. Willerson, Paul W Armstrong. 2006. Acute Myocardial Infarction. , 611-646.
CrossRef507
Alberico L. Catapano, Michael H. Davidson, Christie M. Ballantyne, William E. Brady, Russell A. Gazzara, Joanne E. Tomassini, Andrew M. Tershakovec. (2006) Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients*. Current Medical Research and Opinion 22:10, 2041-2053
CrossRef508
Kiran K. Khush, David D. Waters. (2006) Effects of Statin Therapy on the Development and Progression of Heart Failure: Mechanisms and Clinical Trials. Journal of Cardiac Failure 12:8, 664-674
CrossRef509
Vera Bittner. 2006. Women and Coronary Heart Disease. , 689-720.
CrossRef510
John Mulhall, Patrick Teloken, Gerald Brock, Edward Kim. (2006) Obesity, Dyslipidemias and Erectile Dysfunction: A Report of a Subcommittee of the Sexual Medicine Society of North America. The Journal of Sexual Medicine 3:5, 778-786
CrossRef511
Akinlolu O. Ojo. (2006) Cardiovascular Complications After Renal Transplantation and Their Prevention. Transplantation 82:5, 603-611
CrossRef512
Virginia M. Miller, Muthuvel Jayachandran, John A. Heit, Whyte G. Owen. (2006) Estrogen therapy and thrombotic risk. Pharmacology & Therapeutics 111:3, 792-807
CrossRef513
Goran Stankovic, D. Larry Sparks. (2006) Change in circulating C-reactive protein is not associated with atorvastatin treatment in Alzheimer's disease. Neurological Research 28:6, 621-624
CrossRef514
Gordon D. O. Lowe, Mark B. Pepys. (2006) C-reactive protein and cardiovascular disease: Weighing the evidence. Current Atherosclerosis Reports 8:5, 421-428
CrossRef515
Amber L. Beitelshees, Howard L. McLeod. (2006) Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. Trends in Pharmacological Sciences 27:9, 498-502
CrossRef516
Jessica L. Mega, David A. Morrow, Christopher P. Cannon, Sabina Murphy, Richard Cairns, Paul M. Ridker, Eugene Braunwald. (2006) Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. Journal of Thrombosis and Thrombolysis 22:1, 71-76
CrossRef517
Patrick Mathieu, Philippe Pibarot, Jean-Pierre Despres. (2006) Metabolic syndrome: the danger signal in atherosclerosis. Vascular Health and Risk Management 2:3, 285-302
CrossRef518
Jacques Amar, Laurence Perez, Rémi Burcelin, Bernard Chamontin. (2006) Arteries, inflammation and insulin resistance. Journal of Hypertension 24:Suppl 5, S18-S20
CrossRef519
Gábor Földes, Stephan von Haehling, Stefan D Anker. (2006) Toll-like receptor modulation in cardiovascular disease: a target for intervention?. Expert Opinion on Investigational Drugs 15:8, 857-871
CrossRef520
Christopher P. Cannon, Kausik K. Ray, Eugene Braunwald. (2006) Reply. Journal of the American College of Cardiology 48:4, 852-853
CrossRef521
Yoshimasa Aso, Sadao Wakabayashi, Tomoki Nakano, Ruriko Yamamoto, Kohzo Takebayashi, Toshihiko Inukai. (2006) High serum high-sensitivity C-reactive protein concentrations are associated with relative cardiac sympathetic overactivity during the early morning period in type 2 diabetic patients with metabolic syndrome. Metabolism 55:8, 1014-1021
CrossRef522
Hongbao Ma, Kusai S. Aziz, Ruiping Huang, George S. Abela. (2006) Arterial wall cholesterol content is a predictor of development and severity of arterial thrombosis. Journal of Thrombosis and Thrombolysis 22:1, 5-11
CrossRef523
Bart Staels. (2006) Metformin and pioglitazone: effectively treating insulin resistance. Current Medical Research and Opinion 22:s2, S27-S37
CrossRef524
Robyn Domsic, Kathleen Maksimowicz-McKinnon, Susan Manzi. (2006) Prevention of cardiovascular disease in patients with rheumatic diseases. Best Practice & Research Clinical Rheumatology 20:4, 741-756
CrossRef525
Raed Osman, Philippe L L'Allier, Nader Elgharib, Jean-Claude Tardif. (2006) Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. Vascular Health and Risk Management 2:3, 221-237
CrossRef526
Patricia M Kearney, Colin Baigent. (2006) Statins: are any questions unanswered?. Current Opinion in Lipidology 17:4, 418-425
CrossRef527
Stephen J Nicholls, Ilke Sipahi, Paul Schoenhagen. (2006) The ACTIVATE study: lessons for the future of atherosclerotic therapy. Future Lipidology 1:4, 421-428
CrossRef528
Elizabeth C. HSIA, Kristin M. RULEY, Mahboob U. RAHMAN. (2006) Infliximab (RemicadeR): from bench to clinical practice. A paradigm shift in rheumatology practice. APLAR Journal of Rheumatology 9:2, 107-118
CrossRef529
Stephen D Wiviott, Christopher P Cannon. (2006) Update on lipid-lowering therapy and LDL-cholesterol targets. Nature Clinical Practice Cardiovascular Medicine 3:8, 424-436
CrossRef530
O. M. Steinmetz, U. Panzer, R. A. K. Stahl, U. O. Wenzel. (2006) Statin therapy in patients with chronic kidney disease: to use or not to use. European Journal of Clinical Investigation 36:8, 519-527
CrossRef531
Christian A. Schneider. (2006) Improving macrovascular outcomes in type 2 diabetes: outcome studies in cardiovascular risk and metabolic control. Current Medical Research and Opinion 22:s2, S15-S26
CrossRef532
Jeffrey A. Switzer, David C. Hess. (2006) Statin therapy for coronary heart disease and its effect on stroke. Current Atherosclerosis Reports 8:4, 337-342
CrossRef533
Matthew K Ito, Robert L Talbert, Sotirios Tsimikas. (2006) Statin-Associated Pleiotropy: Possible Beneficial Effects Beyond Cholesterol Reduction. Pharmacotherapy 26:7part2, 85S-97S
CrossRef534
Jack A. DeHovitz, Joseph G. Feldman, Susan Holman, Howard Minkoff. (2006) High Sensitivity C-Reactive Protein and Response to Highly Active Antiretroviral Therapy in Women with HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 42:3, 383-384
CrossRef535
Thao Pham, Laure Gossec, Arnaud Constantin, Stephan Pavy, Eric Bruckert, Alain Cantagrel, Bernard Combe, René-Marc Flipo, Philippe Goupille, Xavier Le Loët, Xavier Mariette, Xavier Puéchal, Thierry Schaeverbeke, Jean Sibilia, Jacques Tebib, Daniel Wendling, Maxime Dougados. (2006) Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 73:4, 379-387
CrossRef536
Jason B. Thompson, Juan J. Rivera, Roger S. Blumenthal, Peter Danyi. (2006) Primary prevention for patients with intermediate framingham Risk Scores. Current Cardiology Reports 8:4, 261-266
CrossRef537
Robert P. Giugliano, Eugene Braunwald. (2006) The Year in Non–ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology 48:2, 386-395
CrossRef538
S. Shenhar-Tsarfaty, E. Ben Assayag, I. Bova, Y. Vered, S. Berliner, O. Rogowski, I. Shapira, N. M. Bornstein. (2006) Wide-range C-reactive protein efficacy in acute ischemic stroke patients. Acta Neurologica Scandinavica 114:1, 29-32
CrossRef539
Sabine Steffens, François Mach. (2006) Drug Insight: immunomodulatory effects of statins—potential benefits for renal patients?. Nature Clinical Practice Nephrology 2:7, 378-387
CrossRef540
Joseph B. Muhlestein, Heidi T. May, Jonathan R. Jensen, Benjamin D. Horne, Richard B. Lanman, Farangis Lavasani, Robert L. Wolfert, Robert R. Pearson, H. Daniel Yannicelli, Jeffrey L. Anderson. (2006) The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia. Journal of the American College of Cardiology 48:2, 396-401
CrossRef541
Göran K. Hansson, Peter Libby. (2006) The immune response in atherosclerosis: a double-edged sword. Nature Reviews Immunology 6:7, 508-519
CrossRef542
James P. Corsetti, Wojciech Zareba, Arthur J. Moss, David L. Rainwater, Charles E. Sparks. (2006) Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation. Atherosclerosis 187:1, 191-197
CrossRef543
Ralph G. Brindis, Edward Fischer, Gary Besinque, Alan Gjedsted, Philip C. Lee, Tom Padgett, Michael Petru, Jenni Raley, Eleanor Levin, Anita Strohmeier. (2006) Acute Coronary Syndromes Clinical Practice Guidelines. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 5:2, 69-102
CrossRef544
Haralampos J. Milionis, Evangelos Rizos, Michael Kostapanos, Theodosios D. Filippatos, Irene F. Gazi, Emmanuel S. Ganotakis, John Goudevenos, Dimitri P. Mikhailidis, Moses S. Elisaf. (2006) Treating to target patients with primary hyperlipidaemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Current Medical Research and Opinion 22:6, 1123-1131
CrossRef545
Stephen J. Nicholls, Ilke Sipahi, Paul Schoenhagen, Tim Crowe, E. Murat Tuzcu, Steven E. Nissen. (2006) Application of intravascular ultrasound in anti-atherosclerotic drug development. Nature Reviews Drug Discovery 5:6, 485-492
CrossRef546
Maciej R. Czerniuk, Renata Gorska, Krzysztof J. Filipiak, Grzegorz Opolski. (2006) C-reactive protein in patients with coexistent periodontal disease and acute coronary syndromes. Journal of Clinical Periodontology 33:6, 415-420
CrossRef547
Tracy S. Zimmermann, Amy C. H. Lee, Akin Akinc, Birgit Bramlage, David Bumcrot, Matthew N. Fedoruk, Jens Harborth, James A. Heyes, Lloyd B. Jeffs, Matthias John, Adam D. Judge, Kieu Lam, Kevin McClintock, Lubomir V. Nechev, Lorne R. Palmer, Timothy Racie, Ingo Röhl, Stephan Seiffert, Sumi Shanmugam, Vandana Sood, Jürgen Soutschek, Ivanka Toudjarska, Amanda J. Wheat, Ed Yaworski, William Zedalis, Victor Koteliansky, Muthiah Manoharan, Hans-Peter Vornlocher, Ian MacLachlan. (2006) RNAi-mediated gene silencing in non-human primates. Nature 441:7089, 111-114
CrossRef548
Stephen J. Nicholls, E. Murat Tuzcu, Tim Crowe, Ilke Sipahi, Paul Schoenhagen, Samir Kapadia, Stanley L. Hazen, Chuan-Chuan Wun, Michele Norton, Fady Ntanios, Steven E. Nissen. (2006) Relationship Between Cardiovascular Risk Factors and Atherosclerotic Disease Burden Measured by Intravascular Ultrasound. Journal of the American College of Cardiology 47:10, 1967-1975
CrossRef549
Anne M. Gillis. (2006) Tincture of Time. Journal of the American College of Cardiology 47:9, 1818-1819
CrossRef550
Mònica Tous, Vicent Ribas, Joan Carles Escolà-Gil, Francisco Blanco-Vaca, Laura Calpe-Berdiel, Blai Coll, Natàlia Ferré, Carlos Alonso-Villaverde, Anna Rull, Jordi Camps, Jorge Joven. (2006) Manipulation of inflammation modulates hyperlipidemia in apolipoprotein E-deficient mice: A possible role for interleukin-6. Cytokine 34:3-4, 224-232
CrossRef551
Cesare R. Sirtori, Remo Fumagalli. (2006) LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention. Atherosclerosis 186:1, 1-11
CrossRef552
Andreas Pfützner, Eberhard Standl, Hermann-Josef Strotmann, Jan Schulze, Cloth Hohberg, Georg Lübben, Sabine Pahler, Thomas Schöndorf, Thomas Forst. (2006) Association of high-sensitive C-reactive protein with advanced stage β-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus. Clinical Chemistry and Laboratory Medicine 44:5, 556-560
CrossRef553
Rodolfo Paoletti, Andrea Poli, Andrea Cignarella. (2006) The emerging link between nutrition, inflammation and atherosclerosis. Expert Review of Cardiovascular Therapy 4:3, 385-393
CrossRef554
Mitchell S. V. Elkind. (2006) Inflammation, Atherosclerosis, and Stroke. The Neurologist 12:3, 140-148
CrossRef555
H Yasuda, P S T Yuen, X Hu, H Zhou, R A Star. (2006) Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney International 69:9, 1535-1542
CrossRef556
Shu-Chu Shiesh, Tse-Chuan Chou, Xi-Zhang Lin, Pai-Chi Kao. (2006) Determination of C-reactive protein with an ultra-sensitivity immunochemiluminometric assay. Journal of Immunological Methods 311:1-2, 87-95
CrossRef557
Sotirios Tsimikas, James T. Willerson, Paul M. Ridker. (2006) C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients. Journal of the American College of Cardiology 47:8, C19-C31
CrossRef558
Dana E. King, Brent M. Egan, Arch G. Mainous, Mark E. Geesey. (2006) The Effect of Extended-Release Metoprolol Succinate on C-Reactive Protein Levels in Persons With Hypertension. The Journal of Clinical Hypertension 8:4, 257-260
CrossRef559
Rodolfo Paoletti, Chiara Bolego, Andrea Poli, Andrea Cignarella. (2006) Metabolic syndrome, inflammation and atherosclerosis. Vascular Health and Risk Management 2:2, 145-152
CrossRef560
Karen MJ Douglas, Naveed Sattar, George D Kitas. (2006) Potential role of statins and PPARs in rheumatoid arthritis. Future Rheumatology 1:2, 259-274
CrossRef561
Marc L De Buyzere, Ernst-Robert Rietzschel. (2006) C-reactive proteinʼs place on the cardiovascular stage: prima ballerina or chorus girl?. Journal of Hypertension 24:4, 627-632
CrossRef562
Paul Schoenhagen. (2006) 3-D Intravascular ultrasound (IVUS) and IVUS-Palpography: insights into the mechanical behavior of the coronary vessel wall. The International Journal of Cardiovascular Imaging 22:2, 153-155
CrossRef563
Dan Justo. (2006) Smoldering systemic inflammation: a link between schizophrenia, smoking and obesity. Acta Psychiatrica Scandinavica 113:4, 245-246
CrossRef564
James E. Muller, Ahmed Tawakol, Sekar Kathiresan, Jagat Narula. (2006) New Opportunities for Identification and Reduction of Coronary Risk. Journal of the American College of Cardiology 47:8, C2-C6
CrossRef565
Stella S. Daskalopoulou, Dimitri P. Mikhailidis. (2006) Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Current Medical Research and Opinion 22:3, 511-528
CrossRef566
Charles J. Lowenstein, Munekazu Yamakuchi. 2006. Statins, Inflammation, and Cardiomyopathy: Old Pathways, New Targets. , 155-166.
CrossRef567
Mahmoud Suleiman, Rania Khatib, Yoram Agmon, Riad Mahamid, Monther Boulos, Michael Kapeliovich, Yishai Levy, Rafael Beyar, Walter Markiewicz, Haim Hammerman, Doron Aronson. (2006) Early Inflammation and Risk of Long-Term Development of Heart Failure and Mortality in Survivors of Acute Myocardial Infarction. Journal of the American College of Cardiology 47:5, 962-968
CrossRef568
Kamyar Kalantar-Zadeh, Kevin C. Abbott, Florian Kronenberg, Stefan D. Anker, Tamara B. Horwich, Gregg C. Fonarow. (2006) Epidemiology of Dialysis Patients and Heart Failure Patients. Seminars in Nephrology 26:2, 118-133
CrossRef569
Carlos A.G. Van Mieghem, Eugène P. McFadden, Pim J. de Feyter, Nico Bruining, Johannes A. Schaar, Nico R. Mollet, Filippo Cademartiri, Dick Goedhart, Sebastiaan de Winter, Gaston Rodriguez Granillo, Marco Valgimigli, Frits Mastik, Anton F. van der Steen, Willem J. van der Giessen, Georgios Sianos, Bianca Backx, Marie-Angèle M. Morel, Gerrit-Anne van Es, Andrew Zalewski, Patrick W. Serruys. (2006) Noninvasive Detection of Subclinical Coronary Atherosclerosis Coupled With Assessment of Changes in Plaque Characteristics Using Novel Invasive Imaging Modalities. Journal of the American College of Cardiology 47:6, 1134-1142
CrossRef570
Leif R. Erhardt, A. Gotto. (2006) The evolution of European guidelines: Changing the management of cholesterol levels. Atherosclerosis 185:1, 12-20
CrossRef571
Martin Soubrier, Christian Roux. (2006) Statins in rheumatology. Joint Bone Spine 73:2, 159-168
CrossRef572
Bhavya Voleti, Alok Agrawal. (2006) Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist. Molecular Immunology 43:7, 891-896
CrossRef573
N. Giladi, M. Mordechovich, L. Gruendlinger, H. Shabtai, D. Merims, S. Naor, R. Baltadzhieva, J. M. Hausdorff, A. Y. Gur, N. M. Bornstein. (2006) "Brain Screen". Journal of Neurology 253:3, 307-315
CrossRef574
T. Ueland, M. N. Vissers, A. Wiegman, J. Rodenburg, B. Hutten, L. Gullestad, L. Ose, N. Rifai, P. M. Ridker, J. J. P. Kastelein, P. Aukrust, A. G. Semb. (2006) Increased inflammatory markers in children with familial hypercholesterolaemia. European Journal of Clinical Investigation 36:3, 147-152
CrossRef575
Zhiqiang Wang, Wendy E. Hoy. (2006) Population distribution of high sensitivity C-reactive protein values in Aboriginal Australians: A comparison with other populations. Clinical Biochemistry 39:3, 277-281
CrossRef576
Harm H.H. Feringa, Virginie H. van Waning, Jeroen J. Bax, Abdou Elhendy, Eric Boersma, Olaf Schouten, Wael Galal, Radosav V. Vidakovic, Marco J. Tangelder, Don Poldermans. (2006) Cardioprotective Medication Is Associated With Improved Survival in Patients With Peripheral Arterial Disease. Journal of the American College of Cardiology 47:6, 1182-1187
CrossRef577
Caren McHenry Martin, Jina Almond. (2006) New Frontiers for Cardiac Risk Assessment: C-Reactive Protein. The Consultant Pharmacist 21:3, 188-206
CrossRef578
Kailash Prasad. (2006) C-Reactive Protein (CRP)-Lowering Agents. Cardiovascular Drug Reviews 24:1, 33-50
CrossRef579
Madhumathi Rao, Bertrand L. Jaber, Vaidyanathapuram S. Balakrishnan. (2006) UNRESOLVED ISSUES IN DIALYSIS: Inflammatory Biomarkers and Cardiovascular Risk: Association or Cause and Effect?. Seminars in Dialysis 19:2, 129-135
CrossRef580
Karam M. Kostner, Robert B. Fahti, Colin Case, Peter Hobson, Jil Tate, Thomas H. Marwick. (2006) Inflammation, complement activation and endothelial function in stable and unstable coronary artery disease. Clinica Chimica Acta 365:1-2, 129-134
CrossRef581
Colleen Fogarty, Kenneth Kornman. 2006. Nutrigenomics. , 1-10.
CrossRef582
Sameer K Mehta, James A de Lemos. (2006) Appropriate invasive and conservative strategies for patients with non-ST elevation acute coronary syndromes. Current Opinion in Internal Medicine 5:1, 24-28
CrossRef583
M. Soubrier, M. Dougados. (2006) Athérome et polyarthrite rhumatoïde. La Revue de Médecine Interne 27:2, 125-136
CrossRef584
M. K. Thomas, D. Narang, R. Lakshmy, R. Gupta, N. Naik, S. K. Maulik. (2006) Correlation Between Inflammation and Oxidative Stress in Normocholesterolemic Coronary Artery Disease Patients ‘on’ and ‘off’ Atorvastatin for Short Time Intervals. Cardiovascular Drugs and Therapy 20:1, 37-44
CrossRef585
Aryeh M. Abeles, Michael H. Pillinger. (2006) Statins as antiinflammatory and immunomodulatory agents: A future in rheumatologic therapy?. Arthritis & Rheumatism 54:2, 393-407
CrossRef586
Göran K. Hansson, Anna-Karin L. Robertson, Cecilia Söderberg-Nauclér. (2006) INFLAMMATION AND ATHEROSCLEROSIS. Annual Review of Pathology: Mechanisms of Disease 1:1, 297-329
CrossRef587
Peter Schwandt. (2006) C-reactive protein and cerebral small-vessel disease. Future Lipidology 1:1, 9-11
CrossRef588
Susanne B. Schwedler, János G. Filep, Jan Galle, Christoph Wanner, Lawrence A. Potempa. (2006) C-Reactive Protein: A Family of Proteins to Regulate Cardiovascular Function. American Journal of Kidney Diseases 47:2, 212-222
CrossRef589
J.L. Martín-Ventura, L.M. Blanco-Colio, A. Gómez-Hernández, B. Muñoz-García, M. Vega, J. Serrano, L. Ortega, G. Hernández, J. Egido, J. Tuñón. (2006) El tratamiento con dosis altas de atorvastatina disminuye la inflamación en la aterosclerosis carotídea humana. Clínica e Investigación en Arteriosclerosis 18:1, 18-23
CrossRef590
Kezhong Zhang, Xiaohua Shen, Jun Wu, Kenjiro Sakaki, Thomas Saunders, D. Thomas Rutkowski, Sung Hoon Back, Randal J. Kaufman. (2006) Endoplasmic Reticulum Stress Activates Cleavage of CREBH to Induce a Systemic Inflammatory Response. Cell 124:3, 587-599
CrossRef591
Kevin A. Deans, Naveed Sattar. (2006) "Anti-Inflammatory" Drugs and Their Effects on Type 2 Diabetes. Diabetes Technology & Therapeutics 8:1, 18-27
CrossRef592
Brian K Irons, Ronald Shane Greene, Timothy A Mazzolini, Krystal L Edwards, Rebecca B Sleeper. (2006) Implications of Rosiglitazone and Pioglitazone on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus. Pharmacotherapy 26:2, 168-181
CrossRef593
Tomomi Koizumi, Andrew M. Wilson, David A. Clark, Peter J. Fitzgerald. (2006) Latent plaque rupture in a patient undergoing stenting for acute coronary syndrome and diffuse coronary disease: A case report and review of literature. Catheterization and Cardiovascular Interventions 67:2, 241-245
CrossRef594
C. Y. Huang, T. C. Wu, W. T. Lin, H. B. Leu, C. P. Lin, S. J. Lin, J. W. Chen. (2006) Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients. European Journal of Clinical Investigation 36:2, 76-84
CrossRef595
Jeffrey A Switzer, David C Hess. (2006) Statins in stroke: prevention, protection and recovery. Expert Review of Neurotherapeutics 6:2, 195-202
CrossRef596
Matthias Briel, Alain J Nordmann, Heiner C Bucher. (2006) Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses. Current Opinion in Internal Medicine 5:1, 29-33
CrossRef597
Stephen J. Nicholls, Ilke Sipahi, E. Murat Tuzcu. (2006) Evaluación de la progresión y la regresión de la aterosclerosis coronaria mediante ecografía intravascular. ¿Un nuevo cambio de paradigma?. Revista Española de Cardiología 59:1, 57-66
CrossRef598
Kevin D. O’Brien, Alan Chait. (2006) Serum amyloid A: The “other” inflammatory protein. Current Atherosclerosis Reports 8:1, 62-68
CrossRef599
Lionel H Opie, Patrick J Commerford, Bernard J Gersh. (2006) Controversies in stable coronary artery disease. The Lancet 367:9504, 69-78
CrossRef600
Ori Rogowski, Itzhak Shapira, Einor Ben Assayag, Nathan M Bornstein, Sharon Toker, Samuel Melamed, Arie Shirom, Shlomo Berliner. (2006) Lack of significant effect of low doses of aspirin on the concentrations of C-reactive protein in a group of individuals with atherothrombotic risk factors and vascular events. Blood Coagulation & Fibrinolysis 17:1, 19-22
CrossRef601
Alan S Maisel, Vikas Bhalla, Eugene Braunwald. (2006) Cardiac biomarkers: a contemporary status report. Nature Clinical Practice Cardiovascular Medicine 3:1, 24-34
CrossRef602
Nerses Sanossian, Bruce Ovbiagele. (2006) Multimodality Stroke Prevention. The Neurologist 12:1, 14-31
CrossRef603
Frank M. van der Sande, Jeroen P. Kooman, Karel M.L. Leunissen. (2006) The Predictive Value of C-Reactive Protein in End-Stage Renal Disease: Is It Clinically Significant?. Blood Purification 24:4, 335-341
CrossRef604
Ulrich Laufs, Florian Custodis, Michael B??hm. (2006) HMG-CoA Reductase Inhibitors in Chronic Heart Failure. Drugs 66:2, 145-154
CrossRef605
Yu-Hua Sun, Yue-Jin Yang, Wei-Dong Pei, Yong-Jian Wu, Run-Lin Gao. (2006) Patients With Low High-Density Lipoprotein-Cholesterol or Smoking are More Likely to Develop Myocardial Infarction Among Subjects With a Visible Lesion or Stenosis in Coronary Artery. Circulation Journal 70:12, 1602-1605
CrossRef606
Simon P. Mooijaart, Jimmy F. P. Berbée, Diana van Heemst, Louis M. Havekes, Anton J. M. de Craen, P. Eline Slagboom, Patrick C. N. Rensen, Rudi G. J. Westendorp. (2006) ApoE Plasma Levels and Risk of Cardiovascular Mortality in Old Age. PLoS Medicine 3:6, e176
CrossRef607
Atsushi Iwata, Shin-ichiro Miura, Kazuyuki Shirai, Akira Kawamura, Sayo Tomita, Yoshino Matsuo, Bo Zhang, Hiroaki Nishikawa, Koichiro Kumagai, Kunihiro Matsuo, Keijiro Saku. (2006) Lower Level of Low-density Lipoprotein Cholesterol by Statin Prevents Progression of Coronary Restenosis after Successful Stenting in Acute Myocardial Infarction. Internal Medicine 45:15, 885-890
CrossRef608
Nicola Abate, Manisha Chandalia. (2006) Other than potency, are all statins the same?. Current Atherosclerosis Reports 8:1, 26-31
CrossRef609
Eric P Plaisance, Peter W Grandjean. (2006) Physical Activity and High-Sensitivity C-Reactive Protein. Sports Medicine 36:5, 443-458
CrossRef610
François Mach. (2006) New anti-inflammatory agents to reduce atherosclerosis. Archives Of Physiology And Biochemistry 112:2, 130-137
CrossRef611
Rong-Ze Yang, Mi-Jeong Lee, Hong Hu, Toni I. Pollin, Alice S. Ryan, Barbara J. Nicklas, Soren Snitker, Richard B. Horenstein, Kristen Hull, Nelson H. Goldberg, Andrew P. Goldberg, Alan R. Shuldiner, Susan K. Fried, Da-Wei Gong. (2006) Acute-Phase Serum Amyloid A: An Inflammatory Adipokine and Potential Link between Obesity and Its Metabolic Complications. PLoS Medicine 3:6, e287
CrossRef612
B.J. Gersh. (2006) C-Reactive Protein Levels and Outcomes After Statin Therapy. Yearbook of Cardiology 2006, 282-283
CrossRef613
Norikazu Andoh, Junichi Minami, Toshihiko Ishimitsu, Masami Ohrui, Hiroaki Matsuoka. (2006) Relationship Between Markers of Inflammation and Brachial-Ankle Pulse Wave Velocity in Japanese Men. International Heart Journal 47:3, 409-420
CrossRef614
Paul E. Szmitko, Subodh Verma. (2006) C-Reactive Protein and the Metabolic Syndrome: Useful Addition to the Cardiovascular Risk Profile?. Journal of the CardioMetabolic Syndrome 1:1, 66-69
CrossRef615
J VANDER. (2006) C-Reactive Protein Levels and Outcomes After Statin TherapyRidker PM, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) Investigators (Harvard Med School, Boston) N Engl J Med 352:20–28, 2005§. Yearbook of Ophthalmology 2006, 116-117
CrossRef616
Stefan Anker, Stephan von Haehling. 2005. Statins. , 425-450.
CrossRef617
Steven R. Steinhubl, L. Kristin Newby, Marc Sabatine, Shinichiro Uchiyama, Myles Connor, Matthias Endres, Alvaro Avezum, Eric Wahlberg. (2005) Platelets and Atherothrombosis: An Essential Role for Inflammation in Vascular Disease — A Review. International Journal of Angiology 14:4, 211-217
CrossRef618
Jorge L Sepulveda, Jawahar L Mehta. (2005) C-reactive protein and cardiovascular disease: a critical appraisal. Current Opinion in Internal Medicine 4:6, 561-570
CrossRef619
Vijay K Verma, Steven M Hollenberg. (2005) Update on acute coronary syndromes and ST-elevation myocardial infarction. Current Opinion in Internal Medicine 4:6, 614-618
CrossRef620
Thomas Pearson, Margo Denke, Patrick McBride, Wendy P Battisti, William E. Brady, Joanne Palmisano. (2005) Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: Subanalyses of data from a randomized, double-blind, placebo-controlled trial. The American Journal of Geriatric Pharmacotherapy 3:4, 218-228
CrossRef621
Mukesh K. Jain, Paul M. Ridker. (2005) Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms. Nature Reviews Drug Discovery 4:12, 977-987
CrossRef622
Kwang Kon Koh, Seung Hwan Han, Michael J. Quon. (2005) Inflammatory Markers and the Metabolic Syndrome. Journal of the American College of Cardiology 46:11, 1978-1985
CrossRef623
H. M. Colhoun, D. J. Betteridge, P. N. Durrington, G. A. Hitman, H. A. W. Neil, S. J. Livingstone, M. J. Thomason, J. H. Fuller, . (2005) Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 48:12, 2482-2485
CrossRef624
James K Liao. (2005) Clinical implications for statin pleiotropy. Current Opinion in Lipidology 16:6, 624-629
CrossRef625
Mark A. Moyad, Gregory S. Merrick, Wayne M. Butler, Kent E. Wallner, Robert W. Galbreath, Brian Kurko, Edward Adamovich. (2005) Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 66:6, 1150-1154
CrossRef626
Jean Rouleau. (2005) Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) trial. The American Journal of Medicine 118:12, 28-35
CrossRef627
William B. Kannel. (2005) Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 40:12, 1215-1220
CrossRef628
Wajeh Y Qunibi. (2005) Does sevelamer have anti-atherosclerotic properties in maintenance hemodialysis patients?. Nature Clinical Practice Nephrology 1:1, 18-19
CrossRef629
Philip J. Podrid, Robert J. Myerburg. (2005) Epidemiology and stratification of risk for sudden cardiac death. Clinical Cardiology 28:S1, 3-11
CrossRef630
Sajoscha Sorrentino, Ulf Landmesser. (2005) Nonlipid-lowering effects of statins. Current Treatment Options in Cardiovascular Medicine 7:6, 459-466
CrossRef631
Geoffrey S. Ginsburg, Mark P. Donahue, L. Kristin Newby. (2005) Prospects for Personalized Cardiovascular Medicine. Journal of the American College of Cardiology 46:9, 1615-1627
CrossRef632
Jennifer G. Robinson, Brian Smith, Nidhi Maheshwari, Helmut Schrott. (2005) Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?. Journal of the American College of Cardiology 46:10, 1855-1862
CrossRef633
Ralph L Sacco, James K Liao. (2005) Drug Insight: statins and stroke. Nature Clinical Practice Cardiovascular Medicine 2:11, 576-584
CrossRef634
Kausik K Ray, Christopher P Cannon. (2005) Optimal goals for statin use in patients with coronary artery disease. Current Opinion in Cardiology 20:6, 525-529
CrossRef635
Mary M. McDermott, Luigi Ferrucci, Kiang Liu, Michael H. Criqui, Philip Greenland, David Green, Jack M. Guralnik, Paul M. Ridker, Lloyd M. Taylor, Nader Rifai, Lu Tian, Jane Zheng, William H. Pearce, Joseph R. Schneider, Ed Vonesh. (2005) D-Dimer and Inflammatory Markers as Predictors of Functional Decline in Men and Women with and without Peripheral Arterial Disease. Journal of the American Geriatrics Society 53:10, 1688-1696
CrossRef636
Huijun Sun, Tomonari Koike, Tomonaga Ichikawa, Kinta Hatakeyama, Masashi Shiomi, Bo Zhang, Shuji Kitajima, Masatoshi Morimoto, Teruo Watanabe, Yujiro Asada, Yuqing E. Chen, Jianglin Fan. (2005) C-Reactive Protein in Atherosclerotic Lesions. The American Journal of Pathology 167:4, 1139-1148
CrossRef637
Katherine M. Field. (2005) Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors on High-Sensitivity C-Reactive Protein Levels. Pharmacotherapy 25:10, 1365-1377
CrossRef638
Kausik K. Ray, Christopher P. Cannon, Richard Cairns, David A. Morrow, Nader Rifai, Ajay J. Kirtane, Carolyn H. McCabe, Allan M. Skene, C. Michael Gibson, Paul M. Ridker, Eugene Braunwald. (2005) Relationship Between Uncontrolled Risk Factors and C-Reactive Protein Levels in Patients Receiving Standard or Intensive Statin Therapy for Acute Coronary Syndromes in the PROVE IT-TIMI 22 Trial. Journal of the American College of Cardiology 46:8, 1417-1424
CrossRef639
Sonia Waiczies, Timour Prozorovski, Frauke Zipp. (2005) Modulating T cell signaling cascades by HMG-CoA reductase inhibitors. Signal Transduction 5:5, 231-244
CrossRef640
Kausik K. Ray, Christopher P. Cannon. (2005) The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary Syndromes. Journal of the American College of Cardiology 46:8, 1425-1433
CrossRef641
Pablo Gómez-Fernández. (2005) Estatinas y efectos beneficiosos. Medicina Clínica 125:15, 578-579
CrossRef642
Stefano De Servi, Matteo Mariani, Giuseppe Mariani, Antonino Mazzone. (2005) C-Reactive Protein Increase in Unstable Coronary Disease. Journal of the American College of Cardiology 46:8, 1496-1502
CrossRef643
Kausik K. Ray, Christopher P. Cannon, Carolyn H. McCabe, Richard Cairns, Andrew M. Tonkin, Frank M. Sacks, Graham Jackson, Eugene Braunwald. (2005) Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology 46:8, 1405-1410
CrossRef644
Antonio M. Gotto. (2005) Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease. Journal of the American College of Cardiology 46:7, 1219-1224
CrossRef645
Ian T. Meredith, Julie C. Plunkett, Stephen G. Worthley, Sarah A. Hope, James D. Cameron. (2005) Systemic inflammatory markers in acute coronary syndrome: association with cardiovascular risk factors and effect of early lipid lowering. Coronary Artery Disease 16:7, 415-422
CrossRef646
Pål Aukrust, Arne Yndestad, Camilla Smith, Wiggo J Sandberg, Thor Ueland, Torgun Wæhre, Bente Halvorsen, Lars Gullestad, Jan Kristian Damås. (2005) Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation. Expert Opinion on Pharmacotherapy 6:13, 2169-2180
CrossRef647
Peter P. Toth. (2005) New insights in the treatment of dyslipidemia: A focus on cardiovascular event reduction and the antiatherosclerotic effects of atorvastatin. Current Atherosclerosis Reports 7:5, 335-343
CrossRef648
Robert P. Giugliano, Eugene Braunwald. (2005) The Year in Non
ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology 46:5, 906-919
CrossRef649
Keith C Ferdinand. (2005) Rosuvastatin: a risk–benefit assessment for intensive lipid lowering. Expert Opinion on Pharmacotherapy 6:11, 1897-1910
CrossRef650
Stephan J. L. Bakker, Ron T. Gansevoort, Erik M. Stuveling, Rijk O. B. Gans, Dick Zeeuw. (2005) Microalbuminuria and C-reactive protein: Similar messengers of cardiovascular risk?. Current Hypertension Reports 7:5, 379-384
CrossRef651
Edward T. H. Yeh. (2005) High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. Clinical Cardiology 28:9, 408-412
CrossRef652
X. Pintó. (2005) Efectos inmunomoduladores de las estatinas. Clínica e Investigación en Arteriosclerosis 17, 1-8
CrossRef653
Neil L. Coplan, Alexander Chernobelsky. (2005) Global Risk Stratification to Improve Cardiovascular Prevention: Integration of Traditional Risk Factors, Emerging Risk Factors, and New, Noninvasive Cardiovascular Imaging. The American Heart Hospital Journal 3:4, 265-268
CrossRef654
W. P. D. Lemahieu, M. Hermann, A. Asberg, K. Verbeke, H. Holdaas, Y. Vanrenterghem, B. D. Maes. (2005) Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with Tacrolimus. American Journal of Transplantation 5:9, 2236-2243
CrossRef655
Judith A. Aberg, Robert A. Zackin, Susan W. Brobst, Scott R. Evans, Beverly L. Alston, W. Keith Henry, Marshall J. Glesby, Francesca J. Torriani, Yijun Yang, Susan I. Owens, Carl J. Fichtenbaum. (2005) A Randomized Trial of the Efficacy and Safety of Fenofibrate versus Pravastatin in HIV-Infected Subjects with Lipid Abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Research and Human Retroviruses 21:9, 757-767
CrossRef656
J. Rubiés-Prat. (2005) Factores de riesgo cardiovascular. Medicine - Programa de Formación Médica Continuada Acreditado 9:38, 2506-2513
CrossRef657
Eric Van Ganse, Laurent Laforest, Evo Alemao, Glenn Davies, Stephen Gutkin, Don Yin. (2005) Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Current Medical Research and Opinion 21:9, 1389-1399
CrossRef658
R. Kahn, J. Buse, E. Ferrannini, M. Stern. (2005) The metabolic syndrome: time for a critical appraisal. Diabetologia 48:9, 1684-1699
CrossRef659
Thomas W. Wakefield, Peter K. Henke. (2005) The Role of Inflammation in Early and Late Venous Thrombosis: Are There Clinical Implications?. Seminars in Vascular Surgery 18:3, 118-129
CrossRef660
Raaj R Sankatsing, Eric de Groot, J Wouter Jukema, Pim J de Feyter, Dudley J Pennell, Paul Schoenhagen, Steven E Nissen, Erik SG Stroes, John JP Kastelein. (2005) Surrogate markers for atherosclerotic disease. Current Opinion in Lipidology 16:4, 434-441
CrossRef661
Tryfon Vainas, Frank R.M. Stassen, Rick de Graaf, Eric L.L. Twiss, Selma B. Herngreen, Rob J. Th.J. Welten, Luc H.J.M. van den Akker, Marja P. van Dieijen-Visser, Cathrien A. Bruggeman, Peter J.E.H.M. Kitslaar. (2005) C-reactive protein in peripheral arterial disease: Relation to severity of the disease and to future cardiovascular events. Journal of Vascular Surgery 42:2, 243-251
CrossRef662
Sheila A Doggrell. (2005) Relating statin therapy to C-reactive protein levels. Expert Opinion on Pharmacotherapy 6:9, 1597-1600
CrossRef663
Paul Schoenhagen. (2005) Atherosclerosis imaging and circulating blood biomarkers: insights into subclinical atherosclerotic plaque burden and disease activity. The International Journal of Cardiovascular Imaging 21:4, 443-445
CrossRef664
L. MASOTTI, E. CECCARELLI, S. FORCONI, R. CAPPELLI. (2005) Prognostic role of C-reactive protein in very old patients with acute ischaemic stroke. Journal of Internal Medicine 258:2, 145-152
CrossRef665
Vasilios G. Athyros, Dimitri P. Mikhailidis, Athanasios A. Papageorgiou, Triandafillos P. Didangelos, Athanasia Peletidou, Drosia Kleta, Asterios Karagiannis, Anna I. Kakafika, Konstantinos Tziomalos, Moses Elisaf. (2005) Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 54:8, 1065-1074
CrossRef666
Antonio Tello, Francisco Marín, Vanessa Roldán, Ana García-Herola, Sofía Lorenzo, Vicente E. Climent, Luis de Teresa, Francisco Sogorb. (2005) Efecto de dosis máximas de atorvastatina en la inflamación, la trombogénesis y la función fibrinolítica en pacientes con cardiopatía isquémica de alto riesgo. Revista Española de Cardiología 58:8, 934-940
CrossRef667
(2005) Intensive Lipid Lowering with Atorvastatin in Coronary Disease. New England Journal of Medicine 353:1, 93-96
Full Text668
Hugh Clements-Jewery, David J Hearse, Michael J Curtis. (2005) Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation. British Journal of Pharmacology 145:5, 551-564
CrossRef669
Christopher S. Carlson, Shelley Force Aldred, Philip K. Lee, Russell P. Tracy, Stephen M. Schwartz, Mark Rieder, Kiang Liu, O. Dale Williams, Carlos Iribarren, E. Cora Lewis, Myriam Fornage, Eric Boerwinkle, Myron Gross, Cashell Jaquish, Deborah A. Nickerson, Richard M. Myers, David S. Siscovick, Alexander P. Reiner. (2005) Polymorphisms within the C-Reactive Protein (CRP) Promoter Region Are Associated with Plasma CRP Levels. The American Journal of Human Genetics 77:1, 64-77
CrossRef670
Charles Daniel Meyers, Nathan Wong, Moti L Kashyap. (2005) Anticipating the evolution of clinical cholesterol guidelines: implications of recent statin intervention trials. Future Cardiology 1:4, 461-471
CrossRef671
Gary E. Sander, Thomas D. Giles. (2005) Medical Management of Myocardial Ischemia. The American Journal of Geriatric Cardiology 14:4, 205-209
CrossRef672
Mahesh Patel, Darren K. McGuire. (2005) How aggressive should lipid lowering be among patients with acute coronary syndromes?. Current Cardiology Reports 7:4, 283-287
CrossRef673
Ankie Amos, L. Kristin Newby. (2005) Using biomarkers to assess risk and consider treatment strategies in non-ST-segment elevation acute coronary syndromes. Current Cardiology Reports 7:4, 263-269
CrossRef674
Abrams, Jonathan, . (2005) Chronic Stable Angina. New England Journal of Medicine 352:24, 2524-2533
Full Text675
Guenther Boden. (2005) New benefits of statin treatment. Current Diabetes Reports 5:3, 165-166
CrossRef676
Kausik K Ray, Christopher P Cannon. (2005) Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials. Expert Opinion on Pharmacotherapy 6:6, 915-927
CrossRef677
Colin Macphee, G Martin Benson, Yi Shi, Andrew Zalewski. (2005) Lipoprotein-associated phospholipase A 2 : a novel marker of cardiovascular risk and potential therapeutic target. Expert Opinion on Investigational Drugs 14:6, 671-679
CrossRef678
Paul Schoenhagen, Richard D. White, E. Murat Tuzcu. (2005) Comprehensive imaging of coronary artery disease Impact on contemporary treatment approaches. Comprehensive Therapy 31:2, 159-165
CrossRef679
Graham Jackson. (2005) Lipids and cardiovascular risk reduction - new targets, new challenges. International Journal of Clinical Practice 59:6, 617-618
CrossRef680
D. Mergner, P. Rosenberger, K. Unertl, H. K. Eltzschig. (2005) Präoperative Evaluation und perioperatives Vorgehen bei kardialen Risikopatienten. Der Anaesthesist 54:5, 427-441
CrossRef681
Rama Natarajan, Qiangjun Cai. (2005) Monocyte retention in the pathology of atherosclerosis. Future Cardiology 1:3, 331-340
CrossRef682
Paul M. Ridker, David A. Morrow, Lynda M. Rose, Nader Rifai, Christopher P. Cannon, Eugene Braunwald. (2005) Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/l. Journal of the American College of Cardiology 45:10, 1644-1648
CrossRef683
Cornelis Kluft. (2005) Does reducing a patient's CRP levels with statin therapy reduce their risk of recurrent cardiovascular events?. Nature Clinical Practice Cardiovascular Medicine 2:5, 244-245
CrossRef684
Hansson, Göran K., . (2005) Inflammation, Atherosclerosis, and Coronary Artery Disease. New England Journal of Medicine 352:16, 1685-1695
Full Text685
Woloshin, Steven, Schwartz, Lisa M., . (2005) Distribution of C-Reactive Protein Values in the United States. New England Journal of Medicine 352:15, 1611-1613
Full Text686
(2005) C-Reactive Protein Levels and Outcomes after Statin Therapy. New England Journal of Medicine 352:15, 1603-1605
Full Text687
(2005) C-reactive protein levels and cardiovascular risk after statin therapy. Nature Clinical Practice Cardiovascular Medicine 2:3, 118-118
CrossRef688
Stanley M. Zagorski, Nicole N. Papa, Mathew H. Chung. (2005) The effect of weight loss after gastric bypass on C-reactive protein levels. Surgery for Obesity and Related Diseases 1:2, 81-85
CrossRef689
Simon Frantz. (2005) Cardiovascular disease: A dual target. Nature Reviews Drug Discovery 4:3, 198-198
CrossRef690
Ehrenstein, Michael R., Jury, Elizabeth C., Mauri, Claudia, . (2005) Statins for Atherosclerosis — As Good as It Gets?. New England Journal of Medicine 352:1, 73-75
Full Text691
Nissen, Steven E., Tuzcu, E. Murat, Schoenhagen, Paul, Crowe, Tim, Sasiela, William J., Tsai, John, Orazem, John, Magorien, Raymond D., O'Shaughnessy, Charles, Ganz, Peter, . (2005) Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease. New England Journal of Medicine 352:1, 29-38
Full Text692
José Vivancos-Mora, Antonio C. Gil-Núñez. (2005) Lipids and Stroke: The Opportunity of Lipid-Lowering Treatment. Cerebrovascular Diseases 20:2, 53-67
CrossRef693
Erik Stroes. (2005) Statins and LDL‐cholesterol lowering: an overview. Current Medical Research and Opinion 21:s6, S9-S16
CrossRef694
Mark A. Moyad. (2005) Promoting general health during androgen deprivation therapy (ADT): A rapid 10-step review for your patients. Urologic Oncology: Seminars and Original Investigations 23:1, 56-64
CrossRef695
Mark A. Moyad, Gregory S. Merrick. (2005) Statins and cholesterol lowering after a cancer diagnosis: Why not?. Urologic Oncology: Seminars and Original Investigations 23:1, 49-55
CrossRef696
Toshihiro KITA, Yoshihiko SUZUKI, Tanenao ETO, Kazuo KITAMURA. (2005) Long-Term Anti-Hypertensive Therapy with Benidipine Improves Arterial Stiffness over Blood Pressure Lowering. Hypertension Research 28:12, 959-964
CrossRef697
John A. Tsiouris. (2005) Metabolic depression in hibernation and major depression: An explanatory theory and an animal model of depression. Medical Hypotheses 65:5, 829-840
CrossRef
- Letters
